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Abstracts 
In the present thesis, I tried to vary the central nitrogen-heterocyclic cores, the functionalised 
side chains and its position of attachment. As a synthetic strategy, palladium-catalyzed 
coupling reactions were used to introduce side chains and aryl substituents into the central 
heterocycle. In this way the utility of such reactions to heterocyclic systems, which were 
neglected so far, could be figured out. 
Halogen substituted diaryl heterocycles are important intermediates in the synthesis of general 
structures. The introduction of the desired side chains by Carbon-Carbon bond formation 
reactions was achieved by Sonogashira coupling and Heck coupling. Buchwald-Hartwig 
amination and nucleophilic substitution were used to establish side chains which are 
connected to the core heterocycle by heteroatom-Carbon bonds. Sonogashira reaction turned 
out to be the most effective and convenient method to introduce functionalized alkynyl group 
into the heterocyclic cores.  
In the present work, more than 180 compounds were synthesized. Among them, about 130 
compounds are new products. 86 of them fit into the general structure. 
Keywords: calcineurin-inhibitor, diaryl heterocycles, palladium-catalyzed, cross-coupling, 
functionalised side chain, inhibiting activity, organic synthesis,  
 
Zusammenfassung 
In dieser Dissertation versuche ich, die zentralen Nitrogen-heterocyclischen Kerne, die 
Seitenketten und deren Position zu variieren. Als synthetische Strategie wurden Palladium-
katalysierte Kupplungsreaktionen verwendet, um Seitenketten und Aryl-Substituenten 
einzuführen. 
Halogensubstituierte Diarylheterocyclen sind wichtige Intermediate in der Synthese der 
allgemeine Strukture. Die Einführung der gewünschten Seitenketten durch Carbon-Carbon 
und Carbon-Nitrogen-Bindungsknüpfung wurde durch Sonogashira-Kupplung, Heck-
Kupplung und Buchwald-Hartwig-Aminierung erzielt. Mit der Sonogashira-Reaktion kann 
eine funktionalisierte Alkynylgruppe in die heterocyclischen Kerne effektiv und bequem 
eingeführt werden. Eine anschliessende katalytische Hydrierung der Alkynylgruppe führt zu 
funktionalisierten Alkyl substituierten Diarylheterocyclen.  
In der vorliegenden Arbeit wurden mehr als 180 Substanzen synthetisiert. Unter ihnen sind 
ungefähr 130 neue Substanzen. 86 von ihnen passen in die allgemeine Strukture. 
Schlagwörtern: calcineurine-Inhibitor, Heterocyclen, Palladium-katalysierte, cross-Kuplung, 
funktionalisierte Seitenketten, inhibitiertung Aktivität, organische Synthese 
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Chapter 1: Introduction 
1.1 Background of the project 
 
1.1.1 Calcineurin and its physiological roles  
 
Calcineurin (CaN) is a serine/threonine protein phosphatase [1-5], activated by calcium and 
the calmodulin-calcium complex. CaN was first purified from bovine brain, where it was 
found in high concentrations in neurons (over 1 % of total protein in brain). CaN is widely 
distributed in mammalian tissues and plants. There are two kinds of calcineurins: calcineurin 
A and calcineurin B. 
Calcineurin activity [6] is necessary for the synthesis of several cytokine genes through the 
dephosphorylation of a family of transcription factors known as NF-AT (nuclear factor of 
activated T cells). By inhibiting calcineurin activity, cyclosporin A (CsA) and FK506 prevent 
the nuclear translocation of NF-AT secondary to dephosphorylation, thereby suppressing T 
cell activation. 
Calcineurin has numerous physiological roles in budding yeast including recovery from -
factor-induced growth arrest, salt and temperature tolerance, Ca2+ homeostasis, and Mn2+ 
tolerance. In addition, calcineurin inhibits the activity of the vacuolar H+/Ca2+ exchanger and 
causes conversion of the K+ channel to the high-affinity state. 
 
1.1.2 Inhibitors of calcineurin  
 
Calcineurin inhibitors [3, 6-12], which specifically inhibit T-cell activation, are essential for 
T-cell activation and proliferation. They are very important for the activities of cells, 
metabolism and the health of humans. In order to cure a series of diseases (heart diseases, skin 
diseases, etc.) caused by lacking calcineurin inhibitors, many synthetic chemists and 
medicinal chemists are interested in developing new calcineurin inhibitors. 
 
(1) Natural calcineurin inhibitors  
A number of natural cyclic peptides have been isolated and demonstrated to be inhibitors of 
calcineurin and other serine/threonine protein phosphatases. The most potent, specific and 
well-known inhibitor of calcineurin is the immuno-suppressant drug, cyclosporin A. Other 
cyclic peptides, for example, microcystin LR, AKAP79 (A-kinase-anchoring-protein 79), and 
FKBP12, are also useful inhibitors of calcineurin. 
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A few non-peptide natural products also have inhibitory activities against calcineurins and 
other serine/threonine protein phosphatases, such as FK506, okadaic acid, and dibefurin. 
Some known natural calcineurin inhibitors are shown in Figure 1.1. 
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Figure 1.1 Natural product inhibitors of calcineurin 
 
(2) Synthetic calcineurin inhibitors  
Several synthetic compounds have been found to be reasonable inhibitors of calcineurin and 
other phosphatases. They are, exo-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid (an 
endothal derivative), a variety of alkylphosphonic acid derivatives containing an additional 
thiol or carboxylate group, tyrphostin A8 and PD 144795 (a benzothiophene derivative). 
Some of the known synthetic inhibitors of calcineurin are shown in Figure 1.2. 
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Tyrphostin A8PD 144795 Endothal derivative  
 
Figure 1.2 Synthetic inhibitors of calcineurin  
 
(3) Necessity to develop new non-peptidic calcineurine inhibitors 
So far, the most important calcineurin inhibitors are from natural origin (natural peptidic 
calcineurin inhibitors). Peptidic drugs normally cause the problem of easy in vivo hydrolysis 
and short live time. The immunosuppressive currently used results in a number of unwanted 
side effects, such as neurotoxicity, nephrotoxicity and carcinogenity [1]. The known synthetic 
calcineurin inhibitors usually have poor inhibiting activities. Therefore, there is a high need to 
develop better calcineurine inhibitors, in particular to non-peptidic compounds. 
 
1.1.3 Our research background  
 
On the basis of previous work in our group [13-16], we try to develop a series of special 
calcineurin inhibitors, which have better inhibiting power or higher selectivity than the known 
calcineurin inhibitors. These inhibitors will represent a guidance structure for new immune 
suppressive drug with lower side effect. 
For this purpose, an assembly of three aromatic systems and an aminoalkyl unbranched chain 
was developed as the guidance structure (Figure 1.3). The polar central heteroaromatic ring is 
hydrophilic, and always flanked by two typically hydrophobic aromatic rings and a saturated 
unbranched side chain. The side chain is terminated by a hydrophilic functional group. The 
results of this thesis will help to refine our structural model of calcineurin-inhibiting 
heterocycles. 
 
 
 
 
 
 
 
 
Figure 1.3 The generic structural component of guiding structure 
Hydrophilic 
π-system
Hydrophobic
π-system 
Hydrophobic
π-system 
Hydrophilic
functional 
group
Saturated 
unbranched 
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In this guidance structure, the polar hydrophilic π-systems are normally nitrogen containing 
heterocycles, the two hydrophobic π-systems are unsubstituted or substituted aromatic 
systems or arylvinyl systems, but not polar heteroaromatic systems. The terminal hydrophilic 
functional groups are unsubstituted and substituted amino groups, hydroxy group, etc. 
So far, only a few structural types of this kind are known. The ring-chain-transformation-
synthesis concept, developed by us [16a] represents an efficient entrance to such structures 
and provided access to pyrazolo[1,5-a]pyrimidines and other heterocyclic derivatives with 
aminoalkyl substituents in 7-position. ( Scheme 1.1)  
 
N
N
H
NAr1
Cl
R I
H2N
Ar2
+
N
N N
Ar1
Ar2
n
NMeR
n
1
 
 
Scheme 1.1 Synthesis of pyrazolo[1,5-a]pyrimidines by ring-chain-transformation 
 
 
Some structural examples with high activity of calcineurin inhibitor are successfully 
synthesized by our group [16], using ring-chain-transformation and other synthetic routes. 
They are either bicyclic heterocycles (Figure 1.4) or monocyclic heterocycles (Figure 1.5). 
 
Bicyclic heterocycles: 
 
N
N
N N
Cl
Me2N
N
N N
NHMe2N
N
N N
O
Me2N
Cl
2  Lie-1476
IC50 = 1.5 µM
3   Lie-1330
IC50 = 7.5 µM
4   Lie1412
IC50 = 2.0 µM  
 
Figure 1.4 Potent bicyclic heterocyclic inhibitors 
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Monocyclic heterocycles: 
 
N
N
Cl
S NMe2
5 Lie-1396
IC50 = 6.0 µM
N
S
N
H
MeO Br
7   Lie-1427
IC50 = 18 µM
N
N
Cl
O NMe2
6   Lie-1393
IC50 = 14.0 µM  
 
Figure 1.5 Potent monocyclic heterocyclic inhibitors 
 
These known examples are limited to pyrazolo[1,5-a]triazines, pyrazolo[1,5-a]pyrimidines, 
pyrimidines, triazines and thiazoles as the core heterocycles. 
 
1.2 Target molecules and synthetic strategies 
 
1.2.1 Synthetic target molecules 
 
According to the analysis and discussion above, a synthetic target molecular model of non-
peptide calcineurin inhibitors are designed as below (Figure 1.6). The general structure 8 will 
be followed up in the present work.  
Heterocyclic
   core
Ar2Ar1
Y Aliphatic chain Z
Synthetic target molecules
8
 
Figure 1.6 Synthetic target molecules 
 
The following variation of structural parameters is envisaged: 
Ar1, Ar2: phenyl, substituted phenyl, pyridyl, and other aromatic group. 
Y: CH2, CH=CH, C≡C, C=O, CH2NH, CH(OH), NH, NR, O, S. 
Z: NH2, NHR, NR1R2, OH, OR, CO2R,CN, CONH2, CONR2, etc.  
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Aliphatic-chain: unbranched chain (saturated or unsaturated chain) with 2 to 5 carbon 
atoms. 
Heterocyclic cores: mono-, or bicyclic nitrogen-containing heterocycles, such as  
pyrazolo[1,5-a]pyrimidine, purine, pyrido[2,3-b]pyrazine, imidazo[1,2-a]pyridine, 
pyrimidine, pyridine, pyrazine, oxazole, pyrazole, imidazole.  
 
 
1.2.2 Disconnection of target molecules 
 
The desired target molecules can be retrosynthetically disconnected as follow: 
 
X = I,  Br, Cl
Heterocyclic
   core
Ar2Ar1
Y Aliphatic chain Z
Heterocyclic
   core
Ar2Ar1
X
Heterocyclic
  core
Ar2Ar1
Y = C, O, S, NH, etc.
Z = NH2, NMe2, OH, etc.8
9
10
Heterocyclic
   core
XAr1
X
Heterocyclic
   core
XX
X
9B
9A
Heterocyclic
  core
XAr1 Heterocyclic
  core
XX
10C
10B
Heterocyclic
  core
Ar1
10A
 
 
Scheme 1.2 Disconnection of target molecules 
 
Chapter 1: Introduction 
_________________________________________________________________________________________________________________________________ 
 
7
 
1.2.3 Synthetic strategies for target molecules 
 
The chemo-, regio-, stereoselective formation of new carbon-carbon (carbon-oxygen or 
carbon-nitrogen) bonds is our major goal.  
At first, we synthesized a series of heterocyclic ring cores, and introduced one or more 
leaving groups X (I, Br, Cl) into the heterocyclic cores, then one or two aryl groups were 
introduced. In the last and most important step, the side chains were introduced into the 
heterocycles. 
 
Introducing the Y-aliphatic-chain-Z chain into diarylheterocycle is the key step of our 
project. In order to introduce the Y-aliphatic-chain-Z into the heterocyclic cores, there are 
two main methods. One way is using nucleophlic substitution, and the other one is using Pd-
catalyzed cross-coupling reactions. 
 
Classic nucleophilic substitution is used for active electron deficient halo-heterocycles. For 
example, the nucleophilic substitution of 4-chloro-2,6-diphenylpyrimidine [17] is shown in 
Scheme 1.3: 
 
t-Bu-OK, 83 %
NaOH/EtOH, 61 %
N N
Ph
ClPh
NH2(CH2)2NMe2
HO(CH2)2NMe2
HS(CH2)2NMe2
N N
Ph
NH(CH2)2NMe2Ph
N N
Ph
O(CH2)2NMe2Ph
N N
Ph
S(CH2)2NMe2Ph
93 %
11
12
13
 
Scheme 1.3 Introducing branch chains by nucleophilic substitution 
 
 
The transition metal catalyzed cross-coupling reactions, which were developed starting from 
the 1970s, are extensively used for the formation of C-C bonds, C-N bonds, C-O bonds and 
C-P bonds. Among them, the most important are Pd-catalyzed cross-coupling reactions. This 
is a good way to introduce aryl group as well as aliphatic groups into carbocyclic arenes or 
heteroarenes. 
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1.3 Pd-catalyzed cross-coupling of heterocycles 
 
Palladium was discovered by W. H. Wollaston in 1803. It is known for its ability to absorb 
large amounts of hydrogen gas (up to 900 times of its own volume of H2 at room 
temperature), which led to one of its earliest chemical uses, as a hydrogenation catalyst. In the 
last few decades, palladium compounds have been used as catalyst to develop many new 
synthetic transformations, such as carbon-carbon and carbon-heteroatom coupling reactions 
(e.g., by Buchwald-Hartwig, Heck, Suzuki-Miyaura, Kumada, Negishi, Nozaki-Hiyama, 
Sonogashira, Stille, and Tsuji-Trost) [18-23]. The Pd-catalyzed cross-coupling reactions 
gained increasing popularity amongst pharmaceutical chemists as they are generally tolerant 
of a wide-range of functional groups and therefore can be used for the synthesis of 
complicated molecules.  
 
 
1.3.1. Overview of relevant Pd-catalyzed cross-coupling  
 
1.3.1.1 Cross-coupling reactions with organometallic reagents 
 
Palladium-catalyzed cross-coupling reactions of organohalides (organotriflates, etc.) with 
organometallic reagents follow a general mechanistic cycle. The L2Pd(0) 17, as a 14-electron 
structure [the active catalyst PdL is 12 electron when P(o-tol)3 is used as the ligand] is 
sometimes reduced from a Pd(II) species 14 by an organometallic reagent R1M 15. The 
transmetalation product 16 from 14 and 15 undergoes a reductive elimination step, giving rise 
to the Pd(0) species 17, along with the homocoupling product R1-R1. This is one of the 
reasons why the organometallic coupling partners are often used in a slight excess relative to 
the electrophilic partners. When the Pd(0) catalyst 17 is generated, the catalytic cycle goes 
through a three-step sequence. (a) Electrophile R2-X 18 undergoes an oxidative addition step 
to Pd(0) to afford a 16-electron Pd(II) intermediate 19. (b) Subsequently, 19 undergoes a 
transmetalation and isomerisation step with the organometallic reagent R1M 15 to produce the 
intermediate 21. When there is more than one group attached to the metal M, such as with Sn, 
the order of transmetalation for different substituents is: 
alkynyl > vinyl > aryl > allyl ~ benzyl >> alkyl 
 
The transmetalation step, often rate-limiting, is the step to which attention should be directed 
if the reaction goes awry. (c) Finally, with appropriate syn geometry, intermediate 21 
undergoes a reductive elimination step to produce the coupling product R2—R1 22, 
regenerating the palladium (0) catalyst 17 to close the catalytic cycle (Scheme 1.4). 
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L2Pd(0)
Pd
L
L
R2 XPd
L
R2
L
R1
oxidative
addition
  transmetalation 
and isomerization
   reductive
  elimination
R2-X
R1MMX
R2-R1
17 18
1921
20
22
15
L2Pd(II) + R1M L2Pd(II)
R1
R1
R1-R1 + L2Pd(0)
transmetalation reductive
elimination
14 15 16 17
 
Scheme 1.4 Catalytic cycle of coupling reactions of organometallic reagents 
 
 
(1) Negishi coupling 
 
The Negishi reaction is the Pd-catalyzed cross-coupling between organozinc reagents and 
organohalides (or triflates) [24-26], for an example [27] see Scheme 1.5. It is compatible with 
many functional groups including ketones, esters, amine and nitriles. Organozinc reagents are 
usually generated and used in situ by transmetalation of Grignard or organolithium reagents 
with ZnCl2. In addition, some organo halides can be oxidatively added to Zn (0) to give the 
corresponding organozinc reagents. The Negishi coupling is often advantageous over other 
cross-coupling, because organozinc reagents have a high tolerance of functional groups.  
 
N
N
I
N
N
R
+ R ZnI
Pd(PPh3)2Cl2
DME
R= Cl, CO2Et
23
64-92 %
 
 
Scheme 1.5 Example of the Negishi coupling reaction 
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(2) The Stille coupling  
 
The Stille coupling is the Pd-catalyzed cross-coupling between an organostannane and an 
electrophile to form a new C-C single bond [28-30], for an example [31] see Scheme 1.6. 
This is regarded as one the most versatile methods in Pd-catalyzed cross-coupling reactions 
with organometallic reagents for two reasons. First, the organostannanes are readily prepared, 
purified and stored. Second, the conditions of the Stille reaction tolerate a wide variety of 
functional groups. In contrast to the Suzuki, Kumada, Heck, and Sonogashira reactions which 
are run under basic conditions, the Stille reaction can be run under neutral conditions. The 
pitfall of the Stille reaction is the toxicity of stannanes, making it not suitable for large-scale 
synthesis or the synthesis of pharmaceutical products.  
 
N
N
Me3SnO
OHC Br
+
OOHC
N
N
SMe
SMe
Pd(PPh3)2Cl2
DCE, reflux
100 %
24  
 
Scheme 1.6 Examples of the Stille coupling reactions 
 
 
(3) The Suzuki coupling 
 
The Suzuki reaction is the Pd-catalyzed cross-coupling between organoboron reagents and 
organohalides (or triflates) [32-34], some examples [35, 36] are shown in Scheme 1.7 . 
 
NHCbz
1) 9-BBN, THF
2) 4-bromopyridine
     PdCl2(dppf), 
     NaOH, H2O, 88 %
N
N
BrMeO2C
N
MeO2C
NO2
3-O2NC6H5B(OH)2
Pd(PPh3)4, benzne
aq.Na2CO3, reflux, 73 % 25
26
(a)
(b)
NHCbz
 
 
Scheme 1.7 Example of the Suzuki coupling reactions 
 
In comparison to the abundance of heterarylstannanes, heteroarylboron reagents are not as 
prevalent. There are major reasons why one should consider the Suzuki coupling when 
designing a Pd-catalyzed reaction in heteroaryl synthesis. First, a growing number of 
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heteroarylboron reagents are known now. Second, judiciously designing the coupling partners 
will enable the use of a heteroaryl halide to couple with a known organoboron reagent for the 
use of certain molecules. Third, there is no toxicity issue involved in organoboron reagents. 
Therefore, Suzuki reaction is a more attractive choice in carbon-carbon bond formation 
reactions.  
 
 
(4). The Kumada coupling 
 
The Kumada coupling represents the Pd-catalyzed cross-copling of a Grignard reagent with 
an electrophile such as an alkenyl-, aryl-, and heteroaryl halide or triflate [37-39], for an 
example [40] see Scheme 1.8. The advantage of this reaction is that numerous Grignard 
reagents are commercially available. Those that are not commercially available may be 
readily prepared from the corresponding halides. Another advantage is that the reaction can 
often be run at room temperature or lower. A drawback of this method is the intolerance of 
many functional groups (such as –OH, -NH2, -C=O, etc.) by the Grignard reagents.  
NCl Cl
NClN MgBr
N
PdCl2(dppb)
THF, 58%
+
27  
Scheme 1.8 Example of the Kumada coupling reaction 
 
 
(5) The Hiyama coupling 
 
The Hiyama coupling is the Pd-catalyzed cross-copling of an organosilicon reagent (activated 
by F or alkyloxy) with organohalides (or triflates) [41-42], for an example [43] see Scheme 
1.9. One of the advantages of the Hiyama coupling is that organosilicon reagents are 
innocuous. Another advantage is the better tolerance of functional groups in comparison to 
other strong nucleophilic organometallic reagents.  
 
R Si(OMe)3 R
N
+
N
Br
C5H11
Pd(OAc)2, PPh3
Bu4NF, DMF, reflux
R =
2872 %
 
 
Scheme 1.9 Example of the Hiyama coupling reaction 
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1.3.1.2 The Sonogashira reaction 
 
The Sonogashira reaction is the palladium-catalyzed cross-coupling reaction between terminal 
alkynes with aryl and vinyl halides in the presence of an aliphatic amine or inorganic base 
under mild conditions [44-46]. The proposed catalytic cycle is shown in Scheme 1.10: 
 
L2Pd(0)
Pd
L
L
Ar XPd
L
Ar
L
C
oxidative
addition
   reductive
  elimination
29
30
31
33
34
Ar-X
CuX
C R
R
nucleophilic
attack
Ar C C R
32
RCu
HX
base
 
 
Scheme 1.10 Catalytic cycle of the Sonogashira coupling 
 
Some examples [47, 48], which are also interesting with respect to this thesis are shown in 
Scheme 1.11:  
N
N
I
Pd(PPh3)2Cl2
CuI, TEA, RT
N
N
OH
N
N
Br
OH
+
N
N
NMe2Pd/C, CuI, PPh3
K2CO3
DME-H2O
35
36
NMe2
+
(a)
(b)
50 %
56 %
 
 
Scheme 1.11 Examples of the Sonogashira coupling reactions 
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1.3.1.3 The Heck reaction 
 
The Heck reaction is the palladium-catalyzed cross-coupling reaction of organohalides (or 
triflates) and olefins [49-51]. Nowadays it has become an indispensable tool for organic 
synthesis. The proposed catalytic cycle is shown in Scheme 1.10: 
 
L2Pd(0)
Pd
L
L
Ar X
oxidative
addition
   syn-elimination
37
38
39
40
Ar-X
R
syn-addition
R
PdL2XArR
Ar
H-PdL2X
base - HX
41
42
43
 
 
Scheme 1.12 Catalytic cycle of the Heck coupling 
 
 
Some useful known examples [52, 53], where side chain with terminal N-atom were 
introduced are shown in Scheme 1.11:  
 
N
N
I
+
N
NPd(OAc)2
TEA
N
Br
N
NH
Ts
+
Pd(OAc)2, P(o-Tol)3
TEA-MeCN
N
N
44
(a)
(b)
45
37 %
70 %
Ts
H
N
 
 
Scheme 1.13 Examples of the Heck coupling reaction 
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1.3.1.4 The Buchwald-Hartwig C-N bond formation 
 
The direct Pd-catalyzed C-N bond formations of aryl halides with amines were discovered by 
Buchwald and Hartwig independently in 1995 [54, 55]. Pd(OAc)2 or Pd2(dba)3 was often 
chosen as catalyst, and t-Bu3P, BINAP, or other bulky phosphorous compound was used as 
ligand. It is an effective way to introduce substituted amino groups into aromatic rings. The 
proposed catalytic cycle is shown in Scheme 1.14: 
 
L2Pd(0)
Pd
L
L
Ar X
Pd
L
Ar
L
N
oxidative
addition
  transmetalation 
and isomerization
   reductive
  elimination
46 47
48
50
51
49
Ar-X
HN
R1
R2
HX
R2
R1
N
R1
R2
Ar
 
 
Scheme 1.14 Catalytic cycle of the Buchwald-Hartwig amination 
 
 
Some useful examples [56, 57] are shown in Scheme 1.15:  
 
N
Cl
N
N
O
O
H
N Pd2(dba)3, ligand
t-BuOK, dioxane+
O Br O NPh2+
Ph2NH
Pd(OAc)2, t-Bu3P
t-Bu-ONa, o-xylene
52
53
(a)
(b)
85 %
100 %
 
 
Scheme 1.15 Examples of the Buchwald-Hartwig amination 
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1.3.2 Pd-catalyzed cross-coupling reactions of heterocycles 
 
1.3.2.1 The characteristics and importance of Pd-catalyzed cross-coupling reactions of 
heterocycles 
 
The applications, in which the palladium chemistry is used for the synthesis of heterocycles, 
have increased exponentially. Several review articles summarize the development of 
palladium chemistry in the synthesis of heterocyclic products [58-62]. The importance of 
these reactions is shown below: 
 
(1) A myriad of heterocycles are biologically active and therefore of paramount importance to 
medicinal and agricultural chemists. Many heterocycle-containing natural products have 
elicited great interest from both academic and industrial research groups. Today palladium-
catalyzed cross-coupling reaction is the common method to the synthesis of a wide range of 
fine chemicals, pharmaceutical intermediates and active pharmaceutical ingredients. 
In addition, palladium-mediated polymerisation of heterocycles is extensively used in material 
chemistry. Heterocycles are also important as ligands in coordination chemistry of palladium  
 
(2) Palladium chemistry involving heterocycles has its unique characteristics stemming from 
the heterocycles’ inherently structural and electronic properties in comparison with the 
corresponding carbocyclic aryl compounds. 
 
One example illustrating the striking difference in reactivity between a heteroarene and a 
carbocyclic arene is called “heteroaryl Heck reaction”, which is defined as an intermolecular 
or intramolecular Heck reaction occurring onto heteroaryl recipient. Intermolecular Heck 
reaction of carbocyclic arenes as the recipients are rare, whereas heterocycles including 
thiophenes, furans, thiazoles, oxozoles, imidazoles, pyrroles and indoles, etc. are excellent 
substrates. For instance, the heteroaryl Heck reaction of 2-chloro-3,6-diethylpyrazine and 
benzoxazole occurred at the C(2) position of benzoxazole to elaborate the  
pyrazinylbenzoxazole 54 [63] (Scheme1.16 ).  
 
Chapter 1: Introduction 
_________________________________________________________________________________________________________________________________ 
 
16
 
N
N
Cl
N
N
O
N N
O
+
Pd(PPh3)4
KOAc
DMA, reflux
65 %
54  
 
Scheme 1.16 Intermolecular heteroaryl Heck reaction 
 
The second salient feature of heterocycles is the marked activation at position α- and γ- to the 
heteroatom. For N-containing 6-membered heterocycles, the presence of N-atom polarizes the 
aromatic ring, thereby activating α and γ positions, making them more prone to nucleophilic 
attack. The order of SNAr displacement of heteroaryl halides with EtO- is: 
 
4-chloropyrimidine > 2-chloroquinoline > 2-chloropyridine >> chlorobenzene 
7×105 3×102 1  
 
There is certain similarity in the order of the reactivities between SNAr displacement reactions 
and oxidative additions in palladium chemistry. Therefore, the ease with which the oxidative 
addition occurs for these heteroaryl chlorides has a comparable trend. Even α- and γ-chloro-
N-heterocycles are sufficiently activated for Pd-catalyzed reactions, whereas chlorobenzene 
requires sterically hindered, electron-rich phosphine ligands. 
 
As a consequence of α and γ activation of di- or trihaloheterocycle, Pd-catalyzed chemistry 
may take place regioselectively at the more activated position. This phenomenon is rarely 
seen in carbocyclic analogues.  
 
 
1.3.2.2. Regioselective Pd-catalyzed cross-coupling of heterocycles 
 
Regioselectivity of reactions are very interesting and also very important in organic synthesis, 
especially in the synthesis of heterocycles. In this way, a functional group can be introduced 
to the desired position of a substrate. There are a lot of regioselective reactions involving Pd-
catalyzed cross-coupling of heterocycles.  
 
In polyhalo-pyrimidines, the 4-position is more active than 2-position, allowing regiospecific 
Pd-catalyzed coupling at 4-position. The reaction of 2,4-dichloropyrimidine and 
styrylstannane first preceeded regiospecifically at C(4), giving rise to 55, which was 
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subsequently coupled with phenylstannane at C(2), under more forcing conditions to afford 
disubstituted pyrimidine 56 [64]. 
 
N
NPh
N
N
Cl
Cl
Ph
N
NCl
Ph
Ph
SnBu3
Pd(PPh3)2Cl2, DMF
70 °C, 7 h, 74 %
Pd(PPh3)2Cl2, DMF
130°C, 15 h, 54 %
PhSnBu3
55 56  
 
Scheme 1.17 Synthesis of 2,4-disubstituted pyrimidine  
 
 
In Pd-catalyzed cross-coupling of polyhalopyridines, the 2-position is more active than 4-
position and 3-position. For example, the Suzuki reaction of 2,4-dichloropyridine [65] and the 
carbonylation reaction of 2,3-dichloro-5-methoxypyridine occurred regioselectively at 2-
position [66].  
 
NCl
Cl
N
+
N
Pd(PPh3)4, THF
BEt2
aq. K2CO3, reflux
57 % N
Cl
58
N
Pd(PPh3)2Cl2, dppf
Cl
ClMeO
N CO2Me
ClMeO
+ CO
(15 bar) MeOH, AcONa, 145 °C
3 h, 94 %
59
 
 
Scheme 1.18 Regioselective Pd-catalyzed  
cross-couplings of polyhalopyridine 
 
 
The positional preference can be overridden by choosing different leaving groups. Thus, the 
iodo-substituted position is more active than the chloro-substituted position. When 2-chloro-
3-iodopyridine reacts with 4-methylaniline, catalyzed by Pd(OAc)2, the amino group was 
introduced to 3-position [67]. Similarly, the reaction of 2-chloro-5-iodopyridine with an olefin 
took place at 5-position [68, 69].  
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N Cl
I
N Cl
NH
+
NH2
Pd(OAc)2, BINAP
Cs2CO3, toluene
reflux, 52 %
N
I
Cl
N
NCO2Me
+
NCl
Pd(OAc)2(PPh3)2, DMF
piperidine, HCO2H
70 °C, 65 h, 35 %
60
61
CO2Me
(a)
(b)
 
Scheme 1.19 Regioselective Pd-catalyzed cross-coupling of halopyridines  
 
Facing the vast variety of heterocyclic compounds, the aspect of reactivity and 
regioselectivity of Pd-catalyzed cross-coupling reactions of heterocycles is still a weakly 
explored and important field of organic synthesis. We tried to employ these reactions in the 
synthesis of new calcineurin inhibitors with the general structure 8. Either the aryl groups or 
the fuctionalized side chains can be introduced into the central heterocycles in this way. 
 
 
1.3.3 Prospected application of Pd-catalyzed cross-coupling to the synthesis of new 
calcineurin inhibitors 
 
1.3.3.1 Introducing aryl groups to the heterocycles 
 
There are a lot of ways to introduce aryl groups to the heterocycles, for example, Suzuki 
coupling, Negishi coupling, Kumada coupling, Hiyama coupling, etc. The most important and 
most effective reaction is the Suzuki reaction, using aromatic halides cross-coupling with aryl 
boronic acid. Some examples [70, 71] which are interesting to our project are shown in 
Scheme 1.20:  
N NH2
BrBr
N NH2
ArAr2 ArB(OH)2
Pd(PPh3)2Cl2
Na2CO3,toluene
   MeOH-H2O
63
N
N N
N
Bn
Cl
N
N N
N
Bn
Ar
ArB(OH)2
Pd(PPh3)4
K2CO3, Toluene
62
(a)
(b)
62-95 %
71 % Ar = 4-MeO-Phenyl 
 
Scheme 1.20 Introducing aryl groups to heterocycles by Suzuki couplings 
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1.3.3.2 Introducing the functionalized side chains 
 
In the establishment of calcineurin inhibiting assemblages of the general structure 8, the 
introduction of the functionalized side chains is often the key step to the target molecules. The 
application of Pd-catalyzed cross-coupling reactions envisaged for these synthetic 
transformations is shown by the following protocols. When the side chain contains π-bond, it 
should be possible to transform it into saturated side chain by reduction or hydrogenation. 
 
 
(1) Using Heck cross-coupling 
 
Designed synthetic strategy: 
 
Het-X
CO2Me
N
Het
CO2Me
NHet
Het
CH2OH
Het
CH2NH2
reduction or
hydrogenation
64 65
66 67
( Het-X are halo-heterocycles
  X is Cl, Br or I )
reduction or 
hydrogenation
Pd catalyst
Pd catalyst
 
 
Scheme 1.21 Introducing side chains by the Heck coupling 
 
 
 
(2) Using Sonogashira cross-coupling 
 
Designed synthetic strategy: 
 
 
Het-X
CH2NR1R2
(CH2)nOH
CH2NR1R2Het Het (CH2)3NR1R2
(CH2)nOH
Het Het (CH2)n+2OH
( n = 1 - 4 )
68 69
70 71
reduction or 
hydrogenation
reduction or
hydrogenation
Pd catalyst
Pd catalyst
 
 
Scheme 1.22 Introducing side chains by the Sonogashira coupling 
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(3) Using Suzuki cross-coupling 
 
Designed synthetic strategy: 
 
R
9-BBN
R = NHTr, OTr, NPhth
Het--X
Het (CH2)3-R
R = OH, NH2
B R
72 73
Pd catalyst
 
 
Scheme 1.23 Introducing side chains by the Suzuki coupling 
 
 
(4) Using Negishi cross-coupling 
 
Designed synthetic strategy: 
 
Het X
Pd catalyst
BrZn (CH2)n R
Het (CH2)n R
R = CO2Et, CN, Cl
n = 3-5
Het (CH2)n R'
R' = OH, NH2, NR1R2
n = 3-6
74 75
substitution
or reduction
 
 
Scheme 1.24 Introducing side chains by the Negishi coupling 
 
 
(5) Using Buchwald-Hartwig amination  
 
Designed synthetic strategy: 
 
reduction
Het X
R1NH(CH2)nNR2R3
R1NH(CH2)nR
N(CH2)nNR2R3HetPd catalyst
Pd catalyst
R1
N(CH2)nRHet
R1
N(CH2)nR'Het
R1
R1,R2, R3 = H, alkyl, aryl
R1 = H, alkyl, aryl ; n = 2 - 5;
R = CO2Et, CN; R' = OH, NH2
n = 2 - 5
76
77 78
 
Scheme 1.25 Introducing side chains by the Buchwald-Hartwig amination  
 Chapter 2: Pyrazolo[1,5-a]pyrimidine derivatives 
 
 
2.1 Introduction 
 
Pyrazolo[1,5-a]pyrimidines are purine analogues and have useful properties as antimetabolites 
in purine biochemical reactions. Compounds of this class have attracted wide pharmaceutical 
interest because of antitrypanosomal activity [72], antischistosomal activity [73]. They are 
used as HMG-CoA reductase inhibitors [74], COX-2-selective inhibitors [75], AMP 
phosphodiesterase inhibitors [76], KDR kinase inhibitors [77], selective peripheral 
benzodiazepine receptor ligands [78], and antianxiety agents [79]. These interesting biological 
properties initiate activities to develop new efficient general procedures for the synthesis of 
pyrazolo[1,5-a]pyrimidine derivatives. 
N
N N 1
2
34
5
6
7
pyrazolo[1,5-a]pyrimidine 
 
Pyrazolo[1,5-a]pyrimidine is composed of a pyrimidine ring and a pyrazole ring. The 
pyrimidine part is π-electron deficient, so the nucleophilic displacement takes place more 
readily. The 7-position is more active than the 5-position. The pyrazole part is π-electron 
excessive, and can readily undergo electrophilic substitution.  
Although cross-coupling reactions have been extensively used in organic synthesis of 
heterocyclic compounds, to the best of our knowledge, only a few publications are devoted to 
cross-couplings of pyrazolo[1,5-a]pyrimidines. Shiota and Yamamori [80] reported the 
regioselective coupling of organzinc reagents 80 with 5,7-dichloropyrazolo[1,5-a]pyrimidine 
79. When the reaction was catalyzed by lithium chloride, the 7-substituted product 81 was 
obtained, while catalysis by Pd(PPh3)4 afforded  the 5-substituted product 82. By further 
Pd(PPh3)4 catalyzed reaction of 81 or 82 with phenylboronic acid, phenyl groups could be 
introduced into 5-position or 7-position respectively. (Scheme 2.1)  
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N
N N
Cl
Cl
N
N N
Cl
Pd(PPh3)4
DMF, RT
52 %
7
5
3
2
Ar
N
N N
Cl
Ar
N
N N
Ph
Ar
Pd(PPh3)4
Pd(PPh3)4 N
N N
Ph
Ar
PhB(OH)2
PhB(OH)2
LiCl
52 %
( Ar: 2'-Cyano-biphenyl-4-yl)
90 %
77 %
79
81 83
82 84
ArCH2ZnBr
     (80)
ArCH2ZnBr
     (80)
 
Scheme 2.1 Regioselective cross-coupling reactions of organzinc reagent with 5,7-
dichloropyrazolo[1,5-a]pyrimidine 
 
Kumar [81] reported the synthesis of 3-aryl-7-diethylamino-pyrazolo[1,5-a]pyrimidines 85 by 
Suzuki coupling of 3-bromopyrazolo[1,5-a]pyrimidines. Fraley reported the Suzuki cross-
coupling reactions of 3-bromo-6-arylpyrazolo[1,5-a]pyrimidines [82] and 6-bromo-3-aryl- 
pyrazolo[1,5-a]pyrimidines [76] and obtained products 86 and 87, respectively.(Scheme 2.2)  
N
N N
NEt2
Pd(PPh3)2Cl2ArB(OH)2
20-55 %
+
2 M NaOH
DME-H2O
Br
N
N N
NEt2
Ar
85
86
N
N N Pd(PPh3)4ArB(OH)2
40-60 %
+ Na2CO3
dioxane, reflux
Br
Ar'
N
N N
Ar
Ar'
87N
N N
Pd(PPh3)4
74 %
+ Na2CO3
dioxane, reflux
Br
N O
B
OO
S
N
N N
S
N
O
 
Scheme 2.2 Suzuki corss-coupling of bromopyrazolo[1,5-a]pyrimidines 
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We envisaged the synthesis of calcineurin-inhibiting compounds with the general structure 8 
with the pyrazolo[1,5-a]pyrimidine system as the core heterocycle. They would be 
synthesized by Pd-catalyzed cross-coupling reactions of halo-pyrazolo[1,5-a]pyrimidines. 
Routes to the starting materials are described in the following chapters. Since the reactivity of 
halo-leaving groups in Pd-catalyzed cross-coupling reactions drop in the sequence of I > Br 
>> Cl, we preferred to start with iodo- or bromo-pyrazolo[1,5-a]pyrimidines, but the chloro-
compounds were also included. 
 
 
2.2 Synthesis of substituted pyrazolo[1,5-a]pyrimidines 
2.2.1 Synthesis of pyrazolo[1,5-a]pyrimidines by ring closure  
 
The pyrazolo[1,5-a]pyrimidine skeleton is usually prepared by condensation of 3-amino-
pyrazoles or 4-amino-pyrazoles with 1,3-diketones, using hydrochloric acid [83], acetic acid 
[84], ethanol [85, 86], or ethanol/hydrochloric acid as solvent. We synthesized a series of 
substituted pyrazolo[1,5-a]pyrimidine derivatives 88a-88h and 89a-89c in this way. (Scheme 
2.3 and Table 2.1) 
 
  R1= H, CH3,
     Ph, 4-ClPh
N
N
H
NH2
R
N
N
H
NH2
Ph
N
N N
R3
R2
R1R2 R3
O O
+
R2,R3= CH3, Ph,
             4-ClPh
H+
88a-88h
+ R1 R2
O O
H+
N
N N
R2
R1
Ph
89a, R1=R2=CH3
89b, R1=CH3, R2=Ph
89c, R1= R2=Ph
66-89 %
75-86 %
 
 
Scheme 2.3 Synthesis of substituted pyrazolo[1,5-a]pyrimidines 
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Table 2.1 Pyrazolo[1,5-a]pyrimidines 88 and 89 
Product R1 R2 R3 Yield (%)       Mp (°C) 
88a   Ph Me Ph 89 185-186 (EtOH)  
88b 4-Cl-Ph Me Ph 66 156-158 (EtOH) 
88c Me Ph Ph 74 113-114 ( EtOH/hexane)  
88d Ph Me 4-Cl-Ph 77 155-117 (EtOH) 
88e Me Me Ph 78 81-82 (EtOH)  
88f Me Me Me 68 69-70 (hexane/Et2O)  
88g Ph Ph Ph 77 154-155 (EtOH)  
88h H Ph Ph 89 85-86 (EtOH) 
89a Me Me  75 91-2 (EtOH/hexane) 
89b Me Ph  86 124-5 (EtOHl) 
89c Ph Ph  86 163-4 (EtOH) 
 
 
In an analogous manner, mono- or dihydroxy-pyrazolo[1,5-a]pyrimidines *** were 
synthesized by using β-ketoesters or malonates instead of 1,3-diketones, e.g., 3-amino-4-
phenylpyrazole was reacted with ethyl benzoylacetate, using acetic acid as solvent, affording 
the 2,5-diphenyl-7-hydroxypyrazolo[1,5-a]pyrimidine 90 [73]. 3-Amino-4-phenylpyrazole 
was reacted with diethyl malonate, using EtONa as base to obtain 3-phenyl-5,7-
dihydroxypyrazolo[1,5-a]pyrimidine 91 [87]. 3-Amino-5-methylpyrazole reacted with ethyl 
acetoacetate and diethyl malonate giving 2,5-dimethyl-7-hydroxy-pyrazolo[1,5-a]pyrimidine 
92 [88] and 2-methyl-5,7-dihydroxypyrazolo[1,5-a]pyrimidine 93 [87], respectively. (Scheme 
2.4) 
 
*** In fact, there are two tautomers in these hydroxypyrazolo[1,5-a]pyrimidines: pyrazolo[1,5-
a]pyrimidone and hydroxypyrazolo[1,5-a]pyrimidine, moreover, pyrazolo[1,5-a]pyrimidone is the 
main structure, we wrote and named these compounds here hydroxypyrazolo[1,5-a]pyrimidines for 
convenience and simplifying. 
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N
N
H
NH2
Ph
+ Ph OEt
O O HOAc
N
N N
OH
Ph
90
Ph
N
N
H
NH2
Ph
+
EtO OEt
O O
EtONa/EtOH
N
N N
OH
HO
91
Ph
N
N
H
NH2 OEt
O O
EtO OEt
O O
N
N
H
NH2
N
N N
OH
92
N
N N
OH
HO
93
reflux
HOAc
reflux+
+ EtONa/EtOH
74 %
48 %
71 %
82 %  
 
Scheme 2.4 Synthesis of hydroxypyrazolo[1,5-a]pyrimidines 
 
 
 
 
2.2.2 Halogen substituted pyrazolo[1,5-a]pyrimidines 
 
There are three principal ways to prepare halopyrazolo[1,5-a]pyrimidines: 
a) cyclisation of halogen-containing open chain precursors.  
b) nucleophilic substitution of hydroxyl groups of pyrazolo[1,5-a]pyrimidines by 
halogen.  
c) electrophilic substitution of H-atoms of pyrazolo[1,5-a]pyrimidines by halogen.  
 
Using bromine or NBS as bromating agent, 1,3-diketones are readily brominated at the active 
CH2 position [89, 90]. By further treatment with 3-aminopyrazoles, new 6-bromo-
pyrazolo[1,5-a]pyrimidines 95 and 97 could be obtained by ring closure route (a). (Scheme 
2.5) 
 
 
 
Chapter 2: Pyrazolo[1,5-a]pyrimidine derivatives 
_________________________________________________________________________________________________________________________________ 
 
26
N
N
H
NH2
Ph
Ph
O O
HOAc, reflux N
N N
Ph
95
N
N
H
NH2
O O
N
N N
97
O O
NBS
CCl4
Br
Br
Ph
O O
Br
Br
Br2
HOAc, reflux
94
96
Ph70 %
89 %
 
 
Scheme 2.5 Synthesis of 6-bromo-pyrazolo[1,5-a]pyrimidines 
 
 
Following the SN-route (b) for halopyrazolo[1,5-a]pyrimidines, 2,5-diphenyl-7-hydroxy-
pyrazolo[1,5-a]pyrimidine 90 was refluxed with POCl3 or POBr3, using N, N-dimethylaniline 
as catalyst. The corresponding 7-Cl [74] and 7-Br substituted pyrazolo[1,5-a]pyrimidine 
products, 98 and 99, could be obtained in high yields. 2,5-Diphenyl-7-chloro-pyrazolo[1,5-
a]pyrimidine 98 reacted with 57 % hydroiodic acid in a subsequent SN-reaction providing the 
corresponding 7-iodopyrazolo[1,5-a]pyrimidine 100. (Scheme 2.6) 
 
N
N N
OH
Ph
90
Ph
reflux
N
N N
Cl
Ph
Ph
N
N N
I
Ph
Ph
N
N N
Br
Ph
Ph
POCl3
POBr3
toluene, reflux
57 % HI
98
99 100
N,N-dimethylaniline
N,N-dimethylaniline
98 %
96 % 95 %
 
 
Scheme 2.6 Synthesis of 7-halo-2,5-diphenylpyrazolo[1,5-a]pyrimidines 
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The structure of the new products 98, 99, 100 and 120 (also see page 39), were confirmed by 
NMR-data. It is worth mentioning that the compound 120 exhibits a strong up field shift of 
the H-6 signal as compared with its isomer 98. Furthermore a strong effect of the halo-
substituents was observed on the 13C-signal of position C-6, within the series 98, 99, and 100. 
Some NMR data of these compounds are shown in Table 2.2: 
 
Table 2.2 NMR data of of compounds 98, 99, 100 and 120 (δ, ppm) 
 
 120 98 99 100 
H-6 6.80 7.49 7.61 7.86 
H-2 8.38 8.53 8.52 8.51 
Ph-H 7.18-7.96 7.25-8.17 7.25-8.16 7.25-8.12 
C-6 108.80 105.58 109.72 117.45 
C-7 144.70 139.03 128.99 103.94 
C-2 143.40 143.54 143.28 142.60 
C-3 110.82 112.31 112.46 112.79 
C-4 148.35 145.81 145.30 143.30 
C-5 150.70 155.65 155.16 154.47 
 
N
N N
R7
R5
2
R3
7
6
5 3
1
4
8
9
             R3     R5     R7
120   Ph    Cl      Ph
 98    Ph    Ph      Cl
 99    Ph    Ph      Br
100   Ph    Ph       I  
 
 
5,7-Dihydroxy-3-phenylpyrazolo[1,5-a]pyrimidine 91 and 5,7-dihydroxy-2-methyl-
pyrazolo[1,5-a]pyrimidine 93 could be transformed into the corresponding 5,7-dichloro-
pyrazolo[1,5-a]pyrimidines 101 [91] and 102 [92], respectively, by refluxing in POCl3 in the 
presence of N,N-dimethylaniline. (Scheme 2.7) 
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93
POCl3
N,N-dimethylaniline
reflux
N
N N
Cl
Cl
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Ph
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POCl3
N,N-dimethylaniline
reflux
53 %
57 %
 
 
Scheme 2.7 Synthesis of 5,7-dichloro- pyrazolo[1,5-a]pyrimidines 
 
 
Following the route (c), i.e. to introduce halogen by electrophilic substitution of H-atoms, 
substituted pyrazolo[1,5-a]pyrimidine 88a was treated with NBS, using CCl4 as solvent under 
reflux. The substituted 3-bromopyrazolo[1,5-a]pyrimidine 103 was obtained in good yield. 
88a-88h reacted with NIS [93] in THF under reflux providing substituted 3-iodopyrazolo[1,5-
a]pyrimidines 104a-104h. (Scheme 2.8, Table 2.3) 
 
N
N N
Ph
Me
Ph
103
N
N N
Ph
Me
Ph
88a
NBS/CCl4
Br
N
N N
R3
R2
R1
104a-104h
N
N N
R3
R2
R1
88a-88h
NIS/THF
I
reflux
reflux
87 %
45-90 %
 
 
Scheme 2.8 Synthesis of 3-halopyrazolo[1,5-a]pyrimidines 
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Table 2.3 3-Iodopyrazolo[1,5-a]pyrimidines 104a-104h 
 
Product R1 R2  R3 Yield (%) Mp (°C) 
104a Ph Me Ph 70 164-166 (EtOAc) 
104b 4-Cl-Ph Me Ph 69 166-168 (EtOAc) 
104c Me Ph Ph 78 138-140 (EtOAc) 
104d Ph Me 4-Cl-Ph 83 63-65 (EtOAc) 
104e Me Me Ph 63 90-91 (EtOAc) 
104f Me Me Me 45 132-133 (EtOAc) 
104g Ph Ph Ph 81 202-203 (EtOAc) 
104h H Ph Ph 90 160-161 (EtOAc) 
 
 
We further chose a pyrazolo[1,5-a]pyrimidine compound, where the halo leaving group was 
found in a alkyl substituent, allowing uncatalyzed nucleophilic substitutions with substituted 
amines to introduce the functionalized side chain. 5-Methyl-3,7-diphenylpyrazolo[1,5-
a]pyrimidine 89b reacted with NBS in the presence of AIBN using CCl4 as solvent under 
reflux. 5-Brromomethyl-3,7-diphenylpyrazolo[1,5-a]pyrimidine 105 was obtained. (Scheme 
2.9) 
 
N
N N
Ph
Ph
N
N N
Ph
Ph
Br
89b 105
NBS, CCl4
AIBN, reflux, 58 %
 
 
Scheme 2.9 Synthesis of 5-bromomethyl- 
3,7-diphenylpyrazolo[1,5-a]pyrimidine 
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2.3 Heck cross-coupling of pyrazolo[1,5-a]pyrimidines 
 
2.3.1 Heck cross-coupling of 3-halopyrazolo[1,5-a]pyrimidines 
 
Heck cross-coupling reaction has shown great versatility in the construction of carbon-aryl 
bonds [94, 95]. Pd(PPh3)2Cl2 [bis(triphenylphosphino)palladium(II) chloride] and Pd(OAc)2 
are usually used as catalysts. Therefore, we tried to apply this useful reaction to introduce 
alkene moieties with a terminal O- or N-containing functional group into pyrazolo[1,5-
a]pyrimidines, allowing subsequent reduction to hydroxyl or aminoalkyl side chains. 
 
3-Bromo-5-methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidine 103 was treated with methyl 
acrylate, using Pd(PPh3)2Cl2 as catalyst, triethylamine as base, acetonitrile as solvent under 
argon. No reaction took place, even at refluxing temperature. But using the same conditions, 
treatment of the corresponding iodo-compounds 104 with monosubstituted alkenes, such as 
methyl acrylates, acrylonitrile, or styrene, provided the anticipated coupling products 106-109 
in high yields (Scheme 2.10 and Table 2.4). These products possess E-configuration, 
according to 1H-NMR spectra (CH=CH, J = 15-19 Hz). 
 
N
N N
Ph
Ph
Br
N
N N
R3
R2
R1
I
N
N N
R3
R2
R1
N
N N
Ph
Ph
O
O
R4
Pd(PPh3)2Cl2
Et3N, MeCN
argon, reflux
O
O
+
R4
+
Pd(PPh3)2Cl2
Et3N, MeCN
argon, reflux
 106a-h,  R4 = CO2Me,
 107a-c,  R4 = CN, 
 108,  R1 = H,  R2 = R3 = R4 = Ph,
 109,  R1 = H,  R2 = R3 = Ph,
          R4 = CO2CH2CH2NMe2
103
104
106a
( E )
 
 
Scheme 2.10 Heck cross-coupling of 3-halopyrazolo[1,5-a]pyrimidines with 
mono-substituted alkenes 
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Table 2.4 Pyrazolo[1,5-a]pyrimidines 106-111 
 
Product R1 R2 R3 R4 Yield (%)  Mp (°C) 
106a Ph Me Ph CO2Me 91 155-156  
106b 4-Cl-Ph Me Ph CO2Me 93 149-151 
106c Me Ph Ph CO2Me 94 164-165 
106d Ph Me 4-Cl-Ph CO2Me 89 162-164 
106e Me Me Ph CO2Me 90 194-196 
106f Me Me Me CO2Me 62 173-175 
106g Ph Ph Ph CO2Me 90 215-216  
106h H Ph Ph CO2Me 86 134-135 
107a Ph Me Ph CN 52 206-208 
107b 4-Cl-Ph Me Ph CN 43 180-182  
107c Me Ph Ph CN 79 164-165 
108 H Ph Ph Ph 36 174-176  
109 H Ph Ph CO2CH2- 
CH2NMe2 
57 glassy 
material 
 
 
Using the same conditions, treatment of 104e or 104h with di-substituted alkenes such as 
methyl methylacrylates, or methyl crotonate, gave only low yields of coupling products 110 
and 111, respectively. Remarkably, the Z-isomers were formed in these cases, according to 
NOE spectra, where NOEs were observed between =C-H and =C-CH3 or =C-CH2. (Scheme 
2.11) 
N
N N
Ph
I
N
N N
Ph
Ph
I
N
N N
Ph
Pd(PPh3)2Cl2
Et3N, MeCN
argon, reflux
O
O
+
+
Pd(PPh3)2Cl2
Et3N, MeCN
argon, reflux
111
104e
104h
110
O
O
O
O
H
O
O
N
N N
Ph
Ph
H
CH2CO2Me
O
O
27 %
14 %
 
Scheme 2.11 Heck reactions of 3-iodopyrazolo[1,5-a]pyrimidines with di-substituted alkenes 
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Attempts to use dimethyl maleate or dimethyl fumarate as alkenes in Heck reaction of 3-
iodopyrazolo[1,5-a]pyrimidines 104 failed, as did the reaction with acrolein diethyl acetal 
(3,3-diethyl-1-propene).  
 
2.3.2 Heck cross-coupling of 7-iodopyrazolo[1,5-a]pyrimidine 
 
Attempts to use 7-iodo-3,5-diphenylpyrazolo[1,5-a]pyrimidine to undergo Heck cross-
coupling reactions with methyl acrylate, using several kinds of reaction conditions were 
unsuccessful. Only unchanged starting materials were isolated. (Scheme 2.12) 
 
N
N N
I
Ph
Ph
100
N
N N
Ph
Ph
O O
+
Heck reaction
112
CO2Me
 
 
Reaction conditions: 
a) Pd(PPh3)Cl2, Et3N, CH3CN, 80°C, 24 h  
(b) Pd/C, Et3N, 80°C, 24 h 
(c) Pd(OAc)2, Et3N, 80°C, 24 h 
(d) Pd(OAc)2, P(o-tolyl)3, Et3N, CH3CN, 100°C, 24 h  
 
Scheme 2.12 Heck cross-coupling reaction of 100 
 
It seems that position 7 of the pyrazolo[1,5-a]pyrimidine is not active enough to undergo 
Heck coupling. However, in Suzuki coupling, it turns out to be possible to act as reactant (see 
Scheme 2.17, page 39). 
 
 
2.4 Sonogashira cross-coupling of halopyrazolo[1,5-a]pyrimidines 
2.4.1 Sonogashira cross-coupling of 3-iodopyrazolo[1,5-a]pyrimidines 
(a) Pd/C as catalyst 
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3-Iodo-5-methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidine 104a was first chosen as staring 
material in cross-coupling with propargyl alcohol in several kinds of catalytic systems. The 
homogeneous catalytic systems of Pd(PPh3)2Cl2, Pd(PPh3)4, and Pd(OAc)2 were not active 
enough and failed or provided only low yields of coupling product. But using Pd/C as 
heterogeneous catalyst, CuI as co-catalyst, PPh3 as ligand, K2CO3 as base in DME/water, it 
turned out to be more effective. The optimization of reaction conditions are shown in Table 
2.5. 
 
Table 2.5 Effect of reaction conditions of Sonogashira cross-coupling 
N
N N
Ph
Ph
I
N
N N
Ph
Ph
OH
Pd catalyst
base
Solvent, 24 h
OH
104a
113g
+
 
 
 
Entry 
 
Catalyst 
 
Base 
 
Solvent 
 
Temperature 
 
Yield (%) 
      
1 Pd(PPh3)2Cl2, CuI Et3N MeCN RT 9 
2 Pd(PPh3)2Cl2, CuI (i-Pr)2NEt CH2Cl2 RT 14 
3 Pd(OAc)2, PPh3, 
Bu4NHSO4 
Et3N MeCN-H2O RT 27 
4 Pd(PPh3)2Cl2, CuI Et3N Et3N-DMF 50°C 50 
5 Pd(PPh3)2Cl2, CuI Et3N Et3N 80°C 0 
6 Pd(PPh3)2Cl2, CuI Et3N DMF-Et3N 100°C 0 
7 Pd(PPh3)4, CuI, Et3N  Et3N-DMF 50°C 43 
8 Pd(PPh3)2Cl2, CuI Et2NH Et2NH 50°C 40 
9 10% Pd-C, CuI, PPh3 K2CO3 DME-H2O 80°C 72 
 
 
Pd/C is one of the most common heterogeneous palladium catalysts, and many recent reports 
have demonstrated it is a convenient, inexpensive, reusable, and highly active catalyst [96]. 
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Pd/C catalyst is widely used in Suzuki-Miyaura coupling [97], Heck coupling [98], and 
Sonogashira coupling [99]. Using Pd/C catalyst in aqueous media, substituted 3-iodo-
pyrazolo[1,5-a]pyrimidines 104a-104d, 104h were successfully coupled with N,N-
dimethylpropargyl amine, propargyl alcohol, and 3-butyn-1-ol (see Table 2.6).  
 
Table 2.6 Pd/C catalyzed Sonogashira reactions of 3-iodo-pyrazolo[1,5-a]pyrimidines 
 
N
N N
R3
R1
R2
I
N
N N
R2
R1
R3
R
10% Pd-C
CuI, PPh3
DME-H2O
Ar, 80 °C
R
104a-d, 104h
113a-j
K2CO3
+
 
 
 
Product 
 
R1 
 
R2 
 
R3 
 
R 
 
 
Yield (%) 
113a Me Ph  Ph CH2NMe2 76 
113b H Ph Ph CH2NMe2 91 
113c Ph Me Ph CH2NMe2 70 
113d p-Cl-Ph Me Ph CH2NMe2 69 
113e Ph Me p-Cl-Ph CH2NMe2 54 
113f H Ph Ph CH2OH 78 
113g Ph  Me  Ph CH2OH 72 
113h Ph Me Ph CH2CH2OH 71 
113i H Ph Ph CH2CH2OH 75 
113j Me Ph Ph CH2CH2OH 70 
 
 
104a reacted with 3-butynyl p-toluenesulphonate to give only 18 % yield of the desired 
product 113k. However, 36 % yield of the 3-but-3-en-1-ynyl substituted pyrazolo[1,5-a]-
pyrimidine 114 was isolated as major product. Under the same reaction conditions, the 
reaction of the 3-iodo pyrazolo[1,5-a]pyrimidine 104h with 3-amino-phenylacetylene, did not 
result in the desired product, but a homo-coupling (Glaser coupling) product 115 in high yield 
(Scheme 2.13). Obviously, two hydrogen atoms were removed, although there is no definite 
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dehydrogenating agent in the reaction systems. This unusual result was independently found 
by Faivlamb [100]. Mechanistic explanation is not on hand yet. When the experiment was 
repeated under the same conditions without 104h, the diyne 115 was isolated only 74 %. The 
result indicated that 104h accelerated the home-coupling of 3-amino-phenylacetylene. 
 
Ph
N
N N
Ph
Ph
I
N
N N
Ph
Ph
10% Pd/C
CuI, PPh3
DME-H2O
Ar, 80 °C
104a
K2CO3
+
OTs
N
N N
Ph
OTs
+
113k (18%) 114 (36%)
N
N N
Ph
Ph
I
+
NH2 10% Pd/C
CuI, PPh3
DME-H2O
Ar, 80 °C
K2CO3
H2N NH2
104h 115 (100 %)  
 
Scheme 2.13 
 
 
113a and 113b were hydrogenated with H2, catalyzed by 10 % Pd/C in ethanol at room 
temperature and atmosphere pressure. The desired target products 116a, and 116b were 
isolated in modest yields (Scheme 2.14).  
 
N
N N
Me2N
N
N N
Me2N
Ph
Ph
R1
Ph
Ph
R1
10 % Pd/C, H2
Ethanol, RT
113a, R1=Me
113b, R1=H
116a, R1=Me, 37%
116b, R1=H, 40%  
 
Scheme 2.14 Catalytic hydrogenations of 113a and 113b 
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Attempts to use Pd/C catalyst to undergo cross-coupling of 3-iodo-pyrazolo[1,5-a]pyrimidine 
104h with N-methylpropargylamine, propargylamine or N-propargyl-phthalimide, were 
unsuccessful. Therefore, other catalytic systems were tested for these cases. 
 
 
(b) Other conditions for Sonogashira reactions of 3-iodo-pyrazolo[1, 5-a]pyrimidine 
3-Iodo-pyrazolo[1,5-a]pyrimidine 104a reacted with (4-ethynyl-phenyl)-N,N-dimethylamine, 
using Pd(PPh3)2Cl2 as catalyst (no CuI) in a solution of piperdine at 80 °C for 24 h, 44 % of 
coupling product 117 was isolated. On the other hand, using Pd(PPh3)2Cl2 and CuI as catalyst 
in a solution of Et3N and DMF at 50°C, it turned out to be suitable for the coupling of 3-iodo-
pyrazolo[1, 5-a]pyrimidine 104c with N-propargyl-phthalamide, 36 % of the coupling product 
118 was isolated. (Scheme 2.15) 
 
N
N N
Ph
Ph
I
N
N N
Ph
Ph
104a
+
N
N N
Ph
Ph
I
+
104c
NMe2
NMe2
NPhth
N
N N
Ph
Ph
NPhth
Pd(PPh3)2Cl2
Pd(PPh3)2Cl2
piperdine
CuI
Et3N-DMF
50°C, 38%
80°C, 44 %
S-9
S-11
117
118
 
 
Scheme 2.15 
 
 
 
 
2.4.2 Sonogashira cross-coupling of 7-halopyrazolo[1, 5]pyrimidine 
 
Attempts to use 7-halopyrazolo[1,5-a]pyrimidines in Sonogashira cross-coupling reactions 
with N,N-dimethylpropargyl amine or propargyl alcohol were unsuccessful, although several 
kinds of Pd catalysts and reaction conditions were applied. Unfortunately, no definite 
products could be isolated (Table 2.7). 
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Table 2.7 Reaction conditions of Sonogashira cross-coupling 
 
N
N N
Ph
Ph
X
N
N N
Ph
Ph
R
R
Pd catalyst
119
98, 99, 100 (X= Cl, Br, I)
 
 
 
Entry 
 
Reactant, 
X 
 
 
R 
 
Reaction conditions 
 
Result 
 
1 
 
99, Br 
 
 
OH 
 
Pd(PPh3)2Cl2, CuI, Et3N, RT, 24 h 
 
NDP* 
2 99, Br NMe2 Pd(PPh3)2Cl2, CuI, Et3N, DMF, 
80°C, 24 h 
 
NDP 
3 100, I NMe2 Pd(PPh3)4, CuI, Et3N, 50°C ,24 h NDP 
4 100, I NMe2 10% Pd/C, CuI, PPh3, K2CO3, 
DME-H2O, 80°C, 24 h 
 
NDP 
5 100, I NMe2 10% Pd/C, CuI, PPh3, K2CO3, 
DME-H2O, 80°C, 24 h 
 
NDP 
6 100, I NMe2 Pd(PPh3)2Cl2, CuI, Et3N, 80°C,  
24 h 
 
NDP 
7 100, I NMe2 Pd(PPh3)2Cl2, CuI,  (i-Pr) 2NEt, 
CH2Cl2, RT, 24 h 
 
NDP 
8 98, Cl NMe2 Pd(PPh3)2Cl2, CuI, Et3N, DMF, 
100°C, 24 h 
starting 
material 
 
* NDP: no definite products 
 
 
 
 
2.5 Suzuki cross-coupling of halopyrazolo[1,5-a]pyrimidines 
 
When 5,7-Dichloro-3-phenylpyrazolo[1,5-a]pyrimidine 101 was treated with three 
equivalents of phenylboronic acid and 1.2 equivalent of potassium carbonate using toluene as 
solvent and Pd(PPh3)4 as catalyst, 3,5,7-triphenylpyrazolo-[1,5-a]pyrimidine 89c was isolated 
in 86 % yield. (Scheme 2.16)  
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Under the same conditions as above, 5,7-dichloro-3-phenylpyrazolo[1,5-a]pyrimidine 101 
was coupled with one equivalent of phenylboronic acid and afforded two isomers 98 and 120 
in a ratio of 23:54. The regio-selectivity could be increased by using 2 M aqueous Na2CO3 
and DME at lower temperature (80 °C) providing 120 in 72% yield. (Scheme 2.16) 
 
1 PhB(OH)2
Pd(PPh3)4
K2CO3, toluene,
100°C, 16 h
+
3 PhB(OH)2
Pd(PPh3)4
K2CO3, toluene,
100°C, 16 h
1 PhB(OH)2
Pd(PPh3)4
aq. Na2CO3, DME
80°C, 16 h
120 (72 %)
89c (86 %)
N
N N
Ph
Cl
Cl
101 98 (23 %)120 (54  %)
N
N N
Ph
Cl
Ph
N
N N
Ph
Ph
Cl
N
N N
Ph
Ph
Ph
N
N N
Ph
Ph
Cl
 
 
Scheme 2.16 Suzuki cross-coupling of 101 with phenylboronic acid 
 
 
 
3-Iodo-5,7-diphenylpyrazolo[1,5-a]pyrimidine 104h and 3-iodo-3,5-diphenylpyrazolo[1,5-a] 
pyrimidine 100 could be coupled with phenylboronic acid, catalyzed by Pd(PPh3)4, in the 
presence of K2CO3 in toluene to provide 3,5,7-triphenylpyrazolo[1,5-a]pyrimidine 89c in 62% 
and 99%, respectively, after 16 h at 100°C. (Scheme 2.17) 
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N
N N
I
Ph
Ph
N
N N
Ph
I
Ph
N
N N
Ph
Ph
Ph
PhB(OH)2, Pd(PPh3)4
K2CO3, toluene, 100 °C
62 %
PhB(OH)2, Pd(PPh3)4
K2CO3, toluene, 100 °C
99 %
89 c
104 h
100  
Scheme 2.17  
 
It is worth mentioning that the reactant 100 turned out to be an unsuccessful reactant to other 
Pd-catalyzed cross-coupling reactions, such as Heck coupling reaction and Sonogashira 
coupling (see chapter 2.3.2 and chapter 2.4.2). 
 
Further attempts to introduce aminopropyl or hydroxypropyl chains into the halopyrazolo-
[1,5-a]pyrimidines 104a or 99 by the help of corresponding 9-BBN derivated borane 121 
were performed. Unfortunately, Pd(PPh3)4 catalysis failed under normal reaction conditions. 
(Scheme 2.18) 
N
N N
Ph
I
Ph
N
N N
Br
Ph
Ph
+
R 9-BBN, THF, RT
Ph(PPh3)4 , THF, 
3 M NaOH, reflux
(  R = NHTr, OTr, NPhth )
99
104a
+
N
N N
Ph
CH2CH2CH2R
Ph
121a-c
121a
 121a, 
or121b,
or 121c
Ph(PPh3)4 , THF, 
3 M NaOH, reflux
N
N N
CH2CH2CH2R
Ph
Ph
122
123
BR
 
 
Scheme 2.18 
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2.6 Attempts to Buchwald-Hartwig amination and Negishi coupling of 
halopyrazolo[1,5-a]pyrimidines 
 
While 7-chloro or 7-bromopyrazolo[1,5-a]pyrimidine can easily undergo nucleophilic 
substitution with substituted amines, 3-bromo- or 3-iodopyrazolo[1,5-a]pyrimidine resists 
uncatalyzed nucleophilic substitution. 
Since 3-iodopyrazolo[1,5-a]pyrimidines could successfully be submitted to Suzuki, Heck and 
Sonagashira cross-coupling reactions, Pd-catalyzed amination (also called Buchwald-Hartwig 
amination) was advisable. Unfortunately, all attempts for Buchwald-Hartwig amination of 3-
halopyrazolo[1,5-a]pyrimidines with several kinds of substituted amines under various 
reaction conditions were unsuccessful.(Table 2.8) 
 
Table 2.8 Reaction conditions of Buchwald-Hartwig amination 
N
N N
R7
R2
R5
X
N
N N
R7
R2
R5
NRR'
amine
103: X=Br, 104: X=I 124  
 
Entry Reactants Amines  Reaction conditions Results 
1 103 H2N(CH2)3NMe2 
 
PdCl2(dppf), dppf, t-BuOK, 
dioxane 100°C, 4 days 
 
NDP 
2 104a H2N(CH2)3NMe2 
 
Pd2(dba)3, BINAP, t-BuONa, 
toluene, 100°C, 24 h 
NDP 
3 104a H2N(CH2)3NMe2 K2CO3, glycol, 140°C, 24 h NDP 
4 104a H2N(CH2)3NMe2 
 
Microwave, 180°C, 170W, 
20 min 
NDP 
5 104a H2N(CH2)3NMe2 
 
Pd2(dba)3, BINAP, t-BuONa, 
toluene, 80°C, 24 h 
NDP 
6 104h H2N(CH2)3NMe2 
 
Pd2(dba)3, BINAP, t-BuONa, 
toluene, 80°C, 4 days 
NDP 
7 104h H2N(CH2)3NMe2 
 
Pd(OAc)2, BINAP, t-BuONa, 
toluene, 100°C, 24 h 
NDP 
8 104h Morpholine Pd(OAc)2, BINAP, t-BuONa, 
toluene, 100°C, 24 h 
 
deiodoproduct
9 104h NH(n-Bu)2 Pd(OAc)2, (t-Bu)3P, t-BuONa, 
toluene, 100°C, 24 h 
deiodoproduct 
80% 
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4-Ethoxycarbonyl-butylzincbromide was envisaged to introduce an alkyl chain into 
halopyrazolo[1,5-a]pyrimidine 104a or 100, which could be reduced to a hydroxybutyl group 
later on. Again, all attempts failed, although several catalysts and different conditions were 
used. (Scheme 2.19) 
 
N
N N
Ph
I
Ph
N
N N
I
Ph
Ph
A. Ph(PPh3)4 , THF,   RT, 4 days
EtO2C(CH2)3ZnBr
B. Pd(PPh3)2Cl2,  Et2O, RT, 24 h
C. Pd(PPh3)2Cl2, THF, reflux, 20 h
EtO2C(CH2)3ZnBr
A. Ph(PPh3)4,THF,  RT, 24 h
B. Ph(PPh3)4 ,THF,  reflux, 24 h
C. DMF, LiCl, 24 h
104a
100
N
N N
Ph
(CH2)3CO2Et
Ph
Conditions:
N
N N
(CH2)3CO2Et
Ph
Ph
Conditions:
125
126
 
 
Scheme 2.19 
 
 
 
 
2.7 Pd-free synthesis of pyrazolo[1,5-a]pyrimidine derivatives 
 
2.7.1 Nucleophilic substitution of halopyrazolo[1,5-a]pyrimidine 
 
Chloroatoms adjacent to a 6-ring-N-heteroaromatics are prone to uncatalyzed nucleophilic 
substitutions by amines. Thus, we tried to introduce amino groups into 5-chloro-3,7-
diphenylpyrazolo[1,5-a]pyrimidine 120. The desired products 127 and 128 were obtained in 
good yields. (Scheme 2.20)  
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N
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Scheme 2.20 
 
The latter product 128 fits well into the pattern of envisaged calcineurin inhibitors 8, where 
the side chain is connected to the core heterocycle via a nitrogen atom. 
By benzylic-type nucleophilic subsititution at 5-bromomethyl-3,7-diphenylpyrazolo[1,5-a]-
pyrimidine 105 a further variation of the side chain was achieved, where a nitrogen atom was 
in the centre of the alkyl chain.(formation of 129, Scheme 2.21) 
N
N N
Ph
Ph
Br
N
N N
Ph
Ph
Me2N(H2C)3HN
NH2(CH2)3NMe2
RT, 6 h, 33 %
105 129  
Scheme 2.21 
 
 
2.7.2 Synthesis of pyrazolo[1,5-a]pyrimidine derivatives by ring-chain-transformation 
 
As mentioned before (see chapter 1.1.3, page 4), the ring-chain-transformation is an effective 
tool to synthesize ω-functionalized heterocycles. We tried to apply this type of reaction to 
synthesize 5-hydroxypropylpyrazolo[1,5-a]pyrimidine 131. The known 1,3-dicarbonyl 
precursor 130 [102] was obtained by condensation of acetophone with γ-butyrolactone, and 
could be ring-chain-transformation with 3-amino-4-phenylpyrazole to the desired product 131 
in high yield. (Scheme 2.22) 
O
O O
NaH, Et2O, RT
O
HN N
H2N
Ph
EtOH, HCl
reflux, 83 % (28 %)
N
N N
Ph
Ph
131
O
Ph
HO
130  
Scheme 2.22 
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3.1 Synthesis of purine derivatives 
 
3.1.1 Properties of purine 
 
Purine derivatives are widely found in nature. They have a lot of biological and 
pharmaceutical activities. Among them, C-2, N-9 substituted 6-benzylaminopurine 
derivatives are cyclin-dependent kinase inhibitor [101]. 6-Alkylamino-9-benzyl-9H-purines 
are a class of anticonvulsant agents [103a]. 9-benzyl-6-dimethylamino-9H-purines have 
antirhinovirus activity [103b]. 2,6,9-Trisubstituted purines are selective CDK1 inhibitors 
[104]. 9-Benzylpurines are active against macobacterium tuberculosis [105]. 6-Alkenyl- and 
6-alkynylpurines have cytostatic activity [106, 107]. 2-Alkynylpurines have inhibitory 
activity on platelet aggregation [108] and potent antihypertensive effects [109]. 9-
Substituted purines are potent antiparasitic agents [110], high selective sulfotransferase 
inhibitors [111], and exhibit HIV-1 infectivity [112]. Furthermore, modified purines 
containing carbon substituents in the 2-, 6-, or 8-position are associated with interesting 
biological properties. 
N
N N
H
N1
2
3
4
5
6
7
8
9
Purine
 
Purine is composed of a pyrimidine ring and an imidazole ring. The pyrimidine part is π-
electron-deficient, and then nucleophilic displacement takes place more readily at 6-position 
than at 2-position. The same is observed in the oxidative addition to Pd(0), even purines 
with the otherwise weakll reactive chloro leaving group at position 6 can undergo Pd-
catalyzed cross-coupling reactions. 8-halo-groups could also be substituted in this way. In 
our present work, Pd-catalyzed cross-coupling reactions were used to introduce aryl and in 
particular aminoalkynyl substituent into the purine skeleton in order to establish compounds 
of the general structure 8 as potential calcineurin inhibitors. 
 
 
3.1.2 Overview of Pd-catalyzed coupling reactions of halopurines 
 
Using metal-catalyzed coupling reactions of halopurines is the best choice to realize C-C 
bond formations in different positions. There are many reports about the coupling reactions 
of organozinc, organotin, organoboronic and Grignard reagents. 
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(1) Suzuki coupling 
Halopurines can undergo cross-coupling reactions with arylboronic acid, to introduce aryl 
groups into 2-, 6- or 8-position. When 9-benzyl-6-bromopurine 132 and 6-amino-9-benzyl-
8-bromopurine 133 reacted with a series of aryl boronic acid [103], 134 and 135 were 
obtained. (Scheme 3.1) 
N
N N
N
Cl
Bn
N
N N
N
Ar
Bn
N
N N
N
NH2
Bn
N
N N
N
NH2
Bn
ArBr
ArB(OH)2
Pd(PPh3)4
ArB(OH)2
Pd(PPh3)4
61-95 %
36-96 %
134
133
132
135  
Scheme 3.1 
 
2,6-Dihalopurine 136, 137 and 6,8-dihalopurine 138 can undergo regioselective Suzuki 
cross-coupling reactions, when equal equivalents of phenylboronic acid was used [113, 
114]. 139, 140, 141 were obtained in good yields. (Scheme 3.2) 
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Scheme 3.2 
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(2) Stille coupling 
Halopurines can undergo cross-coupling reactions with organotin reagents. Aryl, alkenyl, 
alkynyl and alkyl groups were introduced into 2-, 6- or 8-position in this way [115-117], 
giving access to products 144, 145, and 146. (Scheme 3.3) 
N
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N
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N
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N
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N
THP
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93 %
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DMF, 60 °C
94 %
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DMF, 60 °C
132
142
143
144
145
146  
Scheme 3.3 
 
2,6-Dihalopurine and 6,8-dihalopurine can undergo regioselective Stille cross-coupling 
reactions, when one equivalent of organotin reagent was used [118-120]. (Scheme 3.4 and 
Scheme 3.5) Again, the regioselectivity depends on either the type of halo-leaving groups 
or the positions. 
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R
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Scheme 3.4  
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Scheme 3.5 
 
(3) Negishi coupling 
9-Benzyl-6-chloropurine and 7-benzyl-6-chloropurine were shown to undergo Negishi 
cross-coupling reactions with phenyl-, benzyl- and alkylzinc reagents, and introduce phenyl-
, benzyl- and alkyl group into the 6-position. 8-Chloro-6-phenyl-9-(tetrahydropyran-2-
yl)purine reacted with benzylzinc chloride at 8-position [114, 115]. (Scheme 3.6) 
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2,6-Dihalopurine and 6,8-dihalopurine can undergo regioselective Negishi cross-coupling 
reactions, when one equivalent of organozinc reagent was used [116]. (Scheme 3.7) 
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Scheme 3.7 
 
(4) Kumada coupling 
Ni- and Pd-catalyzed cross-coupling reactions of halopurines with Grignard reagents were 
used to introduce aryl or alkyl group into 6- or 8-position [121, 122]. (Scheme 3.8) 
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6,8-Dichloro-9-(tetrahydropyran-2-yl)purine 238 reacted with one equivalent of methyl 
magnesium chloride by introducing a methyl group into the 8-position rather than into the 6-
position. This violates the normal positional reactivity sequence [114]. (Scheme 3.9) 
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N N
N
Cl
THP
N
N N
N
Cl
THP
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Fe(acac)3
THF, NMP
37 %
138 166  
Scheme 3.9 
 
 
(5) Coupling with alkylaluminium reagents 
Halopurines can undergo cross-coupling reactions with trialkylalumiunium by introducing 
an alkyl group into 2-, 6- or 8-position [123]. (Scheme 3.10): 
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Scheme 3.10 Pd-catalyzed couplings of halopurines 
with trimethylaluminium 
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(6) Sonogashira coupling 
Alkynyl groups were introduced in into 2-, 6- or 8-position of halopurines by Sonogashira 
reactions with alkynes [108, 109, and 124]. (Scheme 3.11) Generally, high yields of 
products were obtained. 
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N
N N
N
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R
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169
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176  
 
                                                                     R = 2, 3, 5-Tri-O-acetyl-1-ß-D-ribofuranosyl 
 
Scheme 3.11 
 
 
6-Chloro-2-iodopurine can undergo Sonogashira cross-coupling with alkynes 
regioselectively, and the 2-alkynyl substituted products 178 were obtained [124]. (Scheme 
3.12) 
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Scheme 3.12  
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Our strategy of synthesizing potential calcineurin inhibitors of the general structure 8 with 
purine as central heterocycle, was based on the assembly of halopurines with two aryl 
substituents, followed by the introduction of a functionalized side chain by Sonogashira 
coupling or nucleophilic substitution. The aryl groups were either directly connected to the 
purine rings or separated by a methylene group, i.e. a benzyl group. 
 
 
3.1.3 Synthesis of aryl-halopurines as starting materials 
 
Synthesis of purine derivatives started with 2,6-dichloropurine 179 and commercially 
available 6-chloropurine 180. 
N
N N
H
N
Cl
Cl
N
N N
H
N
Cl
2,6-dichloropurine 6-chloropurine
179 180
 
 
The former compound was obtained starting from adenine, which was readily oxidized with 
hydrogen peroxide in aqueous acetic acid to give adenine-1-N-oxide 181. The hydroxylation 
of the N-oxide was carried out with sodium nitrite in acetic acid (diazo-hydrolysis) to give 
hypoxanthine-1-N-oxide 182. 2,6-Dichloropurine 179 was obtained in low yield by treating 
182 with phosphoryl chloride in the presence of catalytic amount of N,N-dimethyl aniline 
[126]. (Scheme 3.13) 
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In order to introduce aryl groups into purine skeletons connected by a CH2- spacer, 2,6-
dichloropurine 179 was N-alkylated with benzyl chloride in DMF in the presence of K2CO3. 
The corresponding 9-benzyl r 137 and 7-benzyl isomer 183 were isolated [127] in yields of 
44 % and 21 %, respectively. Similarly, 6-chloropurine 180 led to the two isomers 132 and 
155 [102] in yields of 50 % and 23 %, respectively, after benzylation. (Scheme 3.14) 
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Scheme 3.14 
 
 
 
The N-benzylated chloropurines 137, 183 and 132 were further submitted to Suzuki 
reactions in order to introduce the second aryl group of the general target structure 8.  
 
9-Benzyl-2,6-dichloro-purine 137 and 7-benzyl-2,6-dichloro-purine 183 reacted with one 
equivalent of phenylboronic acid in the presence of Pd(PPh3)4 and anhydrous K2CO3 to give 
the corresponding 6-phenyl products [113] 140 and 184 in yields of 70 % and 66 %, 
respectively. (Scheme 3.15) 
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Scheme 3.15 
 
Using the same Suzuki coupling conditions, and starting from 9-benzyl-6-chloro-purine 132, 
9-benzyl-6-phenylpurine 134a was obtained in 75% yield [70, 113]. (Scheme3.16) 
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Scheme 3.16 
 
In order to create a second reactive site at the purine skeleton, the chloropurine 132 was 
iodinated with NIS to give the 9-benzyl-6-chloro-8-iodo-purine 152 in a 46 % yield [120]. 
Unexpectedly, this product 152 resisted regioselective Suzuki cross-coupling with one 
equivalent of phenylboronic acid to the envisaged 9-benzyl-6-chloro-8-phenylpurine 154. 
(Scheme 3.17) 
 
N
N N
N
Cl
Bn
132
NIS/THF
reflux 3 d N
N N
N
Cl
Bn
152
I
N
N N
N
Cl
Bn
Ph
154
PhB(OH)2, 
Pd(PPh3)4
K2CO3, toluene
100 °C, 20 h
46%
 
 
Scheme 3.17 
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We further introduced a bromo-substituent into the position-8 of the 9-benzyl-6-phenyl-purine 
134a by bromination with NBS. While this reaction failed in DMF at room temperature, 
refluxing in THF for a long time was appropriate. (Scheme 3.18) 
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Scheme 3.18 
 
 
3.1.4 Introduction of functionalized chains into purines 
 
Introduction of a 3-dimethylaminopropyl chain into the 8-bromopurine 185 could be 
implemented by a two-steps sequence, i.e. first, by Sonogashira coupling of 185 with N,N-
dimethyl propargylamine, followed by catalytic hydrogenation. Both steps gave good yields 
and provided an interesting product 187. (Scheme 3.19) 187 could help to answer the 
question, whether the separation of one of the two aryl groups from the core heterocycle by 
a CH2- spacer in the general structure 8 would effect the calcineurin inhibiting activity. 
N
N N
N
Ph
Bn
185
Br
CH2NMe2
Pd(PPh3)2Cl2 
CuI, TEA, 
80 °C, 24 h
Pd/C, H2
EtOH70 %
86 %
N
N N
N
Ph
Bn
186
NMe2
N
N N
N
Ph
Bn
187
NMe2
 
Scheme 3.19 
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Attempts to introduce the 3-dimethylaminopropynyl chain into the 2-chloropurine 184 
failed even under forcing Sonogashira conditions (Pd(PPh3)4, CuI, TEA, DMF, 100°C, 24 
h). (Scheme 3.20) 
Pd(PPh3)4, CuI
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N
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188
N
N
N
N
Ph
Cl
Bn
184  
Scheme 3.20 
 
As a structural alternative, a 3-dimethylaminopropylamino group could be readily 
introduced into the 2-position of the 2-chloropurine 184 by uncatalyzed nucleophilic 
substitution providing 189 in high yield. (Scheme 3.21) 
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150 °C,  98 %
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Me2N(H2C)3HN
Bn
H2N(CH2)3NMe2
189  
Scheme 3.21 
In an analogous way, the 2-(3-dimethylaminopropylamino)-purine 190 and the 2-(2-
dimethyl-aminoethoxy)-purine 191 could be obtained starting from the isomeric 2-
chloropurine 140 and 3-dimethylaminopropylamine or 2-dimethylaminoethanol, 
respectively. Treatment of 140 with 3-dimethyl-amino-propane-1-thiol, did not lead to the 
desired product 192. (Scheme 3.22) 
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Scheme 3.22 
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3.2 Synthesis of pyrido[2,3-b]pyrazine derivatives 
 
Quinoxaline and pteridine derivatives are very important nitrogen-containing heterocycles 
and have been widely used as pharmaceuticals. Quinoxaline derivatives have also been used 
as photoelectrochemical materials. Pyrido[2,3-b]pyrazine (5-azaquinoxaline) derivatives are 
the analogues of pteridine and quinoxaline, and have potential pharmaceutical activities and 
other applications [128-130]. 
1
2
3
45
6
7
8
N
N
N
N N
N
N N
N
quinoxaline pyrido[2,3-b]pyrazinepteridine  
 
We chose the pyrido[2,3-b]pyrazine system as core heterocycle in potential calcineurin 
inhibitors of the general structure 8. 
 
A starting material 193 with two aryl substituents, suitable for the introduction of the side 
chains by Pd-catalyzed coupling, was easily on hand. Condensation of 5-bromo-2,3-
diaminopyridine with benzil (1,2-diphenyl-ethane-1,2-dione) in refluxing ethanol, in the 
presence of hydrochloric acid, provided 7-bromo-2, 3-diphenylpyrido[2,3-b]pyrazine 193 in 
73 % yield [131, 133]. (Scheme 3.23) 
 
N N
NBr Ph
PhN
Br
NH2
+
OO
Ph Ph
EtOH, HCl
   reflux
73 %
NH2
193  
Scheme 3.23 
 
7-Bromo-2,3-diphenylpyrido[2,3-b]pyrazine 193 was used in uncatalyzed nucleophilic 
substitution before. For instance, Kumari [131] reported the nucleophilic substitution of 193 
with secondary amines. A mixture of 7-substituted and 8-substituted products were 
obtained. Vinot [132] reported the reactions of 193 with organomagnesium reagents. When 
193 reacted with phenylmagnesium bromide, 2,3,7-triphenylpyrido[2,3-b]pyrazine was 
obtained in 28 % yield, while 193 reacted with ethylmagnesium bromide, providing 6-ethyl-
4,6-dihydro compound in 55 % by addition reaction. Armoand [133] reported the reduction 
of pyrido[2,3-b]pyrazine derivatives with NaBH4 to the corresponding 5,6-dihydro 
compound. To the best of our knowledge, there is no report about the cross-coupling 
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reaction of pyrido[2,3-b]pyrazine derivatives. Therefore, it is interesting to do some 
research in this field. 
 
 
3.2.1 Synthesis of 7-alkynylpyrido[2,3-b]pyrazine and related compounds 
(Sonogashira cross-coupling reaction) 
 
ω-Functionalized side chains could be introduced into 7-bromo-2,3-diphenylpyrido[2,3-
b]pyrazine 193 by Sonagashira coupling with 3-butyn-1-ol or N,N-dimethylpropargyl 
amine, catalyzed by Pd(PPh3)2Cl2 and CuI. 4-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-but-
3-yn-1-ol 194a, and [3-(2,3-diphenyl-pyrido[2,3-b]pyrazin-7-yl)-prop-2-ynyl]-dimethyl-
amine 194b were obtained in high yields. Further catalytic hydrogenation of 194b provided 
[3-(2,3-diphenyl-pyrido[2,3-b]pyrazin-7-yl)-propyl]-dimethyl-amine 195 in 54 % yield. The 
aromatic heterocyclic ring was not affected under these reductive conditions. (Scheme 3.24) 
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Ph
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Scheme 3.24 
 
 
 
3.2.2 Synthesis of 7-alkenylpyrido[2,3-b]pyrazine compounds (Heck cross-coupling 
reaction) 
 
As an alternative to the aforementioned Sonogashira/hydrogenation sequence, the 
introduction of aminoalkyl or hydroxyalkyl chains into purines was envisaged by Heck 
coupling followed by reduction. Thus, 7-bromo-2, 3-diphenylpyrido[2,3-b]pyrazine 193 
could be coupled with methyl acrylate, acrylonitrile or N-allyl-phthalimide, catalyzed by 
Pd(OAc)2/P(o-toly)3 in MeCN in the presence of TEA at 100 °C. The corresponding trans-
alkene products 200, 201 and 202 were obtained in variable yields depending on the type of 
alkene. (Scheme 3. 25) 
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Scheme 3.25 
 
 
3.2.3 Suzuki cross-coupling of 7-bromo-2, 3-diphenylpyrido[2,3-b]pyrazine 
 
Since the known reaction of 7-bromo-2,3-diphenylpyrido[2,3-b]pyrazine with phenyl 
magnesium bromide afforded low yield of the corresponding substitution product 203 [133], 
we checked the suitability of the Suzuki reaction to introduce aryl groups into pyrido[2,3-
b]pyrazine series. 
7-Bromo-2, 3-diphenylpyrido[2,3-b]pyrazine 193 reacted with arylboronic acids, in the 
presence of Pd(PPh3)4 and K2CO3 in toluene, affording 2,3,7-triphenylpyrido[2,3-b]pyrazine 
203 and 1-[4-(2,3-diphenyl-pyrido[2,3-b]pyrazin-7-yl)-phenyl]-ethanone 204 in yields of 
96% and 50%, respectively. Thus, the Suzuki cross-coupling is much better than the 
aforementioned uncatalyzed reaction with phenyl Grignard reagent. (Scheme 3.26) 
 
N
N
N
Ph
Ph
Ph
PhB(OH)2, Pd(PPh3)4
K2CO3, toluene, 100 °C
16 h, 96 %
N
N
N Ph
Ph
N
N
N
Br
Ph
Ph
4-Ac-PhB(OH)2, Pd(PPh3)4
K2CO3, toluene, 100 °C
16 h, 50 %
O
193
203
204  
Scheme 3.26 Suzuki cross-couplings of  
7-bromo-2, 3-diphenylpyrido[2,3-b]pyrazine 
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3.2.4 Buchwald-Hartwig amination of 7-bromo-2, 3-diphenylpyrido[2,3-b]pyrazine 
 
Kumuri [131] reported the substitution of 7-bromo-5-azaquinoxaline 193 with secondary 
amines. In case of morpholine, two isomers of products 196 and 197 were isolated, probably 
formed via elimination/addition mechanism. (Scheme 3.27) 
N
H
O
N N
NBr Ph
Ph
N N
N Ph
Ph193
196 ( 54 %)
reflux
N N
NN Ph
Ph
O N
O
+
197 (27 %)  
 
Scheme 3.27 
 
We tried to achieve regioselective introduction of functionalized amines by Pd-catalysis. 
Using typical reaction conditions of Buchwald-Hartwig amination, 7-bromo-2,3-
diphenylpyrido[2,3-b]pyrazine 193 was treated with 1-methyl-piperazine, catalyzed by 
Pd2(dba)3 and BINAP. Only one isomeric of amination product 7-(4-methyl-piperazin-1-yl)-
2,3-diphenylpyrido[2,3-b] pyrazine 198 was obtained in 68 % yield. Similarly, when N,N-
dimethyl-1,3-propan-diamine was used, N'-(2,3-diphenyl-pyrido[2,3-b]pyrazin-7-yl)-N,N-
dimethylpropane-1,3-diamine 199 was obtained in 73 % yield. (Scheme 3.28)  
Pd2(dba)3, BINAP
t-BuONa, toluene
100 °C, 24 h, 73 %
NH
N
NH2(CH2)3NMe2
N N
NBr Ph
Ph
N N
NN Ph
Ph
N N
NMe2N(H2C)3HN Ph
Ph
Pd2(dba)3, BINAP
t-BuONa, toluene
100 °C, 24 h, 68 %
N
193
198
199  
 
Scheme 3.28 
 
Both products 198 and 199 fit into the general structure 8, where the side chain is connected 
to the core heterocycle via a nitrogen bridge. In the former case, the side chain is part of a 
saturated ring.  
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3.3 Synthesis of imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine 
derivatives 
 
3.3.1 Literature survey 
 
Imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivative are analogues of purine and 
have potential pharmaceutical and biological activities [134-137]. 
 
N
N
N
Imidazo[1,2-a]pyridine Imidazo[1,2-b]pyridazine
1
2
34
5
6
7
8
N
N
1
2
34
5
6
7
8
 
 
 
Similar to purine, they are composed of a 6-membered N-heterocycle and an imidazole ring. 
The pyridine (pyrazine) ring is π-electron deficient, and so nucleophilic displacement takes 
place more readily. The imidazole ring is π-electron excessive and can easily undergo 
electrophilic substitution. 
 
There are some reports about the nucleophilic substitutions at imidazo[1,2-a]pyridines and 
imidazo[1,2-b]pyridazines, however, only a few cross-coupling reactions are known. 
 
Thus, 3-iodoimidazo[1,2-a]pyridine derivative 205 [138] and 6-bromoimidazo[1,2-a]-
pyridine derivative 206 [139] underwent Suzuki cross-coupling reactions with 
phenylboronic acid to give 207 and 208. (Scheme 3.29) 
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Scheme 3.29  
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3-Bromo-2-n-butylimidazo[1,2-a]pyridine 210 was coupled in a Negishi reaction with aryl 
methylzinc bromide to give 212, catalyzed by Pd2(dba)3/P(o-toyl)3 [140]. Similarly, 6-
chloro-2-substituted imidazo[1,2-b]pyridazine 211 was transformed into 213 with 4-chloro-
1-butylzinc iodide under Pd(PPh3)2Cl2 catalysis [136]. (Scheme 3.30 ) 
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N
R
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1) ArCH2Br, Zn, THF, RT
2) Pd2(dba)3, P(o-toly)3
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210
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Scheme 3.30 
 
 
Furthermore, 6-bromoimidazo[1,2-a]pyridine 214 underwent Buchwald-Hartwig aminations 
with secondary or primary amines in the presence of Pd2(dba)3 and BINAP [141], providing 
a series of substituted 6-aminoimidazo[1,2-a]pyridines 215. (Scheme 3.31) 
N
N
Ph-F-p
Br  Pd2(dba)3, BINAP N
N
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N
HNR1R2
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yield :
PhNHMe NHO NH PhNH2   BnNH2   n-C6H13NH2NH2
55 % 69 % 85 % 70 % 82 % 58 % 71 %
215214
 
 
Scheme 3.31 
 
 
Gudmundson [142] reported the Heck coupling of 3-iodoimidazo[1,2-a]pyridines such as 
216 with dihydrofuran in the presence of Pd(OAc)2-PhAs3-Ag2CO3 systems. (Scheme 3.32) 
N
N
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Scheme 3.32 
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3.3.2 Preparation of starting materials 
 
6-Bromo-2, 3-diphenylimidazo[1,2-a]pyridine 218 and 6-chloro-2,3-diphenylimidazo[1,2-
b]pyridazine 219 were chosen as starting materials. These compounds possess purine 
analogous heterocycles with two peripheral phenyl groups. In order to achieve compounds 
of the general structure 8, the ω-functionalized side chains were introduced by Pd-catalyzed 
cross-couplings. 
 
These two heterocycles 218 and 219 were prepared by condensation of 2-aminopyridine or 
3-aminopyridazine with desyl bromide in a one-step procedure [143]. (Scheme 3.33) 
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Scheme 3.33 
 
 
 
 
3.3.3 Pd-catalyzed introduction of functionalized side chains  
 
Further following up our strategies to introduce aminoalkyl groups into heterocycles by the 
sequence Sonogashira coupling/hydrogenation, we tried to submit the imidazo[1,2-
a]pyridine 218 and imidazo[1,2-b]pyridazine 219 to this synthetic methodology. 
6-Bromo-2,3-diphenylimidadazo[1,2-a]pyridine 218 reacted with N,N-dimethylpropargyl 
amine to give [3-(2,3-diphenyl-imidazo[1,2-a]pyrimidin-6-yl)-prop-2-ynyl]-dimethyl-amine 
220 in 76% yield, using Pd(PPh3)2Cl2/CuI catalysis. When the reaction was catalyzed by 
Pd/C, PPh3 and CuI, the desired product could not be observed. Further catalytic 
hydrogenation of 220 led to the [3-(2,3-diphenyl-imidazo[1,2-a]pyrimidin-6-yl)-propyl]-
dimethyl-amine 221 in 73 % yield. (Scheme 3.34) 
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Scheme 3.34 
 
 
 
The same sequence could be applied to 6-chloro-2,3-diphenylimidazo[1,2-b]pyridazine 219, 
giving access to the [3-(2,3-diphenyl-imidazo[1,2-a]pyrimidin-6-yl)-propyl]-dimethyl-
amine 224 in high yield via [3-(2,3-diphenyl-imidazo[1,2-a]pyrimidin-6-yl)-prop-2-ynyl]-
dimethyl-amine 223. (Scheme 3.35) 
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Using the catalytic system Pd2(dba)3/BINAP, 6-bromo-2,3-diphenylimidazo[1,2-a]pyridine 
218 could react with morpholine, 1-methyl-piperazine or N,N-dimethyl-1,3-propan-diamine 
to give 6-morpholin-4-yl-2,3-diphenylimidazo[1,2-a]pyridine 225, 6-(4-methyl-piperazin-1-
yl)-2,3-diphenylimidazo[1,2-a]pyridine 226, and N'-(2,3-diphenyl-imidazo[1,2-a]pyridin-6-
yl)-N,N-dimethyl-propane-1,3-diamine 227 (Scheme 3.36). Unfortunately, the most 
interesting product 227, which fits best into the general structure 8, gave only lower yield. 
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4.1 Synthesis of pyrimidine derivatives 
 
Pyrimidine-containing molecules are of paramount importance in nucleic acid chemistry. 
Their derivatives including uracil, cytosine, adenine and guanine, are fundamental building 
blocks for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Pyrimidine 
derivatives exist extensively in nature. They have biological and pharmaceutical activities. 
N-3-substituted pyrimidinones are potent AT1 selective angiotensin II receptor antagonists 
[144]. Pyrimidine amide derivatives are novel antiallergic agents [145]. S-alkylated 
derivatives are potent antiviral agents [146]. 6-Alkylaminoderivatives are inhibitors of 
bacillus subtilis DNA polymerase III [147]. Aziridino derivatives are new cytotoxic agents 
with tumour-inhibitory activity [148]. Arylamino derivatives of pyrimidines are potential 
anti-cytomegalovirus agents [149], 2- or 4-(4-methylpiperazino)pyrimidines are 5-HT2A 
receptor antagonists [150]. 
 
Due to the electronegativity of the two nitrogen atoms, pyrimidine is a π-electron-deficient 
heterocycle. Therefore, nucleophilic displacements of nucleofugal leaving groups take place 
readily. This trend also translates to palladium chemistry. 4-Chloropyrimidine oxidatively 
adds to Pd(0) more readily than 2-chloropyrimidine. 
 
We tried to assemble calcineurin inhibiting products of the general structure 8 with 
pyrimidine as core heterocycle via Pd-catalyzed coupling reactions. 
 
 
 
4.1.1 Overview of Pd-catalyzed coupling reactions of halopyrimidines 
 
4.1.1.1 Pd-catalyzed cross-coupling reactions of monohalopyrimidines 
 
Halogenated pyrimidines can undergo a series of Pd-catalyzed cross-coupling reactions, for 
example, Suzuki reactions, Sonogashira reaction, Stille reactions, Negishi reactions, Heck 
reactions: 
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(1) Suzuki reactions 
5-Bromo-2,4-di-tert-butoxypyrimidine 228 was coupled with 3-methyl-thiophene-2-boronic 
acid, and 5-substituted pyrimidine 229 was obtained [151]. Coupling of the 2-chloropyri-
midine 230 with the arylboronic acid 231 afforded 2-arylpyrimidine 232 [152]. (Scheme 
4.1) 
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N
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+
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61 %
N
N
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reflux, 66 % N
N
OBn
O-n-Pr
228 229
230 232231  
Scheme 4.1 
 
(2) Sonogashira reactions 
2-Iodo-4,6-dimethylpyrimidine was coupled with a series of terminal alkynes, providing 
alkynylpyrimidines 233 in good to excellent yields [153]. The Sonogashira coupling of 5-
bromopyrimidine with N,N-dimethylpropargylamine gave the aminoalkyne 234 [154]. 
(Scheme 4.2) 
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Pd/C, PPh3, CuI N
N
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Scheme 4. 2 
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(3) Stille reactions 
5-Bromopyrimidine was coupled with 1-(trimethylsilyloxy)vinyltin to give 5-(1-trimethyl-
silanyloxy-vinyl)-pyrimidine 235 in 67 % yield [155]. (Scheme 4.3) 
Pd(PPh3)4N
N
+
67  %
Br
N
N
OSiMe3
Bu3Sn
OMe3Si
toluene, 100 °C
235  
Scheme 4.3 
 
(4) Negishi reactions  
2-Iodo-4,6-dimethylpyrimidine was coupled with 3-ethoxycarbonylpropylzinc iodide at 
room temperature, catalyzed by Pd(PPh3)4, to give 4-(4,6-dimethyl-pyrimidin-2-yl)-butyric 
acid ethyl ester 236 in 91 % yield [156]. (Scheme 4.4) 
 
N
N
I
+
RT, 2 h, 91 % N
N
DMA/benzene
EtO2C ZnI
Pd(PPh3)4
CO2Et
236  
 
Scheme 4.4 
 
(5) Heck reactions  
2-Amino-5-bromo-pyrimidine was coupled with benzyl acrylate in 79 % yield [157], 
catalyzed by Pd(OAc)2/P(o-tolyl)3. 4,6-Dimethylpyrimidine-2-acrynitrile 238 was obtained 
in 61 % yield [158] by PdCl2-catalyzed reaction of 2-iodo-4,6-dimethylpyrimidine with 
acrylonitrile. (Scheme 4.5) 
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Scheme 4.5  
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4.1.1.2 Regioselective Pd-catalyzed couplings of polyhalopyrimidines 
 
When more than one halo-substituent exist in a pyrimidine ring, the regioselectivity of 
cross-coupling has to be considered. If the halo-substituents are the same, the 4-position is 
in general more active than the 2-position in Pd-catalyzed cross-coupling reactions. But 
iodo-substituted positions are more active than chloro-substituted positions. 
 
(1) Stille reaction:  
 
The positional reactivity of 5-bromo-2,4-dichloropyrimidine in Stille reactions is: 4-Cl > 5-
Br > 2-Cl. Three different substituents could be introduced by stepwise Stille couplings to 
afford product 243 [159]. (Scheme 4.6) 
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Scheme 4.6 
 
 
(2) Suzuki reaction: 
 
Reaction of 2,4,6-trichloropyrimidine with one equivalent of phenylboronic acid in the 
presence of Pd(OAc)2/PPh3 gave rise to the formation of 2,4-dichloro-6-phenylpyrimidine 
239 with complete regioselectivity in high yield. Accordingly, 2,4,6-trichloropyrimidine 
formed 2-chloro-4,6-diphenylpyrimidine 240, with two equivalents of phenylboronic acid, 
under the same conditions [160]. (Scheme 4.7) 
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Scheme 4.7 
 
 
(3) Sonogashira reactions 
2,4-dichloropyrimidine reacted with one equivalent of 1-hexyne at room temperature, 
catalyzed by Pd(PPh3)2Cl2 and CuI, to give the 2-chloro-4-alkynylpyrimidine 244. 
Subsequent coupling of 244 with 1-hexyne at 65 °C, afforded 2,4-dialkynylprimidine 245 
[161]. The iodo atom of 5-bromo-2-iodopyrimidine was selectively substituted by terminal 
alkynes under typical Sonogashira conditions, affording 5-bromo-2-alkynylpyrimidines 246 
[162]. (Scheme 4.8) 
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Scheme 4.8 
 
 
(4) Heck reaction 
In 5-bromo-4-iodo-2-isopropyl-6-methylpyrimidine 247, a selective substitution of the iodo 
atom was observed in Heck reaction, leading to the 4-styrylpyrimidine 248 [163]. (Scheme 
4.9) 
Chapter 4: Pyrimidines and other monocyclic heterocycles                                                           69 
_________________________________________________________________________________________________________________________________ 
 
N
N
+
Br
Ph Pd(OAc)2, PPh)3
TEA, 140 °C
46  %
I
N
N
Br
Ph
247 248 
Scheme 4.9 
 
 
 
4.1.2 Synthesis of aryl substituted halopyrimidines 
 
The halopyrimidines used in our investigations of Pd-catalyzed cross-couplings were 
obtained via corresponding pyrimidinones. Following a well-established pyrimidine 
synthesis, 2,6-diphenylpyrimidin-4-one 249 was obtained from benamidine and ethyl 
benzoylacetate [164]. 249 was further refluxed with POCl3 and PCl5 to give 75 % of 4-
chloro-2,6-diphenylpyrimidine 250 [165]. After chloro-iodo exchange with HI 4-iodo-2,6-
diphenylpyrimidine 251 was obtained in 42 % yield [165]. (Scheme 4.10) 
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Scheme 4.10 
 
Similarily, 4,6-dichloro-2-phenylpyrimidine 253 and 4,6-diiodo-2-phenylpyrimidine 254 
were obtained in a straight forward way, starting from benzamidine and diethyl malonate 
[166]. (Scheme 4.11) 
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Scheme 4.11 
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2-Chloro-4,6-diarylpyrimidines 240 were synthesized in high yields by Suzuki coupling of 
2,4,6-trichloropyrimidine with 2 equivalents of arylboronic acid [160]. (Scheme 4.12) 
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Scheme 4.12 
 
Using the same conditions, 2-chloropyrimidine 255 with different aryl substituents at 
position 4 and 6 was prepared by stepwise Suzuki reactions of 2,4,6-trichloropyrimidine. 
(Scheme 4.13) 
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Scheme 4.13 
 
 
 
4.1.3 Introduction of side chains into pyrimidines 
 
4.1.3.1 Sonogashira cross-coupling of halopyrimidines 
 
In order to introduce teminal heteroatom functionalized chains into pyrimidines, diaryl-
halopyrimidines were coupled with propargyl amine. Thus, 4-iodo-2,6-diphenylpyrimidine 
251 was treated with N,N-dimethylpropargyl amine, catalyzed by Pd(PPh3)2Cl2 and CuI, 
providing [3-(2,6-diphenyl-pyrimidin-4-yl)-prop-2-ynyl]-dimethyl-amine 256 in 76 % yield. 
256 was further hydrogenated in the presence of Pd/C to give [3-(2,6-diphenyl-pyrimidin-4-
yl)-propyl]-dimethyl-amine 257 in 76 % yield. Analogously, the phthalimidopropynyl 
pyrimidine 258 was obtained in high yield. (Scheme 4.14) 
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Scheme 4.14 
 
 
More forcing conditions were necessary for Sonogashira reactions of 2-chloro-4,6-diaryl-
substituted pyrimidines 240 or 255. After heating at 100 °C for 24 h, the [3-(4,6-diaryl-
pyrimidin-4-yl)-prop-2-ynyl]-dimethylamines 259a-259c were obtained. KOAc turned out 
to be advantageous over triethylamine. (Scheme 4.15) 
 
 
 
Scheme 4.15 
 
 
The C-C triple bonds of 259a-259c could be further hydrogenated in the presence of 10 % 
Pd/C (0.2 equiv.). In the case of the chlorophenyl substituted pyrimidines 259b-259c, the 
chloro substituent was lost during the reduction of the triplet bond [167], i.e. the desired 
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Chapter 4: Pyrimidines and other monocyclic heterocycles                                                           72 
_________________________________________________________________________________________________________________________________ 
 
target molecules with chloro substituted phenyl groups could not obtained by this route. 
(Scheme 4.16) 
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Scheme 4.16 
 
 
 
4.1.3.2 Nucleophilic substitution of halopyrimidines 
 
In potential calcineurin inhibiting compounds fitting into the general structure 8 the side 
chain can also be connected to the core heterocycle via a heteroatom. Such compounds can 
either be obtained by nucleophilic substitution or by Pd-catalyzed coupling. 
 
N,N-dimethyl-1,3-propanediamine, 2-dimethylaminoethanol, and 2-dimethylamino-
ethanethiol, were applied in uncatalyzed nucleophilic substitution with 2-chloro-4,6-
diarylpyrimidine 240.  
 
While high yield of N'-(4,6-diphenyl-pyrimidin-2-yl)-N,N-dimethyl-propane-1,3-diamine 
261 was achieved. N'-(4,6-diphenyl-pyrimidin-2-yl)-N,N-dimethyl-propane-1,3-diamine 
262 and [2-(4,6-diaryl-pyrimidin-2-yl-sulfanyl)-ethyl]-dimethyl-amine 263 were formed in 
low yield (about 30 %). Probably, competing oxidation of the 2-dimethylaminoethanethiol 
to the corresponding disulfide or substitution of chloride by tert-butoxide, respectively, 
could be responsible for the low yields. (Scheme 4.17) 
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Scheme 4.17 
 
 
Reaction of 2,4,6-trichloropyrimidine [168] with two equivalents of propanolamine  
afforded two isomers 264a and 264b in a ratio of 40:49. Subsequent attempts to submit 
264a to a twofold Suzuki reaction to give 265 were unsuccessful. (Scheme 4.18) Therefore, 
the reversed sequence, i. e. first Suzuki coupling and then introduction of the side chain 
seems to be advantageous. 
 
 
Scheme 4.18 
 
N
N
Cl
ClCl
NH2-(CH2)3-OH
THF, RT
N
N
NH(CH2)3OH
ClClN
N
Cl
NH(CH2)3OHCl
N
N
Ph
NHCH2CH2CH2OHPh
PhB(OH)2 , Pd(OAc)2
PPh3, Na2CO3
DME-H2O
(40 %)(49 %)
+
264a 264b
265
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4.2 Synthesis of pyridine derivatives 
Many pyridine-containing molecules are important because of their biological and 
pharmacological properties. They have found applications as precursors of pharmacological 
compounds [169], in the synthesis of liquid crystals [170] or polymers [171], as well as 
ligands [172] for a lot of transition metal complexes.  
Pyridine is a π-electron-deficient heterocycle. Due to the electronegativity of the nitrogen 
atom, the corresponding α and γ position of pyridine bear partial positive charge, making 
them prone to nucleophilic attacks. A similar trend occurs in the context of Pd-catalyzed 
coupling reactions. 
 
4.2.1 Overview of Pd-catalyzed coupling reactions of halopyridines 
Halogenated pyridines underwent a series of Pd-catalyzed cross-coupling reactions, for 
example, Suzuki reactions, Sonogashira reaction, Stille reactions, Negishi reactions, Heck 
reactions, Buchwald-Hartwig amination, etc. Iodide, bromide and chloride could be used as 
suitable leaving groups. If two halogen atoms are found in the pyridine ring, it is possible to 
substitutite one and keep the other. (e.g. formation of 268) 
 
(1) Suzuki reactions [173, 174] 
DME-H2O, K2CO3 
 reflux 18 h, 65 %
NBr NO2
PhH, Na2CO3
 reflux 4 h, 61 %
+
B(OH)2
NPh NO2
N
Cl B(OH)2
OMe
OMe
+ OMe
OMe
N
Pd(PPh3)4
Pd(PPh3)4
266
267  
Scheme 4.19 
 
(2) Kumada reactions [175] 
NCl Cl
+
NCl
PdCl2(dppb)
S MgBr 55 % S
268  
Scheme 4.20 
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(3) Stille reactions [176] 
N
NMeS
+
N
Br
Pd(PPh3)2Cl2
DMF, 80 °C, 10 h 
 55 %
SnBu3
N
NMeS
N
269  
Scheme 4.21 
 
(4) Negishi reactions [173] 
N
+ N
Pd(PPh3)4, THF
reflux, 16 h,  55 %
SBrS
CONEt2
ZnCl CONEt2
270  
Scheme 4.22 
 
(5) Sonogashira reactions [177] 
 
N
N
Pd(PPh3)2Cl2, CuI
TEA/DCM, reflux
 12 h,  79 %
Br
CN+
CN
271  
Scheme 4.23 
 
 
(6) Buchwald-Hartwig aminations [178] 
 
N
Pd(OAc)2 ,BINAP
NaOBu-t, toluene
70 °C, 22 h,  73 %
+
Cl H2N N NH
N
Br
+
H2N
Pd2(dba)3 ,BINAP
NaOBu-t, toluene
70 °C, 2 h,  67 % N
H
N
272
273  
 
Scheme 4.24  
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(7) Heck reactions [179] 
N N
Pd(OAc)2 , PPh3
NaOAc, 130 °C  79 %
NHCOCMe3 NHCOCMe3
+ Ph
Cl Ph
274  
Scheme 4 25 
 
 
Mono couplings are regioselective if two or more different halogen atoms are attached in 
the pyridine ring (I > Br > Cl) or equal halogen atoms are found at different positions (2-
position > 4-position > 3-position). 
 
(1) Kumada reactions [180] 
 
N
Br
Br N
Br
Ar
Ar-MgBr+
PdCl2(dppb)
THF, RT, 87 %
275
 
Scheme 4.26  
 
 
(2) Sonogashira reactions [181, 182] 
 
 
N
Br
Br N
Br+
CuI, TEA, RT
SiMe3
Pd(PPh3)2Cl2
65-74 %
SiMe3
276  
 
Scheme 4.27  
 
 
(3) Suzuki reactions [183, 184]  
 
N
OMe
Br
NCl
Cl
N
+
N
Pd(PPh3)4, THF
BEt2
aq. K2CO3, reflux
57 % N
Cl
278
I
B(OH)2
+
Pd(PPh3)4, DME
aq. Na2CO3, reflux
70 %
N
OMe
BrPh
277
 
 
Scheme 4.28  
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(4) Heck reactions [185, 186] 
 
N
I
Cl
N
NCO2Me
+
NCl
Pd(OAc)2(PPh3)2, DMF
piperidine, HCO2H
70 °C, 65 h, 35 %
280
CO2Me
N
BrCl
OMe
+
OH
Cl
Cl Pd(OAc)2
 NaHCO3
DMF, 120 °C
 6 h, 40 % O
Cl
ClN OMe
Cl
279
 
 
Scheme 4.29  
 
 
 
(5) The carbonylation reactions [187] 
 
N
Pd(PPh3)2Cl2, dppf
Cl
ClMeO
N CO2Me
ClMeO
+ CO (15 bar)
MeOH, AcONa, 145 °C
3 h, 94 %
281  
 
Scheme 4.30  
 
 
(6) Buchwald-Hartwig amination [188] 
N Cl
I
N Cl
NH
+
NH2
Pd(OAc)2, BINAP
Cs2CO3, toluene
reflux, 52 % 282  
Scheme 4.31  
 
4.2.2 Introduction of dimethylaminopropyl chain into pyridine 
We synthesized the dimethylaminopropyl pyridine 287 as a novel representative of 
calcineurin inhibitors of the general structure 8, starting from 2-amino-3,5-dibromopyridine 
and demonstrating the versatility of Pd-catalyzed cross-coupling reactions to introduce all 
three important peripheral groups into the central pyridine ring. 
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2-Amino-3,5-dibromopyridine was first treated with phenylboronic acid to give 2-amino-
3,5-diphenylpyridine 283 under Suzuki conditions [71]. Then 283 was transformed into the 
2-iodo-3,5-diphenylpyridine 284, while some pyridinone 285 was formed as by product. 
(Scheme 4.32) 
2-Iodo-3,5-diphenylpyridine 284 was submitted to Sonogashira coupling with N,N-
dimethylpropargylamine in the presence of Pd(PPh3)2Cl2, CuI and TEA, affording high 
yield of the alkynylated pyridine product 286. Final catalytic hydrogenation of 286 (using 
10 % Pd/C as catalyst, at room temperature under atmosphere pressure) gave 3,5-diphenyl-
2-(3-dimethylaminopropyl) pyridine 287 as desired target product in 71 % yield. (Scheme 
4.32) Interestingly, the deaminated 2-propylpyridine 288 was isolated as by-product in 16 % 
yield. Similarly reductive deamination was reported in literature [189]. 
N
PhPh
O
H
N NH2
BrBr
N NH2
PhPh
N I
PhPh
283
284 285
+
PhB(OH)2
Pd(PPh3)2Cl2
53 %
t-BuONO
I2, CH2I2
(46 %) (16 %)
N
PhPh
CH2NMe2
N
PhPh
N
286
287
CH2NMe2
Pd(PPh3)2Cl2
CuI, Et3N, RT
89 %
H2, 10% Pd/C
ethanol, RT, atm
(71 %)
N
PhPh
+
(16 %)288  
Scheme 4.32 Synthesis of 3,5-diphenyl-2-(3-dimethylaminopropyl) pyridine 
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4.3 Synthesis of pyrazine derivatives 
Minuscule quantities of naturally occurring pyrazines have been found in some foodstuffs 
and are largely responsible for their flavor and aroma. Pyrazine derivatives have potent 
pharmaceutical activities [190]. 
Pyrazine is an electron-deficient, 6π-electron heteroaromatic compound. The inductive 
effects of the nitrogen atoms induce a partially positive charge on the carbon atoms. As a 
consequence, oxidative addition of chloropyrazine takes place more readily than with 
chlorobenzene, and chloropyrazines undergo a wide range of palladium-catalyzed carbon-
carbon bond formation reactions:  
(1) Stille reactions [191] 
N
N
Cl
N
N
+ Sn(p-MeOPh)4
Pd(PPh3)4
DMF, reflux, 5 h
65 %
OMe289  
Scheme 4.33 
 
(2) Suzuki reactions [192, 193] 
N
N
COPh
NH2
Br
N
N
COPh
NH2
S
+
PdCl2(dppb)
EtOH-PhMe, reflux, 48 h
96 %
N
N
Cl
S
B(OH)2
1M Na2CO3
N
H
(HO)2B
N
H
N
N+
Pd(PPh3)4
NaHCO3
4 h, 55 %
290
291
 
Scheme 4.34 
 
(3) Sonogashira reactions [194, 195]. 
N
N
Cl
+
N
N
OMe
+
Pd(PPh3)2Cl2
CuI, TEA, 2h
66 %
Pd(PPh3)4, KOAc
DMF, 100 °C, 2 h
84 %
N
N
Ph
I OH
N
N
OMeHO
292
293  
 
Scheme 4.35 
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(4) Heck reactions [196, 197] 
 
N
N
Cl
+
N
N
Cl
Pd(PPh3)4, KOAc
DMA, 100 °C, 15 h
95 % N
N
Ph
Pd(PPh3)4, KOAc
DMA, reflux
77 %
N
N
S
+ S
294
295
 
 
Scheme 4.36 
 
 
According to the general structure 8, we aimed to pyrazines substituted by two aryl groups 
and one dimethylaminopropyl group. 
 
 
5-Chloro-2,3-diphenylpyrazine 297, as suitable starting material for the Pd-catalyzed 
introduction of the aminoalkyl group, was known and can easily be synthesized in high 
yield [198] starting from benzil and glycine amide in two steps.(Scheme 4.37) 
 
Ph
Ph
O
O NH
NPh
Ph O
glycine amide
 hydrochloride
NaOH, MeOH, reflux N
NPh
Ph
POCl3
H2SO4
Cl
296 297
71 % 93%
 
 
Scheme 4.37 
 
 
 
Only modest yield of 298 was achieved in the Sonogashira coupling of 5-chloro-2,3-
diphenylpyrazine 297 with N,N-dimethylpropargylamine in TEA and DMF. In the case of 
the analogous Sonogashira coupling of 2-chloropyrimidine 240a (see chapter 4.1.3), the 
application of potassium acetate was advantageous over TEA. In the case of 298, it also led 
to an increase in the yield from 38 % to 51%. Pd-catalyzed hydrogenation of 298 provided 
the desired [3-(5,6-diphenyl-pyrazin-2-yl)-propyl]-dimethyl-amine 299 in 58 % yield. 
(Scheme 4.38) 
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NMe2
N
NPh
Ph Cl N
NPh
Ph
NMe2
N
NPh
Ph
NMe2
Pd(PPh3)2Cl2, CuI
TEA, DMF, 100°C
Pd(PPh3)2Cl2, CuI
AcOK, DMF, 100°C
38 %
51 %
Pd/C, H2
EtOH, 58 %
297 298
299
+
 
 
Scheme 4.38 
 
 
 
 
 
 
4.4 Synthesis of oxazole derivatives 
 
In the last decade, several oxazole-containing natural products have been isolated and found 
to be biologically active. Much synthetic effort has been expended in their total synthesis.  
 
N
O
1
2
34
5
 
 
Oxazole is a π-electron-excessive heterocycle. The electronegative nitrogen atom attracts 
electrons so that C(2) is partially positive and therefore susceptible to nucleophilic attack. In 
the other side, electrophilic substitution of oxazoles takes place at the electron-rich position 
C(5) preferentially. More relevant to palladium chemistry, 2-halooxazoles are prone to 
oxidative addition to Pd(0). Even 2-chlorooxazoles are viable substrates for Pd-catalyzed 
reactions. Some examples of known Pd-catalyzed coupling reactions are shown in Scheme 
4.39-Scheme 4.43: 
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(1) Suzuki reactions [199] 
N
OPh
Br
CO2Et
N
O
Cl
+
+
 aq K2CO3 , 90 °C
4 h, 93 %
EtO2C
N
OPh
Ph
CO2Et
Pd(PPh3)4, PhMe
N
O
Ph
EtO2C
PhB(OH)2
PhB(OH)2  aq K2CO3 , 90 °C
4 h, 87 %
Pd(PPh3)4, PhMe
300
301  
Scheme 4.39 
 
(2) Stille reactions [199] 
 
N
O
Cl
+
dioxane, 100 °C
8 h, 84 %
N
OPh
Ph
Br
EtO2C
N
O
EtO2C
+
H2C CHSnBu3
H2C CHSnBu3
Pd(PPh3)2Cl2
N
OPh
Phdioxane, 100 °C
8 h, 83 %
Pd(PPh3)2Cl2
302
303  
Scheme 4.40 
 
(3) Negishi reactions [199] 
 
N
OPh
Br
CO2Et
N
O
Cl
+
+
 THF, 65 °C
16h, 76 %
EtO2C
N ZnBr
N
OPh
Py-2
CO2Et
N ZnBr
Pd(PPh3)4
 THF, 65 °C
16h, 73 %
Pd(PPh3)4
N
O
Py-2
EtO2C
304
305  
Scheme 4.41 
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(4) Sonogashira reactions [200] 
N
O
Br
Ph
N
O Ph
+
+
Pd(PPh3)2Cl2, CuI
TEA, THF, 90 °C
15 h, 83 %
N
O
Ph
N
O
Ph
Br
Ph
Ph
Pd(PPh3)2Cl2, CuI
TEA, THF, 90 °C
4 h, 89 % Ph
Ph
306
307  
Scheme 4.42 
 
(5) Heck reactions [200] 
N
O
Br
Ph
N
O Ph
CO2Et
CN
+
+
Pd(OAc)2, PPh3
TEA, DMF, 120 °C
15 h, 65 %
Pd(OAc)2, PPh3
TEA, DMF, 120 °C
44 h, 50 %
N
O
Ph
CN
N
O
Ph
Br
CO2Et
308
309  
Scheme 4.43 
 
 
4-Bromo-2,5-diphenyloxazole 310 was readily available [201] by bromination of 2,5-
diphenyloxazole. (Scheme 4.45)  
 
N
OPh Ph
N
OPh Ph
Br
NBS/CCl4
reflux
310
43 %
 
 
Scheme 4.44 
 
 
We used 4-bromo-2,5-diphenyloxazole 310, as reactant to introduce an aminopropyl chain 
by Sonogashira coupling with N,N-dimethylpropargylamine. Optimized conditions 
[Pd(Ph3)2Cl2, CuI, AcOK, DMF, 100 °C] provided the coupling product 311 in 66 % yield. 
311was further hydrogenated, using H2 and Pd/C, to give [3-(2,5-diphenyl-oxazol-4-yl)-
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propyl]-dimethyl-amine 312 in 58 % yield. 312 was a further new example of potential 
calcineurin inhibiting compound of the general structure 8. (Scheme 4.45) 
N
OPh Ph
Br
310
+
NMe2
N
OPh Ph
NMe2
TEA, 80°C, 24 h
TEA, DMF, 100°C, 24h
10 %
42 %
Pd/C, H2
EtOH, 58 %
N
OPh Ph
NMe2
311
312
AcOK, DMF, 100°C, 24 h
(A)
(B)
(C) 66 %
Pd(PPh3)2Cl2, CuI
condition A, B or C
 
Scheme 4.45 
 
 
The aminophenylethynyloxazole 313 represents a further variation of the general structure 
8. The side chain amino group is attached to an aromatic ring rather than to a sp3 carbon 
atom. This product was obtained by Sonogashira coupling of 310 with 3-
aminophenylethyne. (Scheme 4.46) 
N
OPh Ph
Br
310
+
NH2
N
O
Ph Ph
NH2Pd(PPh3)2Cl2, 
 CuI, TEA
 80 °C
74 %
313  
Scheme 4.46 
 
Buchwald-Hartwig amination of 4-bromo-2,5-diphenyloxazole 310 with N-methyl-
piperazine furnished low yield of an oxazole 314, which is related to the general structure 8. 
The side chain amino group is part of a saturated ring. (Scheme 4.47) 
N
OPh Ph
Br
310
+
N
OPh
Ph
N
Pd2(dba)3, BINAP 
 t-BuONa, toluene
 110 °C, 24 h
14 %
314
N
H
N
N
 
 
Scheme 4.47 
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4.5 Synthesis of pyrazole derivatives 
 
Aryl pyrazoles possess widespread occurrence as substructures in a large variety of 
compounds with important biological and pharmacological properties. Among them, 1,5-
diphenylpyrazoles are novel non-nucleoside HIV reverse transcriptase inhibitors [202] and 
cyclooxygenase-2 inhibitors [203]. 1,3,5-Trisubstituted pyrazoles are inhibitors of 
cholesterol [204]. Moreover, some substituted pyrazole compounds are potent inhibitors of 
p38 MAP kinase [205] and estrogen receptors [206].  
N
N
H
2
3 4
5
1  
 
Pyrazole is a π-electron-excessive heterocycle. The electronegativity of the nitrogen atom 
attracts electrons so that C(3) and C(5) are partially electropositive and therefore susceptible 
to nucleophilic attack. On the other side, electrophilic substitution of oxazoles takes place at 
the electron-rich position C(4) preferentially. Several Pd-catalyzed coupling reactions of 
halopyrazoles have been reported: 
 
(1) Suzuki reactions [206-208]  
N
N
Cl
CF3
I
N
N
Cl
CF3
Ph
+ PhB(OH)2
Pd(PPh3)4
2 M K2CO3
PhMe-MeOH
reflux, 49 %
N
N
Ph
Et
Ph
I
+ 4-MeOB(OH)2
Pd(OAc)2, PPh3
2 M K2CO3
i-Pr-OH, reflux
70 %
N
N
Ph
Et
Ph
Ph-OMe-4
N
N
I
SO2NH2
B(OH)2
O
+
Pd(PPh3)4
Na2CO3
DME-H2O
reflux, 85 %
N
N
SO2NH2
O
315
316
317
 
 
Scheme 4.48 
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(2) Sonogashira reactions [209, 210] 
Pd(PPh3)4
N
N
Ph
p-MeO-Ph
Ph
I
+
N
N
COAr
I
TMS
N
N
Ph
p-MeO-Ph
Ph
TMS
CuI, TEA
65 %
+
CH2OH
N
N
COAr
CH2OH
Pd(PPh3)2Cl2, CuI
Et2NH,  97 % Ar = 2, 4, 6-
trimethylphenyl
318
319
 
 
Scheme 4.49 
 
 
Starting from phenylhydrazine and benzoylacetone [202] and iodination [204] of the 
intermediate 320, 4-iodo-3-methyl-1,5-diphenylpyrazole 321 was obtained.(Scheme 4.50) 
With its two phenyl groups at the pyrazole ring, compound 321 just needs an additional 
aminoalkyl group to fit into the potential calcineurin inhibiting structure 8. 
 
NHNH2
OO
+
NaOAc
MeOH, H2O
reflux
N
N
Ph
Ph
N
N
Ph
Ph
NIS, DMF
0°C--RT
I
320
321 
 
Scheme 4.50 
 
 
According to our experienced strategy for the introduction of a dimethylaminopropyl chain 
by Sonogashira coupling with N,N-dimethylpropargyl amine, followed by catalytic 
hydrogenation, the envisaged target 323 was afforded in high yield. Remarkably, catalysis 
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with Pd(PPh3)2Cl2 and CuI completely failed, while Pd/C, PPh3 and CuI provided 
quantitative Sonogashira coupling.(Scheme 4.51) 
 
N
N
Ph
Ph
I
Pd(PPh3)2Cl2, CuI
TEA, RT, 24 h
Pd/C,  PPh3, CuI
K2CO3, DME-H2O
80°C, 24 h
0 %
97%
Pd/C, H2
EtOH
N
N
Ph
Ph
NMe2
N
N
Ph
Ph
NMe2
321
322
323
76 %
NMe2
+
 
Scheme 4.51 
 
 
 
 
4.6 Synthesis imidazole derivatives  
 
The imidazole ring is present in a number of biologically important molecules as 
exemplified by the amino acid histidine. It can serve as a general base (pKa = 7.1) or a 
ligand for various metals in biological systems. Furthermore, the chemistry of imidazole is 
prevalent in protein and DNA biomolecules in the form of histidine or adinine/guanine, 
respectively. 
 
Aryl substituted imidazoles exist extensively in nature. They have important biological and 
pharmaceutical activities. For example, substituted 4,5-diaryl-2-thio-imidazoles are potent 
inhibitors of cholesterol acyltransferase [211], 1,2-diarylimidazoles are new series of COX-
2 selective inhibitors [212]; aryl-heteroaryl-imidazoles are potent inhibitors of the MAP 
kinase p38 [213] and highly active, selective histamine H1-receptor agonists [214]. 
 
Imidazole is a π-electron-excessive heterocycle. Electrophilic substitution normally occurs 
at C(4) or C(5), whereas nucleophilic substitution takes place at C(2).  
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In Pd-catalyzed coupling reactions, a halo leaving group can be found in any C-position of 
imidazoles. Several known examples are shown below: 
 
(1) Suzuki reaction [215] 
 
Pd(PPh3)4N
N
Bn
+
PhMe-EtOH-H2O
reflux, 93 %
Br
PhB(OH)2
N
N
Bn
Ph
324
 
Scheme 4.52 
 
(2) Stille reactions [215] 
N
N
Bn
Br
Ph
+ PhSnMe3
Pd(PPh3)2Cl2
PhMe, reflux, 60 %
N
N
Bn
Ph
Ph
325 
Scheme 4.53 
 
(3) Negishi reactions [216] 
 
N
N
Boc
I
Pd(PPh3)2Cl2
DMA, 40 °C, 79 %
IZn CO2Bn
NHTrt
N
N
Boc
+
NHTrt
CO2Bn
t-BuO2C
NHBoc
t-BuO2C
NHBoc326
327  
Scheme 4.54 
 
(3) Sonogashira reactions [217] 
.
N
N
SO2NMe2
Br
Ph +
Pd(OAc)2, PPh3
CO2Et
CuI, K2CO3
DMF, 80 °C, 16 h
78 %
N
N
SO2NMe2
Ph
EtO2C
328
329  
Scheme 4.55 
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(4) Heck reaction [218] 
 
Pd(PPh3)4N
N
SPh +Br
DMF, 140 °C
58 %
N
N
SPh
EtO2C
CO2Me
330  
Scheme 4.56 
 
As expected in Pd-catalyzed cross-coupling of polyhaloimidazoles, the 2-position is more 
active than the 4-position and the 5-position.  
 
(1) Suzuki reaction [219] 
 
N
N
I
I
SEM
I
N
N
I
Ar
SEM
I
+ ArB(OH)2
Pd(PPh3)4
Na2CO3, 45 %
Ar = 1-TBS-indole-3-yl
331
 
Scheme 4.57 
 
(2) Stille reaction [215] 
 
N
N
Bn
Br
Br
+ PhSnMe3
Pd(PPh3)2Cl2
PhMe, reflux, 58 %
N
N
Bn
Ph
Br
332 
Scheme 4.58 
 
(3) Sonagashira reaction [220] 
 
N
N
H
I Pd(PPh3)2Cl2, CuI
TEA, 65 °C, 52 %
t-BuO2C
BocHN I
N
N
H
t-BuO2C
BocHN IPh
Ph
333  
Scheme 4.59  
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4,5-Diphenylimidazole was chosen as starting material and a series of imidazole derivatives 
were prepared to achieve potential calcineurin inhibiting compounds, which fitted into the 
general structure 8. 
 
The 1-(3-aminopropyl)-imidazole 335, where the side chain is not attached to a carbon atom 
but to a nitrogen atom, was synthesized in a Pd-free reaction. Alkylation of 4,5-
diphenylimidazole with N-3-bromopropylphthalimide, and final deprotection of the 
phthalimido product 334 gave 3-(4,5-diphenyl-imidazol-1-yl)-propylamine 335 in 85 % 
yield. (Scheme 4.60) 
 
N
N
Ph
Ph
NPhth
N
H
N
Ph
Ph
334
335
Cs2CO3/DMF
60 oC, 94 %
i N2H4-H2O/ethanol,reflux
ii 4 N HCl,reflux
85 %
Br-(CH2)3NPhth
N
N
Ph
Ph
NH2  
 
Scheme 4.60 
 
 
We further tried to introduce an aminoalkyl chain into position 2 of the imidazole ring. 4,5-
diphenylimidazole was first N-protected by benzylation [221], thus adding a third aryl 
group to the core heterocycle. (Scheme 4.61) 
 
N
H
NPh
Ph
N
N
Ph
Ph
Ph
Cl
+
K2CO3
DMF, 80 °C
93 % 336
 
 
Scheme 4.61 
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Halogenation of 1-benzyl-4,5-diphenyl-imidazole 336 with NBS was successful, but failed 
with NIS in THF. (Scheme 4.62) 
 
N
N
Ph
Ph
Ph
336
N
N
Ph
Ph
Ph
I
NIS, THF, reflux
337
N
N
Ph
Ph
Ph
Br
338
NBS / CH3CN
RT, 60 %
 
Scheme 4.62 
 
 
Sonogashira coupling of 1-benzyl-2-bromo-4,5-diphenylimidazole 338 with N,N-dimethyl-
propargylamine in the presence of Pd(PPh3)2Cl2/CuI gave low yield in DMF. However, 
when TEA was used as solvent, the coupling product 339 could be obtained in 43 %. 339 
was further hydrogenated with hydrogen, catalyzed by 10 % Pd/C, providing [3-(1-benzyl-
4,5-diphenyl-imidazol-2-yl)-propyl]-dimethyl-amine 340 in 63 % yield. (Scheme 4.63) 
 
Pd(PPh3)2Cl2, CuI
TEA, 80 °C, 24 h
43 %
N
NPh
Ph
Ph
Br
338
NMe2
+
N
NPh
Ph
Ph
Pd(PPh3)2Cl2, CuI
TEA/DMF, 100 °C
 24 h, 27 %
CH2NMe2
339
N
NPh
Ph
Ph
CH2NMe2
340
H2, Pd/C
EtOH, 63 %
 
Scheme 4.63 
Chapter 5: Activities of calcineurin inhibitors 
 
5.1 Measurement of calcineurin inhibitory activity 
The enzyme inhibitory effect of a compound is usually characterized by the IC50 value, the 
smaller the IC50 value, the higher is the inhibitory activity. For example the known good 
calcineurin inhibitors, cyclosporin A, microcystin IR and FK506, exhibit IC50 values of 0.5 
µM, 0.2 µM and 0.2 µM, respectively.  
Inhibiting activities of the new compounds synthesized by us are determined up to a value 
of 20 µM. If the inhibiting activity of a compound is lower (i.e. the inhibitor is weak), the 
remaining activity of calcineurin is recorded at a concentration of the inhibitor of 20 µM, 
e.g. “60 % activity at 20 µM” means at 20 µM concentration of inhibitor, 60 % of 
calcineurin protein is still active. Again, the smaller the value, the higher is the activity. If 
the compound does not show inhibition at a concentration of 20 µM, it is termed “not 
active”. 
In pharmacology and biochemistry, in order to determine the efficacy of a drug or inhibitor, 
the following terms are commonly used.  
EC50: Clinical efficacy of a drug (Concentration required) to produce 50% of the maximum 
effect (may be inhibitory or stimulatory effect). This term is used usually with 
pharmaceuticals.  
ED50: Medium effective dose (as opposed to concentration) at which 50 % of individuals 
exhibit the specified quantitative effect.  
IC50: Concentration required producing 50 % inhibition.  
Ki: Inhibitor concentration at which 50% inhibition is observed. It is calculated using 
Michaelis-Menten kinetics.  
 
5.2 Calcineurin inhibitory activity of target molecules 
 
Parallel to the synthesis of new calcineurin inhibiting compounds presented in this thesis, 
other synthetic efforts in our group [16b] concentrated on pyrazolo[1,5-a]pyrimidine 341, 
with a side chain at the position 7. (Figure 5.1) 
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N
N N
Y
Ar1
341
Ar2
R2R1N
n
7
 
Figure 5.1 
 
The best inhibiting activities of these pyrazolo[1,5-a]pyrimidines were achieved with 
compounds 4, 342 and 343. (Figure 5.2) 
 
N
N N
p-Cl-Ph
Ph
O
N
N N
p-Cl-Ph
Ph
HN
N
N N
p-Cl-Ph
Ph
IC50 = 2.0 µM IC50 = 3.0 µM IC50 = 4.5 µM
NMe2
NMe2 NHMe HCl
4 342 343
 
 
Figure 5.2 
 
Calcineurin inhibitory activities of pyrazolo[1,5-a]pyrimidine compounds, synthsized by us, 
are listed in Table 5.1.  
 
Our synthetic strategy allowed to synthesize pyrazolo[1,5-a]pyrimidines, where the ω-
functionalized saturated side chain is attached to other positions than in 341, i.e. position 5 
or position 3. This positional change is tolerated to a certain extent (see Table 5.1 
compounds 128, 129, 116a, 116b), if an aminoalkylamino chain is found in position 5 (see 
compound 128). On the other hand, 3-aminoalkyl substituted pyrazolo[1,5-a]pyrimidines 
show almost no activity (see Table 5.1 compounds 116a and 116b). However, the 
aminopropynyl precursors 113a, 113 b, 113c and 113d exhibit an unexpectedly high 
activity. This indicates that the side chain of the general structure 8 can also be unsaturated. 
Comparison of compounds 113d and 113e reveal a massive effect of the aryl substitutent on 
the inhibition strength. If the terminal group in the side chain is not basic like in the 
phthalimide compound 118 or in the nitrile (compound 107a), the activity gets lost as found 
in other investigation performed in our group [16b]. 
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Table 5.1 Derivatives of pyrazolo[1,5-a]pyrimidine 
 
 
Structure Name Activity Structure Name Activity 
 
N
N N
Ph
Ph
HO
 
 
 
131 
Yl-133 
 
77 % 
activity 
at 20 
µM 
 
N
N N
Ph
Ph
OH 
 
113f 
Yl-
215 
 
28 % 
activity 
at 20 
µM 
 
 
N
N N
Ph
OH
Ph
 
 
 
113g 
Yl-298 
 
77 % 
activity 
at 20 
µM 
 
 
N
N N
Ph
Ph
OH 
 
113k 
Yl-
293 
 
81 % 
activity 
at 20 
µM 
 
 
N
N N
Ph
Ph
OH
 
 
113i 
Yl-354 
 
91 % 
activity 
at 20 
µM 
 
 
 
 
 
 
 
 
 
N
N N
Ph
N
H PhN
 
 
 
128 
Yl-193 
 
IC50 
=18.5 
µm 
 
N
N N
Ph
Ph
H
NMe2N
 
 
 
129 
Yl-
217 
 
51 % 
activity 
at 20 µm
 
 
 
N
N N
Ph
Ph
H2N  
 
 
127 
Yl-308 
 
not 
active 
 
 
   
 
N
N N
Ph
Ph
O
O
 
 
109 
Yl-245 
 
67% 
activity 
at 20 
µM 
 
 
 
N
N N
Ph
Ph
 
 
114 
Yl-
286 
 
78 % 
activity 
at 20 
µM 
 
 
 
N
N N
Ph
Ph
CO2Me 
 
 
106h 
Yl-208 
 
not 
active 
 
 
N
N N
Ph
CO2Me
Ph
 
 
106a 
Yl-
42 
 
not 
active 
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N
N N
Ph
CN
Ph
 
 
 
107a 
Yl-43 
 
not 
active 
 
 
 
 
 
 
 
 
 
N
N N
Ph
N
Ph-Cl-p
 
 
113d 
Yl-209 
 
IC50 = 
8.5 µM 
 
N
N N
Ph-Cl-p
N
Ph
 
 
 
113e 
Yl-
261 
 
53 % 
activity 
at 20 
µM 
 
 
N
N N
Ph
Ph
N
 
 
 
113b 
Yl-197 
 
IC50  = 
11.2 
µM 
 
N
N N
Ph
Ph
N
 
 
116b 
Yl-
266 
 
not 
active 
 
 
N
N N
Ph
Ph
N
 
 
 
113a 
Yl-199 
 
IC50 = 
13.2 
µM 
 
N
N N
Ph
Ph
N
 
 
116a 
Yl-
328 
 
84 % 
activity 
at 20 
µM 
 
 
N
N N
Ph
Ph
N
 
 
 
113c 
Yl-190 
 
IC50 = 
12.0 
µM 
 
 
 
 
 
 
 
N
N N
Ph
Ph
NMe2
 
 
117 
Yl-282 
 
not 
active 
 
 
N
N N
Ph
Ph
NPhth 
 
118 
Yl-
352 
 
94 % 
activity 
at 20 
µM 
 
 
 
Table 5.2 shows the results of calcineurin inhibition tests of compounds fitting into the 
general structure 8, where the central cores are other N-containing bicyclic heterocycles. 
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Unexpectedly, none of the examples reached activities of pyrazolo[1,5-a]pyrimidines. This 
fact demonstrates that the central heterocycle of the structural model 8 plays a crucial role. 
 
 
Table 5.2 Derivatives of other bicyclic heterocycle 
 
Structure Name Activity Structure Name Activity 
 
N
N N
N
Ph
HN
Ph
N
 
 
189 
Yl-
185 
 
84% 
activity 
at 20 
µM 
 
 
N
N N
N
Ph
O
Ph
N  
 
Yl-
202 
 
190 
not 
active 
 
 
N
N N
N
Ph
HN
N
Ph
 
 
192 
Yl-
201 
 
 
not 
active 
 
 
 
 
 
 
 
 
 
N
N N
N
Ph
Ph
CH2NMe2
 
 
186 
Yl-
368 
 
95 % 
activity 
at 20 
µM 
 
 
 
N
N N
N
Ph
Ph
CH2NMe2
 
 
187 
Yl-
376 
 
87 % 
activity 
at 20 
µM 
 
 
 
N N
N Ph
Ph
N
 
 
 
194b 
Yl-
238 
 
90 % 
activity 
at 20 
µM 
 
 
 
N N
N Ph
Ph
N
 
 
195 
Yl-
350 
 
53 % 
activity 
at 20 
µM 
 
 
N N
N Ph
Ph
N
N
 
 
198 
Yl-
247 
 
 
not 
active 
 
 
N N
N Ph
Ph
MeO2C
 
 
200 
Yl-
354 
 
 
not 
active 
 
 
N N
N Ph
Ph
H
N
N  
 
 
199 
Yl-
258 
 
70 % 
activity 
at 20 
µM 
 
 
 
 
N N
N Ph
Ph
PhthNH2C
 
 
202 
Yl-
260 
 
74 % 
activity 
at 20 
µM 
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N N
N Ph
Ph
OH
 
 
 
194a 
Yl-
377 
 
78 % 
activity 
at 20 
µM 
 
 
 
N
N
Ph
Ph
H
N
Me2N
 
 
 
227 
Yl-
252 
 
72 % 
activity 
at 20 
µM 
 
 
N
N
Ph
Ph
N
O
 
 
 
225 
Yl-
237 
 
81 % 
activity 
at 20 
µM 
 
 
 
N
N
Ph
Ph
N
N
 
 
226 
Yl-
240 
 
 
not 
active 
 
 
N
N
Ph
Ph
N
 
 
 
220 
Yl-
242 
 
not 
active 
 
 
N
N
Ph
Ph
N
 
 
221 
Yl-
331 
 
57 % 
active 
at 20 
µM 
 
 
NN
N
Ph
Ph
N
 
 
223 
Yl-
279 
 
94 % 
activity 
at 20 
µM 
 
 
NN
N
Ph
Ph
N
 
 
 
224 
Yl-
324 
 
67 % 
activity 
at 20 
µM 
 
 
Parallel work in our group has led to pyrimidines 344, which exhibit high calcineurin 
inhibiting activities and remarkably low toxicity. (Figure 5.3) 
N
NAr1 Ar2
Y (CH2)n-NR2
N
N
Cl
HN
IC50 = 1.2 µM
N
N
Cl
S NMe2
IC50 = 1.5 µM
344
NMe2
345 346
ClCl
N
N
Cl
S NMe2
IC50 = 2.7 µM
347
Cl
N
N
Cl
O NMe2
IC50 = 3.0 µM
348
Cl
N
N
S NMe2
IC50 = 18.0 µM
349
 
Figure 5.3 
Chapter 5: Activities of calcineurin inhibitors 
_________________________________________________________________________________________________________________________________ 
98
Calcineurin inhibitory activities of pyrimidine compounds, synthesized by us, are listed in 
Table 5.3.  
 
Table 5.3 Derivatives of pyrimidine 
 
Structure Name Activity Structure Name Activity
 
N
N
Ph
Ph S
NMe2 
 
 
261a 
Yl-
211 
 
IC50 
=20 
µM  
 
N
N
Ph
Ph N
H
NMe2 
 
262 
Yl-
210 
 
75 % 
activity 
at 20 
µM 
 
 
N
N
Ph-Cl-p
p-Cl-Ph S
NMe2 
 
261b 
Yl-
314 
 
61 % 
active 
at 20 
µM 
 
 
N
N
Ph
Ph O
NMe2 
 
263 
Yl-
212 
 
76 % 
activity 
at 20 
µM 
 
 
N
N
Ph
Ph NMe2 
 
 
259a 
Yl-
181 
 
75 % 
activity 
at 20 
µM 
 
 
N
N
Ph
Ph NMe2 
 
260 
Yl-
383 
 
46 % 
activity 
at 20 
µM 
 
 
N
N
Ph-Cl-p
p-Cl-Ph NMe2 
 
 
259b 
Yl-
315 
 
not 
active 
 
 
N
N
Ph-Cl-p
Ph NMe2 
 
 
259c 
Yl-
322 
 
not 
active 
 
 
N
N
Ph
Ph NMe2 
 
256 
Yl-
323 
 
53 % 
activity 
at 20 
µM 
 
 
N
N
Ph
Ph NMe2
 
 
257 
Yl-
330 
 
50% 
activity 
at 20 
µM 
 
 
N
N
Ph
Ph NPhth 
 
 
258 
Yl-
346 
 
53 % 
activity 
at 20 
µM 
 
   
 
 
Our synthetic methodology allowed to synthesize 4-dimethylaminopropyl pyrimidine 257, 
which represents an example of structure 344 with X = CH2, and to provide access to 
isomers 260, 261a, 261b, 262 and 263, where the saturated side chains were attached to 
position 2. It turned out that all these analogous or isomers showed a comparable activity. 
For improvement variation of the aryl groups would be advisable. 
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Calcineurin inhibitory activities of other momocyclic N-heterocycles substituted by ω-
functionalized side chains and two aryl groups fitting into the general structure 8, are shown 
in Table 5.4. Unfortunately all these compounds showed much lower activities than the 
corresponding pyrimidines 344. Nevertheless, some surprising results are mentioned here: 
the dimethylaminopropynyl oxazole 311 showed a higher activity than the structure 
analogue 312. 2-Amino-3,5-diphenylpyridine 283 and its oxygen-analogue 285 show a 
modest inhibiting activities, although they do not fit into the general structure 8. 
 
 
Table 5.4 Derivatives of other monocyclic heterocycle 
 
Structure name activity Structure name activity
 
N
NPh
Ph NH2 
 
 
335 
Yl-
219 
 
66 % 
activity 
at 20 
µM 
 
 
N
NPh
Ph NPhth 
 
334 
Yl-
204 
 
60 % 
activity 
at 20 
µM 
 
N
O
Ph
Ph
N
 
 
 
313a 
Yl-
249 
 
 
 
91 % 
activity 
at 20 
µM 
 
 
N
O
Ph
Ph
NH2
 
 
313 
Yl-
269 
 
89 % 
activity 
at 20 
µM 
 
 
N
O
Ph
Ph
NMe2
 
 
 
311 
Yl-
235 
 
78 % 
activity 
at 20 
µM 
 
 
N
O
Ph
Ph
NMe2
 
 
312 
Yl-
367 
 
88 % 
activity 
at 20 
µM 
 
N
OPh Ph
N
N
 
 
 
314 
Yl-
263 
 
68 % 
activity 
at 20 
µM 
 
   
 
N
NPh
Ph
Ph
CH2NMe2
 
 
339 
Yl-
373 
 
87 % 
activity 
at 20 
µM 
 
N
NPh
Ph
Ph
CH2NMe2
 
 
 
340 
Yl-
377 
 
71 % 
activity 
at 20 
µM 
 
N
N
Ph
Ph
N
 
 
 
322 
Yl-
321 
 
 
not 
active 
 
 
N
N
Ph
Ph
N
 
 
323 
Yl-
332 
 
72 % 
activity 
at 20 
µM 
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N
Ph Ph
NMe2 
 
 
298 
Yl-
336 
 
no 
active 
 
 
N
Ph Ph
NMe2 
 
299 
Yl-
341 
 
not 
active 
 
 
N
PhPh
NH2 
 
 
283 
Yl-
317 
68 % 
activity 
at 20 
µM 
 
N
H
PhPh
O
 
 
285 
Yl-
327 
68 % 
activity 
at 20 
µM 
 
N
NPh
NMe2Ph  
 
286 
Yl-
335 
 
81 % 
activity 
at 20 
µM 
 
 
N
NPh
NMe2Ph  
 
 
287 
Yl-
345 
 
62 % 
activity 
at 20 
µM 
 
 
 
Considering the calcineurin inhibitory effects of compounds obtained in our group so far, 
the following structure-activity relations can be summarized: 
 
(1) Effect of core heterocycle 
Pyrazolo[1,5-a]pyrimidine, pyrazolo[1,5-a]triazine and pyrimidine are preferable as core 
heterocycles in the general structure 8 of potential calcineurin inhibitors. 
Some corresponding active calcinerine inhibitors are shown below. (Figure 5.4) 
N
N N
R3
R2 R1
N
N N
Ph
Me2N(H2C)3HN
Ph
CH2NMe2
IC50 = 18.5 µΜ128113a-d,  IC50 = 8.5-13.2 µΜ
N
N
N N
CH2(CH2)4NMe2
p-Cl-Ph
Ph
2, IC50 = 1.5 µΜ
N
N
S-(CH2)2NMe2
p-Cl-Ph Ph
N N
S-(CH2)2NMe2
Ph Ph N
N
O-(CH2)2NMe2
p-Cl-Ph Ph
5, IC50 = 6.0 µΜ 6,  IC50 = 14.0 µΜ261a, IC50 = 20 µΜ
Pyrimidines
Pyrazolo[1,5-a]triazinePyrazolo[1,5-a]pyrimidines
 
Figure 5.4 
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(2) The position of side chain 
 
The optimal position of attachment of the side chain depends on the type of heterocycles. In 
the pyrazolo[1,5-a]pyrimidine series, position 7 of the pyrazolo[1,5-a]pyrimidine core is 
most effective for calcineurin inhibition, compared with connection sites 5 and 3. In 
addition, the CH2NH(CH2)3NMe2 side chain is less effective than NH(CH2)3NMe2.(Figure 
5.5) 
 
N
N N
Ph
Ph
NH(CH2)3NMe2
N
N N
Me2N(H2C)3HN
Ph
Ph
3  
IC50 = 7.5 µM
128
IC50 = 18.5 µM
N
N N
Me2N(H2C)3HNH2C
Ph
Ph
129  
51 % activity at 20 µM 
 
Figure 5.5 
 
In the pyrimidine series, many target molecules with side chains at position 4, and position 
2 were synthesized and tested. It was found that the calcineurin inhibitory activities of these 
two kinds of compounds are similar. (Figure 5.6) 
 
N
N
PhPh
NH(CH2)3NMe2
N N
PhPh
NH(CH2)3NMe2
N
N
PhPh
O(CH2)2NMe2
N N
PhPh
O(CH2)2NMe2
N
N
PhPh
S(CH2)2NMe2
N N
PhPh
S(CH2)2NMe2
N
N
PhPh
(CH2)3NMe2
N N
PhPh
(CH2)3NMe2
261a
IC50 = 20 µM
349
IC50 = 18 µM
263 
76 % activity 
at 20 µM
262
75 % activity 
at 20 µM
263 
46 % activity 
at 20 µM
350 
70 % activity 
at 20 µM
351
75 % activity 
at 20 µM
257
50 % activity 
at 20 µM
 
 
Figure 5.6 
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(3) The effect of substituted groups 
 
Based on some preliminary conclusions of the effect of substituents at the side chain on the 
activity of calcineurin inhibitors of the general structure 8, the following trends can be 
mentioned: 
 
(a) Heterocycles with Me2N(CH2)2S- side chain are more active than the compounds with 
Me2N(CH2)2O- and Me2N(CH2)3NH- side chain. (Figure 5.7) 
 
N
N
S-(CH2)2NMe2
p-Cl-Ph Ph
N N
S-(CH2)2NMe2
Ph Ph
N
N
O-(CH2)2NMe2
p-Cl-Ph Ph
5, IC50 = 6.0 µΜ 6,  IC50 = 14.0 µΜ
261a, IC50 = 20 µΜ
N N
O-(CH2)2NMe2
Ph Ph
N N
NH-(CH2)3NMe2
Ph Ph
263, 76 % at 20 µΜ 262, 75 % at 20 µΜ
N
N
NH-(CH2)3NMe2
p-Cl-Ph Ph
352, IC50 =10.0 µΜ  
 
Figure 5.7 
 
(b) Heterocycles with a Me2NCH2C≡C- side chain are more active than compounds with a 
saturated Me2N(CH2)3- side chain. (Figure 5.8) This trend is similar to a report by Cheng 
[222] on the activities of nicotinic receptors [Me2N(CH2)2O- > Me2N(CH2)2- > 
Me2NCH2C≡C- > Me2N(CH2)3-]. 
 
N
N N
Ph
Ph
CH2NMe2
N
N N
Ph
Ph
N
113a, IC50 = 13.2 µΜ 116a, 84 % at 20 µΜ  
 
Figure 5.8 
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(c) In general, heterocycles with one 4-chlorophenyl or one 3,4-dichlorophenyl are more 
active than the compounds with phenyl. (Figure 5.9) 
 
N
N N
Ph
Ph
CH2NMe2
113c, IC50 = 12.0 µΜ
N
N N
Ph
Ph-Cl-4
CH2NMe2
113d, IC50 =8.5 µΜ
N
N
S-(CH2)2NMe2
p-Cl-Ph Ph
5 
IC50 = 6.0 µΜ
N
N
S-(CH2)2NMe2
Ph Ph
349 
IC50 =18.0 µΜ
N
N
Cl
S-(CH2)2NMe2
IC50 = 1.5 µM
346
Cl
 
 
Figure 5.9 
 
 
On the other hand, our results demonstrated that it is impossible to deduce stringent roles for 
structure-activity relations from the data obtained so far. It would be extremely helpful if 
additional information (e.g. X-ray crystal analytical or NMR data), could be achieved about 
the interaction of an inhibitor with calcineurin. This would allow a prediction of optimized 
structure by the establishment of quantitative structure-activity-relation. 
 
Chapter 6: Summary 
 
 
Our research aimed to the development of new non-peptide calcineurin inhibitors. Such 
compounds are of eminent importance as immuno-suppressants and  are used in the 
treatment of heart insufficiency. Based on a positive test of a few compounds 
(pyrazolopyrimidines and pyrazolotriazines), a general structure 8 (Figure 6.1) of potential 
calcineurin-inhibiting compounds was hypothesized in our group. 
Heterocyclic
   core
Ar2Ar1
Y Aliphatic chain Z
General structure 8  
Figure 6.1 General Structure 8 
 
The structural feature represents an assembly of a heterocyclic core (nitrogen containing 
aromatic heterocycle), furnished with two aryl groups and one side chain with a terminal 
heteroatom functionality. It was necessary to prove to what extend this hypothesis is valid 
and which structure-activity relations exist.  
 
Investigations in Karanik’s thesis [16b] concentrated on pyrazolo[1,5-a]pyrimidines, 
pyrazolo[1,5-a]triazines and pyrimidines, where the aryl groups and the saturated chain (Y 
= NH, O, or S) were varied (Figure 6.2).  
 
N
N N
Ar1 Ar2
Y NR1R2n
N
N
Ar2Ar1
Y NR1R2n
( N )
350 351  
 
Figure 6.2 General Structures of Karanik’s thesis 
 
In the present thesis, we tried to vary the central N-heterocyclic cores, the side chains and its 
position of attachment. In the general structure 8, Y can be CH2 and CH2NH, besides NH, 
O, and S, and the aliphatic chain can be saturated and unsaturated. As a synthetic strategy, 
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Pd-catalyzed coupling reactions were used to introduce side chains and/or aryl substituents 
into the central heterocycle. In this way the utility of such reactions to heterocyclic systems, 
which were neglected so far, could be figured out. 
 
 
■ Synthesis of halogen subsitituted diaryl heterocycles 
 
Halogen substituted diaryl heterocycles are important intermediates in the synthesis of 
general structures 8. In order to introduce aryl groups into the heterocyclic core, Suzuki 
reaction was applied as the key step, for example, synthesis of 9-benzyl-8-bromo-6-
phenylpurine (185) and 3,5-diphenyl-2-iodopyridine (284). (Scheme 6.1) 
N NH2
Br Br
N I
Ph Ph
N
N N
N
Ph
Br
Bn
N
N N
N
Cl
Bn
284
185
132
 
 
Scheme 6.1 
 
If heterocycles with more than one halo-leaving group were used as starting materials, aryl 
group could be introduced by regioselective Suzuki coupling, e. g. synthesis of 5-chloro-
3,7-diphenylpyrazolo[1,5-a]pyrimidine (120), 7 (or 9)-benzyl-2-chloro-6-phenylpurine (140 
and 184) and 2-chloro-4,6-diarylpyrimidines (240 and 255). (Scheme 6.2) 
 
N
N N
Ph
Cl
Ph
101
N
N N
Cl
Cl
Ph
N
N N
N
Ph
Bn
N
N N
N
Cl
Bn
140137120
Cl Cl
N
N
Cl
Cl Cl
N
N
Ar
Cl Ar
N
N
Ph
Cl Ph-Cl-4
240 255  
Scheme 6.2 
 
Chapter 6: Summary 
_________________________________________________________________________________________________________________________________ 
106
Other starting haloheterocycles were obtained either by replacement of hydroxyl groups or 
by halogenation of the unfunctionalized position of the heterocycles. More than 30 
compounds of corresponding halo-heterocycles were synthesized. (Figure 6.3) 
 
N
N N
R2
R1
R
104a-104h, X = I
X
103, X = Br
N
N N
Ph
BrH2C
Ph
105
N
N N
X
Ph
Ph
98, 99, 100
 X = Cl, Br, I
N N
NBr Ph
Ph
193
N
N
N
Cl
Ph
Ph
219
N
N
Br
Ph
Ph
218
N
N
X
Ph Ph
250, X = Cl
251, X = I
N
NPh
Ph Cl
297
N
OPh Ph
Br
310
N
N
Ph
Ph
I
321
N
NPh
Ph
Bn
Br
338
 
Figure 6.3 
 
 
 
■ Introduction of side chains by Pd-catalyzed couplings and nucleophilic substitution 
 
The introduction of the desired side chains by C-C bond formation reactions was achieved 
by Sonogashira coupling and Heck coupling. Buchwald-Hartwig amination and nucleophilic 
substitution were used to establish side chains which are connected to the core heterocycle 
by heteroatom-C bonds.  
 
Sonogashira reaction turned out to be the most effective and convenient method to introduce 
ω-functionalized alkynyl group into the heterocyclic cores. Further catalytic hydrogenation 
of the alkyne moiets led to ω-functionalized alkyl substituted diaryl heterocycles. (Scheme 
6.3) Five bicyclic and six monocyclic core heterocycles could be successfully submitted to 
this reaction sequence.  
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Several reaction conditions and Pd-catalysts were tested. It turned out that Pd/C was 
advantageous over other commonly used Pd(II) or Pd(0) pre-catalysts in a number of cases 
(104a and 321 as starting material).  
 
Diphenyl
Heterocycle X
X = I, Br, Cl
Diphenyl
Heterocycle CH2R
Diphenyl
Heterocycle (CH2)3NMe2
CH2R
halo-heterocycles
 (18 reactants)
alkynes (24 products)
reduced products
(13 products)
Sonogashira reaction
catalytic
hydrogenation
R = NMe2, OH, CH2OH, NPhth
 
 
Scheme 6.3 
 
Heck reaction of 3-iodopyrazolo[1,5-a]pyrimidines (104a-h) or 7-bromo-pyrido[2,3-
b]pyrazine (193) with olefins, allowed to introduce ω-functionalized alkenyl groups into 
these heterocyclic cores. (Scheme 6.4) 
 
N
N N
R3
R2
R1
I
N
N N
R3
R2
R1
R4
R4
Pd(PPh3)2Cl2
Et3N, MeCN
argon, reflux
 106a-h,  R4 = CO2R,
 107a-c,  R4 = CN, 
 109,  R4 = CO2CH2CH2NMe2
104 ( E )
N N
NBr Ph
Ph
R
N N
N Ph
Ph
R
193
200,
201,
202,
Pd(OAc)2 
P(o-Toyl)3
TEA, MeCN
100 °C, 20 h
R = CO2Me
R = CN
R = NPhth
(E)  
 
Scheme 6.4 
 
Buchwald-Hartwig amination of 6-bromoimidazo[1,2-a]pyridine (218), 7-bromo-
pyrido[2,3-b]pyrazine (193) or 4-bromooxazole (310) with ω-functionalized alkylamines, 
allowed the introduction of aminoalkyl chains, which are tethered to the heterocyclic cores 
by a heteroatom. (Scheme 6.5) 
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Diphenyl
Heterocycle Br
Diphenyl
Heterocycle Y-(CH2)nNR1R2
218, 193, or 310
HY-(CH2)nNR1R2
Pd2(dba)3, BINAP
225-227, 198-9, or 314
X = N, NH
 
 
Scheme 6.5 
 
 
Our synthetic affords contributed to the general knowledge about the scope and limitation of 
Pd-catalyzed reactions in heterocyclic chemistry.  
 
By nucleophilic substitution, a series of purines, pyrimidines, and pyrazolo[1,5-
a]pyrimidines with a side chain (X = O, S, NH, or CH2NH) were synthesized (Figure 6.4). 
 
N
N
Ar1
Ar2 Y
(CH2)nNMe2
X = O, S, or NH, n = 2, or 3;
N
N
Ph
Y
(CH2)3NMe2
X = CH2NH, or NH
N
Ph
N
Ph
Y
(CH2)nNMe2
N
N
Bn
X = O,  or NH, n = 2, or 3;
261-263 128, 129 190, 191, 192 (7-benzyl)
 
Figure 6.4 
 
 
 
■ Calcineurin inhibitory activities 
 
Compared with the compounds of high activity independently obtained in our group by 
other methodology, the positions of connections of the side chains and aryl groups in the 
pyrazolo[1,5-a]pyrimidine series could be varied. According to the testing results of the 
compounds, we found out that the connection of the side chain to position 7 of 
pyrazolopyrimidine core is most effective for calcineurin inhibition as compared with other 
connection sites. The necessity of a basic amino group at the terminus of the side chain was 
manifested by our results. It was further detected, that the side chain can be unsaturated. 
(Figure 6.5) 
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N
N N
Ph
Ph
NH(CH2)3NMe2
N
N N
Me2N(H2C)3HN
Ph
Ph
3   
IC50 = 7.5 µM
128
IC50 = 18.5 µM
N
N N
R2
R3
R1
NMe2
113a-113d
IC50 =8.5-13.2 µM  
 
Figure 6.5 
 
Novel pyrimidines, where the amino substituted side chain was connected to position 2 
rather than to position 4, revealed that these two positions are similar effective with respect 
to calcineurin inhibition.  
 
Prior to the present thesis, compounds of the general structure 8 were investigated only with 
pyrazolopyrimidine, pyrazolotriazine and pyrimidine as central heterocyclic core. In the 
course of this thesis, novel compounds with purine, pyridopyrazine, imidazopyridine, 
imidazopyridazine, imidazole, oxazole, pyrazole, pyridine, and pyrazine were developed 
and tested.  
 
The enzyme inhibiting test showed that, unfortunately, all these heterocyclic systems are not 
as effective as pyrazolopyrimidines, pyrazolotriazines and pyrimidines. 
 
The structural model 8 of potential calcineurin inhibitors could be refined and important 
contributions to its scope and limitations were provided. The results further demonstrate the 
vast versatility of Pd-catalyzed coupling reactions in new areas of heterocyclic chemistry.  
 
 
In the present work, more than 180 compounds were synthesized. Among them, about 130 
compounds are new products. 86 of them fit into the general structure 8. 
 
Five publications arouse from these results. Two of them have been published, one is in 
press. Another two are under preparation.  
  
Chapter7: Experimental 
 
7.1 General Remarks 
 
1H NMR and 13C NMR spectra were recorded at 300 MHz and 75.5 MHz, respectively, with a 
Bruker AC-300 in deuterated solvent (CDCl3, DMSO-d6, D2O, CD3OD etc.), with TMS as 
internal standard. The following abbreviations are used in the splitting pattern of 1H NMR: s 
(singlet), br (broad single), d (doublet), dd (double doublet), t (triplet), q (quartet), m 
(multiplet). 
 
EI-Mass spectra (MS) (HP-5995 A) and EI-high resolution mass (HRMS) spectra (MAT 711, 
Varian) were measured at 70 eV. 
 
Elemental analysis was measured at CHNS-932 (Leco) in the microanalytical lab of institute 
of chemistry. 
 
Melting points were determined on a Boetius hot-stage apparatus and were reported 
uncorrected. 
 
TLC analysis was performed on Merck silica gel 60 F254 plates or Merck Al2O3 60F254 neutral 
(Typ E) plates and visualized with UV illumination. 
 
Column chromatography was conducted with Merck silica gel 60 (400-639 mesh) or Merck 
neutral Al2O3 gel (90 standard). The normal solvents hexane, cyclohexane, ethyl acetate, 
dichloromethane were redistilled before use.  
 
The cross-coupling reactions were carried out under argon in oven-dried glasswares. Solvents 
were dried and deoxygenated by standard procedures.  
 
Starting materials were purchased from Aldrich, Lancaster, Acros, and Merck, except 
compounds S1-S11 (see Scheme7.1 to 7.4). 
3-amino-5-arylpyrazoles S2 were prepared according to literatures [223, 224], 3-amino-4-
arylpyrazoles S4 were prepared as described in the literatures [225, 226]. (Scheme 7.1) 
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N
N
H
NH2
Ar
N
N
H
NH2
Ar
S-2
S-4
Ar CN
HCO2Et
EtONa/EtOH Ar CN
CHO
NH2-NH2.H2O
Ar
O
1.DMF, POCl3
2. NH2OH.HCl
Ar C
Cl
C
H
CN NH2-NH2.H2O
S-1
S-3
Ar = Ph, 4-ClPh
Ar = Ph, 4-ClPh  
 
Scheme 7.1 
 
1-(4-chloro-phenyl)-butane-1,3-dione S5 was prepared according to literature [227] (Scheme 
7.2). 
O O
Cl
S-5
Cl
O
1) Ac2O; BF3-Et2O, RT
2) AcONa, H2O, reflux
11 %
 
Scheme 7.2 
 
Allyl-trityl-amine S-6, allyl trityl ether S-7, allyl-phthalamide S-8, and propargyl phthalamide 
S-9 were prepared according to literatures [228-231], respectively (Scheme 7.3). 
NH2 Tr
H
N
OH
Tr
O
Tr-Cl+
Tr-Cl+
DCM, RT
DCM, RT
TEA, DMAP
S-6
S-7
NH2 O
O
O
+
CHCl3 , 70 °C
4 h, 56 %
NPhth S-8
Br N
O
O
+
ethanol , 60 °C
72 h, 48 %
NPhth S-9K
86 %
85 %
 
Scheme 7.3 
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4-Ethynyl-phenyl)-dimethylamine S-11 was prepared according to literature procedures [232]. 
(Scheme 7.4). 
N
Br
OH
+
N
N
OH
Pd(PPh3)2Cl2
CuI, PPh3
piperdine
100 °C, 70 %
KOH/toluene
reflux, 94 %
S-10 S-11
 
 
Scheme 7.4 
 
 
 
 
7.2 Synthesis of pyrazolo[1,5-a]pyrimidine derivatives 
 
7.2.1 Synthesis of pyrazolo[1,5-a]pyrimidines by ring closure 
 
7.2.1.1 Synthesis of 2, 5, 7-tri-substituted pyrazolo[1,5-a]pyrimidines  
 
N
N N
R2
R1
R 88a-88h
 
 
General procedure: 
A 50 ml round flask was charged with appropriate 5-substituted 3-aminopyrazole (20 mmol), 
appropriate 1,3-diketone (22 mmol) and 37 % hydrochloric acid (15 ml). The mixture was 
heated at reflux for 3 h. After the reaction was complete (from TLC), the mixture was cooled, 
neutralized with aq. Na2CO3 and extracted with CHCl3 (3 × 40 ml). The combined organic 
layers were dried with anhydrous MgSO4. The solvent was evaporated and the crude product 
was purified by recrystallization or column chromatography on silica gel. 
 
5-Methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidine (88a) 
 
The crude product was purified by recrystallization with ethanol as solvent, and provided a 
light yellow solid, yield 89 %, mp 185-6 °C. 
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1H-NMR(CDCl3), δ(ppm): 2.62 (s, 3 H, CH3), 6.74 (s, 1 H, H-3), 6.90 (s, 1 H, H-6), 7.43-8.14 
(m, 10 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 24.79 CH3, 92.54 CH(C-3), 108.15CH(C-6), 126.58 CH, 128.50 
CH, 128.64 CH, 129.45 CH, 129.70 CH, 130.90 CH, 131.15 C, 133.10 C, 145.73 C, 150.82 C, 
155.72 C, 158.65 C. 
 
HRMS(EI) calcd for C19H15N3(M+) 285.12660, found 285.12656. 
 
Anal. Calcd. for C19H15N3: C, 79.98; H, 5.30; N, 14.73. 
                                Found: C, 79.81; H, 5.34; N, 14.78. 
 
 
2-(4-Chloro-phenyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidine (88b) 
 
The crude product was purified by recrystallization with ethanol as solvent, and provided a 
light yellow solid, yield 66 %, mp 156-8 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.64 (s, 3 H, CH3), 6.78 (s, 1 H, H-3), 6.88 (s, 1 H, H-6), 7.37-8.12 
(m, 9 H, Ar-H). 
13C-NMR (CDCl3), δ(ppm): 24.79 CH3, 92.50CH(C-3), 108.36 CH(C-6), 127.78 CH, 128.53 
CH, 128.78 CH, 129.41 CH, 130.97 CH, 131.00 C, 131.49 C, 134.60 C, 145.74 C, 150.84 C, 
154.49 C, 158.87 C. 
 
Anal. Calcd. for C19H14ClN3: C, 71.36; H, 4.41; Cl, 11.09; N, 13.41. 
                                    Found: C, 71.52; H, 4.50; Cl, 11.10; N, 13.24. 
 
 
2-Methyl-5,7-diphenylpyrazolo[1,5-a]pyrimidine (88c) 
 
The crude product was purified by recrystallization with ethanol as solvent, and provided a 
light yellow solid, yield 74 %, mp 113-4 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.53 (s, 3 H, CH3), 6.58 (s, 1 H, H-3), 7.24 (s, 1 H, H-6), 7.49-8.09 
(m, 10 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 14.92 CH3, 96.47 CH( C-3), 104.42 CH(C-6), 127.20 CH, 128.68 
CH, 128.87 CH, 129.26 CH, 130.09 CH, 130.87 CH, 131.66 C, 137.73 C, 146.15 C, 150.65 C, 
155.44 C, 155.82 C. 
 
Anal. Calcd. for C19H15N3 : C, 79.98; H, 5.30; N, 14.73. 
                                 Found: C, 79.83; H, 5.36; N, 14.74. 
 
 
7-(4-Chloro-phenyl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidine (88d) 
 
The crude product was purified by recrystallization, using ethanol as solvent, and afforded a 
light yellow solid, yield 77 %, mp 155-7 °C. 
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1H-NMR(CDCl3), δ(ppm): 2.63 (s, 3 H, CH3), 6.74 (s, 1 H, H-3), 6.92 (s, 1 H, H-6), 7.37-8.13 
(m, 9 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 24.80 CH3, 92.69 CH(C-3), 107.95 CH(C-6), 126.53 CH, 128.69 
CH, 128.80 CH, 128.91 CH, 129.50 C, 130.78 CH, 132.91 C, 137.02C, 144.49 C, 150.78 C, 
155.79 C, 158.62 C. 
 
Anal. Calcd. for C19H14ClN3: C, 71.36; H, 4.41; Cl, 11.09; N, 13.41. 
                                    Found: C, 71.16; H, 4.58; Cl, 11.17; N, 13.09. 
 
 
2,5-Dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine (88e) 
 
The crude product was purified by recrystallization, using ethanol as solvent, and provided a 
light yellow solid, yield 78 %, mp 81-2 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.50(s, 3 H, CH3), 2.60(s, 3H, CH3), 6.41(s, 1 H, H-3), 6.67(s, 1H, 
H-6), 7.52-8.03 (m, 5 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 14.83 CH3, 24.69 CH3, 95.18 CH(C-3), 107.50 CH(C-6), 128.60 
CH, 129.20 CH, 130.80 CH, 131.13 C, 145.56 C, 150.37 C, 154.85 C, 158.29 C. 
 
Anal. Calcd. for C14H13N3: C, 75.31; H, 5.87; N, 18.82. 
                                Found: C, 75.19; H, 5.98; N, 18.83. 
 
 
2,5,7-Trimethylpyrazolo[1,5-a]pyrimidine (88f) 
 
The crude product was purified by recrystallization, using diethyl ether/hexane (1/2) as solvent, 
and provided a light brown solid, yield 68 %, mp 69-70 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.52 (s, 3 H, CH3), 2.54 (s, 3 H, CH3), 2.71 (s, 3 H, CH3), 6.36 (s, 1 
H, H-3), 6.48(s, 1 H, H-6). 
13C-NMR(CDCl3), δ(ppm): 14.67 CH3, 17.17 CH3, 24.43 CH3, 95.09 CH(C-3), 107.54 CH(C-
6), 144.90 C, 149.08 C, 154.63 C, 157.98 C. 
 
Anal. Calcd. for C9H11N3: C, 67.06; H, 6.88; N, 26.07. 
                               Found: C, 66.81; H, 7.01; N, 26.14. 
 
 
2,5,7-Triphenylpyrazolo[1,5-a]pyrimidine (88g) 
 
The crude product was purified by recrystallization with ethanol as solvent, and provided a 
light yellow solid, yield 77 %, mp 154-5 °C. 
 
1H-NMR(CDCl3), δ(ppm): 7.09 (s, 1 H, H-3), 7.24 (s, 1 H, H-3), 7.35-8.22 (m, 15 H, Ar-H). 
13C NMR(CDCl3), δ(ppm): 93.76 CH(C-3) , 105.04 CH(C-6), 126.61 CH, 127.22 CH, 128.57 
CH, 128.68 CH, 128.88  CH, 128.93 CH, 129.52 CH, 130.25 CH, 131.46 C,  133.05 C, 137.61 
C, 146.37 C, 151.15 C, 156.09 C, 156.26 C. 
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Anal. Calcd. for C24H17N3: C, 82.97; H, 4.93; N, 12.09. 
                                Found: C, 82.89; H, 4.99; N, 11.99. 
 
 
5,7-Diphenylpyrazolo[1,5-a]pyrimidine (88h) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate(4/1) as eluting solvent, and provide a yellow solid, yield 89 %, mp 85-6 °C. 
 
1H-NMR(CDCl3), δ(ppm): 6.30 (d, 1 H, J = 2.3, H-3), 7.28( s, 1 H, H-3), 7.44-8.08 (m, 10 H, 
Ar-H), 8.11 (d, 1H, J = 2.3, H-2). 
13C-NMR(CDCl3), δ(ppm): 97.19 CH(C-3), 105.22 CH(C-6), 127.29 CH, 128.74 CH, 128.95 
CH, 129.24 CH, 130.31 CH, 130.97 CH, 131.51 C, 137.52 C, 145.21 CH(H-2), 146.85 C, 
149.86 C, 156.22 C. 
Anal. Calcd. for C18H13N3: C, 79.68; H, 4.83; N, 15.49. 
                                Found: C, 79.34; H, 5.06; N, 15.54. 
 
 
 
7.2.1.2 Synthesis of 3,5,7-trisubstituted pyrazolo[1,5-a]pyrimidines 
 
N
N N
R2
R1
89a-89c
Ph  
 
A 50 ml flask was charged with 3-amino-4-phenylpyrazole S-4a (3.18 g, 20 mmol), appropriate 
1,3-diketone (22 mmol) and 37 % hydrochloric acid (15 mL). The mixture was heated at reflux 
for 10 hours. After the reaction was complete (check TLC), the mixture was cooled, neutralized 
with aq. Na2CO3 and extracted with CHCl3 (3 × 40 ml). The combined organic layers were 
dried with anhydrous MgSO4. The solvent was evaporated and the crude product was purified 
by recrystallization 
 
 
5,7-Dimethyl-3-phenylpyrazolo[1,5-a]pyrimidine (89a) 
 
The crude product was purified by recrystallization with ethanol:hexane(4/1) as solvent and 
provided a yellow solid, yield 75 %, mp 91-92 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.54 (s, 3 H, CH3), 2.67 (s, 3 H, CH3), 6.52 (s, 1 H, H-6), 7.17-8.02 
(m, 5 H, Ph-H), 8.32 (s, 1 H, H-2). 
13C-NMR(CDCl3),δ(ppm): 17.08 CH3(C-7), 24.93 CH3(C-5), 108.74 CH(C-6), 109.54 C, 
125.94 CH, 126.19 CH, 128.69 CH, 132.50 C, 142.14 CH(C-2), 144.81 C, 145.22 C, 158.74 C. 
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Anal. Calcd. for C14H13N3 (223.28): C, 75.31; H, 5.87; N, 18.82. 
                                               Found: C, 75.25; H, 5.94; N, 18.84. 
 
 
5-methyl-3,7-diphenylpyrazolo[1,5-a]pyrimidine (89b) 
 
The crude product was purified by recrystallization with ethanol to provide a yellow solid, 
yield 86 %, mp 124-5°C. 
 
1H-NMR(CDCl3), δ(ppm): 2.61 (s, 3 H, CH3), 6.70 (s, 1 H, H-6), 7.17-8.04 (m, 10 H, Ph-H), 
8.32 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 25.06 CH3, 108.71 CH(C-6), 109.57 C, 126.05 CH, 126.34 CH, 
128.69 CH, 128.76 CH, 129.21 CH, 130.90 CH, 131.20 C, 132.41 C, 142.56 CH(C-2), 145.84 
C, 146.24 C, 159.06 C. 
 
Anal. Calcd. for C19H15N3 (285.34): C, 79.98; H, 5.30; N, 14.73. 
                                               Found: C, 79.98; H, 5.41; N, 14.76. 
 
 
3,5,7-Triphenylpyrazolo[1,5-a]pyrimidine (89c): 
 
The crude product was purified by recrystallization with ethanol as solvent, and provided a 
yellow solid, yield 86 %, mp 163-4 °C. 
 
1H-NMR (CDCl3),δ(ppm): 7.17 (s, 1 H, H-6), 7.31-8.18 (m, 15 H, Ph-H), 8.41 (s, 1 H, H-2). 
13C-NMR (CDCl3),δ(ppm): 105.17 CH(C-6), 110.70 C, 126.14 CH, 126.37 CH, 127.35 CH, 
128.74 CH, 128.78 CH, 129.95 CH, 129.28 CH, 130.43 CH, 131.01 CH, 131.39 C, 132.41 C, 
137.38 C, 142.96 CH(C-2), 145.95 C, 147.02 C, 155.91 C. 
 
Anal. Calcd. for C24H17N3 (347.4): C, 82.97; H, 4.93; N, 12.10. 
                                             Found: C, 82.92; H, 5.01; N, 12.13. 
 
 
 
7.2.1.3 Hydroxy-substituted pyrazolo[1,5-a]pyrimidines 
 
7-hydroxy-3,5-diphenylpyrazolo[1,5-a]pyrimidine (90) 
 
N
N N
OH
Ph
90
Ph  
 
A mixture of 4-phenyl-3-aminopyrazole (3.18 g, 0.02 mol) and ethylbenzoyacetate (4.55 g, 
0.022 mol) in acetic acid 5 ml was heated at reflux for 20 h, the solution was evaporated to 
dryness in vacuo and treated with diethyl ether, white solid was obtained, the crude product 
was recrystallized with ethanol, and 4.26 g white solid was obtained, yield 74 %, mp 250-2 °C. 
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1H-NMR(DMSO-d6), δ(ppm): 6.06 (s, 1 H, H-6), 7.28-7.85 (m, 10 H, Ph-H), 8.22 (s 1 H, H-2), 
12.28 (br, 1 H, OH). 
13C-NMR(DMSO-d6), δ(ppm): 95.22 CH,106.23 C, 126.56 CH, 127.67 CH, 128.05 CH, 
128.21 Ch, 128.72 CH, 130.88 CH, 132.92 C, 136.23 C, 142.35 CH(C-2), 144,20 C, 150.67 C, 
156.32 C. 
 
Anal. Calcd. for C18H13N3O(287.32): C, 75.25; H, 4.56; N, 14.63. 
                                                 Found: C, 75.31; H, 4.68; N, 14.59. 
 
 
5,7-dihydroxy-3-phenylpyrazolo[1,5-a]pyrimidine (91) 
 
N
N N
OH
HO
91
Ph  
 
4-Phenyl-3-aminopyrazole S-4a (3.20 g, 0.02 mol) and diethyl malonate (3.23 g, 0.20 mol) 
were added to a solution of sodium (1.8g, 0.077mol) in 200 ml dry ethanol, the mixture was 
heated at reflux for 16 hours, after cooled the precipitate was collected by filter and washed 
with ethanol, and dried in vacuum, the solid (sodium salt) was dissolved in 150 ml water and 
the aqueous phase was acidified with 6 N HCl, the precipitate was collected and dried, the 
crude product was dissolved in 6N aqueous NaOH, and acidified the solution with 6N HCl, and 
provided a pure white solid 2.2 g, yield 50 %, mp 308-310 °C. 
 
Anal. Calcd. for C12H9N3O2(227.22): C, 63.43; H, 3.99; N, 18.49. 
                                                 Found: C, 63.20; H, 4.18; N, 18.32. 
 
 
7-hydroxy-3,5-diphenylpyrazolo[1,5-a]pyrimidine (92) 
 
N
N N
OH
92
 
 
A mixture of 3-amino-2-methylpyrazole (1.95 g, 0.02 mol) and ethyl acetoactate (3.12 g, 0.024 
mol) in 8 ml acetic acid was heated at reflux for 3 hours, after cooled, 40 ml water was added, 
the solution was cooled and the white solid was collected, washed with cold water and 
provided a white solid 2.32 g, yield 71 %, mp 226-8 °C. 
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1H-NMR(DMSO-d6), δ(ppm): 2.44 (s, 3H; CH3), 2.49 (s, 3 H, CH3), 5.27 (br, 1 H, OH), 5.69 
(s, 1 H, H-3), 6.09 (s, 1 H, H-6). 
13C-NMR(DMSO-d6), δ(ppm): 14.20 CH3, 19.68 CH3, 88.52 CH(C-2), 94.14 CH(C-6), 144.21 
C, 151.33 C, 151.47 C, 156.58 C. 
 
Anal. Calcd. for C8H9N3O(163.18): C, 58.88; H, 5.56; N, 25.75. 
                                              Found: C, 58.78; H, 5.87; N, 25.64. 
 
 
5,7-dihydroxy-3-methylpyrazolo[1,5-a]pyrimidine (93) 
 
N
N N
OH
HO
93
 
 
3-Amino-5-methylpyrazole (5.03 g, 51 mmol), diethyl malonate (9.60 g, 60 mmol) was added 
to a solution of sodium (3.2 g,0.14 mol) in 100 ml dry ethanol, the mixture was heated at reflux 
for 16hours, after cooled the precipitate was collected by filter and washed with ethanol, and 
dried in vacuum, the solid (sodium salt) was dissolved in 20ml water and the solution was 
acidified with 10 %  HCl ( to pH value <2), the solution was then cooled and the precipitate 
was collected, washed with cold 1 N HCl and dried, and provided a light yellow solid 6.9 g, 
yield 82 %, mp 244-6 °C. 
 
Anal. Calcd. for C7H7N3O2(165.15): C, 50.91; H, 4.27; N, 24.55. 
                                               Found: C, 50.75; H, 4.48; N, 24.29. 
 
 
 
7.2.2 Synthesis of halogen substituted pyrazolo[1,5-a]pyrimidines 
 
7.2.2.1 Synthesis of 6-bromopyrazolo[1,5-a]pyrimidines 
 
(a) 6-Bromo-5-methyl-3,7-diphenylpyrazolo[1,5-a]pyrimidine (95)  
 
N NH
NH2
Ph
Ph
O O
HOAc, reflux N
N N
Ph
95
Ph
Ph
O O
Br
Br
Br2
94  
 
Scheme 7.5 
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A solution of bromine (6.10 g, 0.038 mol) in 40 ml CCl4 was added dropwise in 45 min to a 
vigorously stirring dispersion of benzoylacetone (6.16 g, 0.037 mol) in CCl4 40 ml and water 
40 ml at 0 °C, the mixture was continue to stir for 1 h, the mixture was separated and the 
aqueous layer was extracted with CCl4 (2 × 30 ml), the combined organic phase was washed 
with brine (2 × 30 ml) and dried with anhydrous MgSO4, the solvent was evaporated in high-
vacuum and provide 9.30 g oily crude 2-bromo-1-phenyl-butane-1,3-dione 94. 
 
A 50 ml round flask was charged with 4-phenyl-3-aminopyrazole S-2a (3.18 g, 20 mmol), 
crude 2-bromo-1-phenyl-butane-1,3-dione 94 (5.8 g, >22 mmol) and conc. hydrochloric acid 
15 ml. The mixture was heated at reflux for 10 h. After the reaction was complete, the mixture 
was cooled, neutralized with aq Na2CO3 and the orange precipitate was collected, washed with 
1 N HCl and water, the crude product was purified by recrystallization from ethanol and 5.10 g 
orange solid was obtained, yield 70 %, mp.129-130 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.73 (s, 3 H, CH3), 7.35-8.00 (m, 10 H, Ph-H), 8.25 (s, 1 H, H-2). 
13C-NMR(CDCl3), δ(ppm): 24.47 CH3, 108.50 C, 126.32 CH, 126.57 CH, 128.76 CH, 129.08 
CH, 129.61 CH, 130.70 CH, 131.09 C, 131.84 C, 142.92 CH(C-2), 146.24 C, 147.16 C, 157.45 
C. 
 
Anal. Calcd for C19H14BrN3 (364.40): C, 62.63; H, 3.87; Br, 21.93; N, 11.53. 
                                                  Found: C, 62.31; H, 4.09; Br, 22.02; N, 11.64. 
 
 
(b) 6-Bromo-2,5,7-trimethylpyrazolo[1,5-a]pyrimidine (97) 
 
N
N
H
NH2
O O
N
N N
97
O O
NBS
CCl4
Br
Br
HOAc, reflux
96  
Scheme 7.6 
 
A soution of acetylacetone (2.02 g, 0.020 mol), NBS (3.60 g, 0.020 mol) in 20 ml CCl4 was 
heated at reflux for 5 h, then filtered and the filtrate was evaporated to dryness and gave 3.4 g 
oily crude 3-bromo-acetylacetone 96. 
 
A mixture of 3-amino-2-methylpyrazole (1.65 g, 0.017 mol) and crude 3-bromo-acetylacetone 
97 (3.10 g, 0.018 mol) in acetic acid 10 ml was heated at reflux for 3 h, after the mixture was 
cooled, 10 ml water was added, the solution was neutralized with 6 N NaOH, and extracted 
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with diethyl ether (2 × 40 ml), the extract was washed with water 30 ml, dried with anhydrous 
MgSO4.the solvent was evaporated, the crude product was recrystallized with water and 
provided 3.64 g light brown solid, yield 89 %, mp 83-4 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.42 (s, 3 H, CH3), 2.62 (s, 3 H, CH3), 2.84 (s, 3 H, CH3), 6.28 (s, 1 
H, H-2). 
13C-NMR(CDCl3), δ(ppm): 14.63 CH3, 17.30 CH3, 26.17 CH3, 95.64 CH(C-2), 105.73 C, 
143.97 C, 147.27 C, 154.96 C, 156.50 C. 
 
Anal. Calcd for C9H10BrN3 (240.10): C, 45.02; H, 4.42; Br, 33.28; N, 17.50. 
                                                 Found: C, 44.96; H, 4.42; Br, 33.49; N, 17.65. 
 
 
 
7.2.2.2 Synthesis of 7-halo-3,5-diphenylpyrazolo[1,5-a]pyrimidine 
 
 
N
N N
Cl
Ph
Ph N
N N
I
Ph
Ph
N
N N
Br
Ph
Ph
98 99 100  
 
 
7-Chloro-3,5-diphenylpyrazolo[1,5-a]pyrimidine (98) 
 
A solution of 7-hydroxy-5,7-diphenylpyrazolo[1,5-a]pyrimidine 90 (4.60 g, 16 mmol), POCl3 
(5 ml, 53 mmol) and N, N-dimethylaniline (0.4 ml, 3.1 mmol) was heated at reflux for 3 h. 
After the mixture was cooled to RT, ice (about 30 ml) was added slowly and carefully. The 
mixture was extracted with chloroform (3 × 30 ml), the combined organic layers were dried 
with anhydrous MgSO4 and concentrated. The crude product was recrystallized with a mixture 
solvent of acetone and pentane, and a yellow crystal 4.81 g was obtained, yield 98 %, mp 159-
60 °C. 
 
1H-NMR(CDCl3), δ(ppm): 7.49 (s, 1 H, H-6), 8.53 (s, 1 H, H-2), 7.28-8.17 (m, 10 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 105.59 CH(C-6),112.31 C, 126.43 CH, 126.63 CH, 127.40 CH, 
128.81CH, 129.06 CH, 130.88 CH, 131.66 C, 136.29 C, 139.03 C, 143.54 CH(C-2), 145.81 C, 
155.65 C. 
 
Anal. Calcd for C18H12ClN3 (305.77): C, 70.71; H, 3.96; Cl, 13.74; N, 11.60. 
                                                  Found: C, 70.78; H, 3.94; Cl, 11.86; N, 13.77. 
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7-Bromo-3,5-diphenylpyrazolo[1,5-a]pyrimidine (99) 
 
A solution of 7-hydroxy-5,7-diphenylpyrazolo[1,5-a]pyrimidine 90 (2.87 g, 10 mmol), POBr3 
(4.59 g, 16 mmol), and N, N-dimethylaniline (0.3 ml, 2.3 mmol) in dry toluene (10 mL) was 
heated at reflux for 3 h. After the solvent was evaporated, ice 30 g was added inside slowly and 
the mixture was extracted with CHCl3 (3 × 30 ml). The combined organic layers were dried 
with anhydrous MgSO4 and concentrated. The crude product was recrystallized with a mixture 
solvent of acetone and pentane to give a yellow crystal 3.35 g, yield 96 %, mp 164-5 °C. 
 
1H-NMR(CDCl3), δ(ppm): 6.77 (s, 1 H, H-6), 8.52 (s, 1 H, H-2 ), 7.27-8.16 (m, 10 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 109.72 CH ( C-6 ), 112.46 C, 126.42 CH, 126.60 CH, 127.41 CH, 
128.79 CH, 128.99 C, 129.04 CH, 130.84 CH, 131.77 C, 136.12 C, 143.28 CH (C-2), 145.30 
C, 155.16 C. 
 
Anal. Calcd for C18H12BrN3 (350.21): C, 61.73; H, 3.45; Br, 22.82; N, 12.00. 
                                                  Found: C, 61.71; H, 3.49; Br, 22.82; N, 12.00. 
 
 
7-Iodo-3,5-diphenylpyrazolo[1,5-a]pyrimidine (100) 
 
A mixture of 7-chloro-5,7-diphenylpyrazolo[1,5-a]pyrimidine (98) (1.53 g, 5 mmol) and 57 % 
aq HI (20 ml) was stirred at room temperature for 3 days, the mixture was diluted with H2O (40 
ml) and the mixture was extracted with CHCl3 (3 × 40ml): The combined organic layers were 
washed with saturated aq Na2S2O3 (2 × 30ml), 10 % aq Na2CO3 (2 × 30ml) and brine (30 ml). 
After dryed with anhydrous MgSO4 and evaporated the solvent, 1.90 g yellow crystal was 
obtained, yield 95 %, mp 172-3 °C. 
 
1H-NMR(CDCl3), δ(ppm): 7.86 (s, 1 H, H-6), 8.51 (s, 1 H, H-2), 7.27-8.51 (m, 10 H, Ar-H). 
13C-NMR ( CDCl3 ), δ(ppm): 103.94 C, 112.79 C, 117.45 CH(C-6), 126.40 CH, 126.52 CH, 
127.43 CH, 128.79 CH, 128.78 CH, 129.02 CH, 130.72 CH, 132.09 C, 135.90 C, 142.60 CH 
(C-2), 143.90 C, 154.47 C. 
 
Anal. Calcd for C18H12IN3 (397.21): C, 54.43; H, 3.05; I, 31.95; N, 10.58. 
                                               Found: C, 54.64; H, 2.89; I, 31.90; N, 10.66. 
 
 
 
7.2.2.3 Synthesis of 5,7-dichloro-pyrazolo[1,5-a]pyrimidines 
 
5,7-dichloro-3-phenylpyrazolo[1,5-a]pyrimidines (101) 
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N
N N
Cl
Cl
101
Ph  
 
 
To a solution of 5,7-dihydroxy-2-phenylpyrazolo[1,5-a]pyrimidine 91 (2.20 g, 10 mmol) in 
phosphoryl chloride 30 ml, N,N-dimethylaniline 3 ml (as catalyst) was added, the resulting 
solution was heated at reflux for 20 hours, the mixture was evaporated in vacuum, 30 ml ice 
was added in the residue slowly and carefully, the mixture was  extracted with ethyl acetate (3 
× 40 ml), the combined organic phase was then washed with saturated aqueous sodium 
bicarbonate (2 × 30 ml), and dried with anhydrous MgSO4, the solvent was evaporated, and the 
crude product was purified by recrystallization with hexane as solvent, and a yellow needle 
crystal 1.40 g was obtained, yield 53 %, mp 153-155 °C  
 
1H-NMR (CDCl3), δ(ppm): 6.91 (s, 1 H, H-6), 7.20-7.91 (m, 5 H, Ph-H), 8.44 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 108.80 CH(C-6), 112.51 C, 126.46 CH, 127.16 CH, 128.89 CH, 
130.46 C, 140.03 C, 144.10 CH(C-2), 149.18 C. 
 
Anal. Calcd. for C12H7Cl2N3: C, 54.57; H, 2.67; Cl, 26.85; N, 15.91. 
                                    Found: C, 54.80; H, 2.69; Cl, 26.99; N, 15.83. 
 
 
5,7-dichloro-2-methylpyrazolo[1,5-a]pyrimidines (102) 
 
N
N N
Cl
Cl
102
 
 
 
To a solution of 5,7-dihydroxy-3-methylpyrazolo[1,5-a]pyrimidine (6.60 g, 40 mmol) in 
phosphoryl chloride 60 ml, N,N-dimethylaniline 5 ml was added, the resulting red solution was 
refluxed for 20 hours, the mixture was evaporated in vacuum, 100ml ice was added in the 
residue slowly, and extracted with ethyl acetate (5 × 60 ml), the combined organic phase was 
then washed with saturated aqueous sodium bicarbonate (4 × 50 ml), and dried with anhydrous 
Na2SO4, the solvent was evaporated, and the crude product was purifed by recrystallization 
with hexane as solvent, and provided a yellow needle crystal 4.57 g, yield 57 %, mp 93-95 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.56 (s, 3 H, CH3), 6.52 (s, 1 H, H-6), 6.89 (s, 1 H, H-2). 
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13C-NMR (CDCl3), δ(ppm): 14.47 CH3, 98.08 CH(C-6), 107.49 CH(C-2), 139.15 C, 148.74 C, 
148.94 C, 157.12 C 
 
Anal. Calcd. for C7H5ClN3: C, 41.61; H, 2.49; Cl, 35.09; N, 20.80. 
                                 Found: C, 41.65; H, 2.57; Cl, 35.14; N, 20.72. 
 
 
 
7.2.2.4 Synthesis of 3-halo-2,5,7-trisubstituted-pyrazolo[1,5-a]pyrimidines 
 
3-Bromo-5-methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidine (103) 
 
N
N N
Ph
Ph 103
Br  
 
 
A solution of 5-methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidine 88a (2.85 g, 10 mmol), NBS 
(1.98 g, 11.0 mmol) in 30 ml CCl4 was stirred at 50 °C for 0.5 h. After cooled, the solution was 
filtered and petroleum ether was added to the filtrate, causing precipitation of 7. The product 
3.15 g was collected as a light yellow crystal, yield 87 %, mp 136-138 °C. 
1H-NMR(CDCl3), δ(ppm): 2.64 ( s, 3 H, CH3), 6.77 (s, 1 H, H-6), 7.36-8.44 (m, 10 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 25.01 CH3, 81.97 C, 109.29 CH(C-6), 128.41 CH, 128.63 CH, 
128.92 CH, 129.03 CH, 129.45 CH, 130.29 C, 131.20 CH, 132.08 C, 146.08 C, 147.50 C, 
152.44 C, 160.12 C. 
 
Anal. Calcd for C19H14BrN3 (364.24): C, 62.63; H, 3.87; Br, 21.93; N, 11.53. 
                                                  Found: C, 62.65; H, 4.01; Br, 22.63; N, 11.66. 
 
 
3-iodo-2,5,7-substituted-pyrazolo[1,5-a]pyrimidine (104a-104h) 
 
N
N N
R2
R1
R
104a-104h
I  
 
General Procedure: 
A 50ml round flask was charged with 10 mmol appropriate pyrazolo[1,5-a]pyrimidine 88, N-
iodosuccinimide, NIS (2.48 g, 11.0 mmol) and 20 ml dry THF. The mixture was heated at 
reflux 24 h. After the mixture was cooled, satd. aq. Na2S2O3 (20 ml) was added and stirred for 
30 min, then the mixture was extracted with AcOEt (4 × 40 ml). The combined organic layer 
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was dried with anhydrous MgSO4, the solvent was evaporated and the crude products purified 
by column chromatography on silica gel using hexane-ethyl acetate (4/1) as eluting solvent and 
provided a pure yellow or orange product. 
 
 
3-Iodo-5-methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidine (104a) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (8/1→3/1) as eluting solvent, and provided a light yellow solid, yield 70 %, mp 164-6 
°C. 
 
1H-NMR(CDCl3), δ(ppm): 2.72 (s, 3 H, CH3), 6.84 (s, 1 H, H-6), 7.55-8.09 (m, 10 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 25.03 CH3, 49.02 C, 109.40CH(C-6), 126.58 CH, 128.88 CH, 
128.96 CH, 129.41 CH, 129.65 CH, 130.33 CH, 131.13 C, 133.21 C, 146.24 C, 150.06 C, 
155.50 C, 160.42 C. 
 
HRMS(EI) calcd for C19H14IN3 (M+) 411.02325, found 411.02322. 
 
Anal. Calcd. for C19H14IN3: C, 55.49; H, 3.43; I, 30.86; N, 10.22. 
                                 Found: C, 55.87; H, 3.52; I, 30.56; N, 10.18. 
 
 
3-Iodo-2-(4-chlorophenyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidine (104b) 
 
The crude product was purified by column chromatography on silica gel, eluenting with 
hexane:ethyl acetate (8/1→3/1), and a light yellow solid was obtained, yield 69 %, mp 166-8 
°C. 
 
1H-NMR(CDCl3),δ(ppm): 2.71 (s, 3 H, CH3), 6.84 (s, 1 H, H-6), 7.41-8.04 (m, 9 H, Ar-H). 
13C-NMR(CDCl3),δ(ppm): 25.03 CH3, 48.90 C, 109.60CH(C-6), 128.53 CH, 128.91 CH, 
129.39 CH, 130.07 CH, 131.21 CH, 131.32 C, 135.03 C, 137.50 C, 146.24 C, 150.10 C, 154.28 
C, 160.61 C. 
 
Anal. Calcd. for C19H13ClIN3: C, 51.20; H, 2.94; N, 9.43. 
                                     Found: C, 50.98; H, 3.15; N, 9.43. 
 
 
3-Iodo-2-Methyl-5,7-diphenylpyrazolo[1,5-a]pyrimidine (104c) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (8/1→3/1) as eluting solvent, and a yellow solid was obtained, yield 78 %, mp 138-40 
°C. 
 
H NMR(CDCl3), δ(ppm): 2.53 (s, 3 H, CH3), 7.30 (s, 1 H, H-6), 7.49-8.18 (m, 10 H, Ar-H). 
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13C NMR(CDCl3), δ(ppm): 15.34 CH3, 53.24 C, 105.20 CH(C-6), 127.36 CH, 128.73 CH, 
128.92 CH, 129.46 CH, 130.46 CH, 130.85 C, 131.13 CH, 137.06 C, 146.80 C, 149.46 C, 
156.54 C, 156.75 C. 
 
Anal. Calcd. for Calcd. for C19H14IN3 : C, 55.49; H, 3.43; I, 30.86; N, 10.22. 
                                                   Found: C, 55.52; H, 3.64; I, 31.23; N, 10.27. 
 
 
 
3-Iodo-7-(4-Chloro-phenyl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidine (104d) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (8/1→3/1) as eluting solvent and a light yellow solid was obtained, yield 83 %, mp 63-5 
°C. 
 
1H-NMR(CDCl3), δ(ppm): 2.70 (s, 3 H, CH3), 6.80 (s, 1 H, H-6), 7.45-8.05 (m, 9 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 25.02 CH3, 49.26 C, 109.20 CH(C-6), 128.33 CH, 128.80 CH, 
128.90 CH, 129.06 CH, 130.61 C, 130.75 CH, 132.67 C, 137.30 C, 144.96 C, 150.02 C, 155.54 
C, 160.37 C 
 
Anal. Calcd. for C19H13ClIN3: C, 51.20; H, 2.94; N, 9.43. 
                                     Found: C, 50.96; H, 3.09; N, 9.46. 
 
 
 
 
3-Iodo-2,5-dimethyl-7-phenylpyrazolo[1,5-a]pyrimidine (104e) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (8/1→3/1) as eluenting solvent; and a yellow solid was obtained, yield 63 %, mp 90-1 
°C. 
 
1H-NMR(CDCl3), δ(ppm): 2.49 (s, 3 H, CH3), 2.67 (s, 3 H, CH3) , 6.73 (s, 1 H, H-6), 7.54-7.99 
(m, 5H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 15.24 CH3, 24.91 CH3, 51.52 C, 108.69 CH(C-6), 128.64 CH, 
129.23 CH, 130.85 C, 131.06 CH, 146.08 C, 149.27 C, 156.10 C, 160.09 C. 
 
Anal. Calcd. for C14H12IN3: C, 48.16; H, 3.46; I, 36.34; N, 12.03. 
                                  Found: C, 48.23; H, 3.50; I, 36.38; N, 12.14. 
 
 
 
3-Iodo-2,5,7-trimethylpyrazolo[1,5-a]pyrimidine (104f) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (8/1→3/1) as eluting solvent; and a brown solid was obtained, yield 45 %, mp 132-3°C. 
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1H-NMR(CDCl3), δ(ppm): 2.51 (s, 3 H, CH3), 2.60 (s, 3 H, CH3), 2.70 (s, 3 H, CH3), 6.53 (s, 1 
H, H-6). 
13C-NMR(CDCl3), δ(ppm): 15.09 CH3, 16.62 CH3, 24.79 CH3, 51.10 C, 108.77 CH(C-6) , 
144.85 C, 148.73 C, 155.24 C, 160.01 C. 
 
Anal. Calcd. for C9H10IN3: C, 37.65; H, 3.51; I, 44.20; N, 14.64. 
                                Found: C, 37.48; H, 3.72; I, 43.63; N, 14.60. 
 
 
3-Iodo-2,5,7-triphenylpyrazolo[1,5-a]pyrimidine (104g) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (8/1→3/1)as eluting solvent; and a yellow solid was obtained, yield 81 %, mp 202-3 °C. 
 
1H-NMR(CDCl3), δ(ppm): 7.24 (s, 1 H, H-6), 7.24-8.24 (m, 15 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 50.67 C(C-3), 105.91 CH(C-6), 127.40 CH, 128.65 CH, 128.86 
CH, 128.92 CH, 129.52 CH, 130.57 CH,130.82 C, 131.18 CH, 132.83 C, 136.99 C, 146.93 C, 
150.2 C, 155.98 C, 156.99 C. 
 
Anal. Calcd. for C24H16IN3: C, 60.90; H, 3.41; I, 26.81; N, 8.88. 
                                  Found: C, 60.64; H, 3.45; I, 27.01; N, 8.82. 
 
 
3-Iodo-5,7-diphenylpyrazolo[1,5-a]pyrimidine (104h) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (10/1→4/1)as eluting solvent, and a yellow solid was obtained, yield 90 %, mp 160-1 
°C. 
 
1H NMR(CDCl3), δ(ppm): 7.31 (s, 1 H, H-6), 7.44-8.15 (m, 10 H, Ar-H), 8.09 (s, 1 H, H-2). 
13C NMR(CDCl3), δ(ppm): 50.24 C(C-3), 105.74 CH(C-6), 127.46 CH, 128.80 CH, 128.98 
CH,129.03 CH, 129.26 CH, 130.69 CH, 131.24 C, 136.90 C, 147.43CH(C-2), 149.01 C, 
149.18 C, 157.22 C. 
 
Anal. Calcd. for C18H12IN3: C, 54.43; H, 3.05; I, 31.95; N, 10.58. 
                                  Found: C, 54.54; H, 3.18; I, 31.34; N, 10.39. 
 
 
7.2.2.5 Synthesis of 5-bromomethyl-3,7-diphenylpyrazolo[1,5-a]pyrimidine (105) 
 
N
N N
Ph
Ph
Br 105
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To a solution of 5-methyl-3,7-diphenylpyrazolo[1,5-a]pyrimidine (89b) (1.43 g, 5 mmol), NBS 
(1.07 g, 6.0 mmol) in 20 ml CCl4, catalytic amount of AIBN (80 mg) was added, the mixture 
was heated at reflux for 3 h, after the mixture was cooled, then filtered, petroleum ether (40-60 
°C) was added to the filtrate, the precipitate was collected and washed with petroleum ether, 
1.05 g orange solid was obtained, yield 58 %, mp 131-3 °C. 
 
1H-NMR(CDCl3), δ(ppm): 4.57 (s, 2 H, CH2), 7.00 (s, 1 H, H-6), 7.16-8.04 (m, 10 H, Ar-H), 
8.40 (s, 1 H, H-2). 
13C-NMR(CDCl3), δ(ppm): 33.31 CH2, 107.58 CH(C-6), 111.11 C, 126.53 CH, 128.71 CH, 
128.78 CH, 129.21 CH, 129.27 CH, 130.82 C, 131.26 CH, 131.82 C, 143.11 CH(C-2), 145.24 
C, 147.48 C, 156.29 C. 
 
Anal. Calcd for C19H14BrN3 (364.24): C, 62.63; H, 3.87; Br, 21.93; N, 11.53. 
                                                   Found:C, 62.65; H, 4.03; Br, 21.83; N, 11.60. 
 
 
7.2.3 Synthesis of 3-alkenylpyrazolo[1,5-a]pyrimidines (Heck cross-coupling 
reactions) 
 
Substituted 3-alkenylpyrazolo[1,5-a]pyrimidines 106a-h, 107a-c, 108, 109, 110, 111; 
 
General Procedure: 
A 50 ml round flask was charged with 3-iodopyrazolo[1,5-a]pyrimidine 104 (0.5 mmol), 
Pd(PPh3)22  (18 mg, 0.025 mmol), MeCN (15 mL), triethylamine (203 mg, 2 mmol) and the 
corresponding alkene (1.5 mmol). The mixture was refluxed under argon for 24 h. The solvent 
was evaporated and the residue was purified by column chromatography on silica gel. 
 
Substituted pyrazolo[1,5-a]pyrimidin-3-yl-acrylic acid methyl ester (106a-h) 
 
N
N N
R3
R2
R1
CO2Me
106a-106h
 
 
 
3-(5-Methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylic acid methyl ester (106a) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (2/1) as eluting solvent; and a yellow solid was obtained, yield 91 %, mp 155-6 °C. 
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1H-NMR(CDCl3), δ(ppm): 2.73 (s, 3 H, CH3), 3.80 (s, 3 H, CH3), 6.92 (s, 1 H, H-6), 7.31 (d, 1 
H, J = 16Hz, =C-H), 7.98 (d, 1 H, J = 16Hz, =C-H), 7.47-8.10 (m, 10 H, Ar-H). 
13C-NMR(CDCl3), δ(ppm): 25.08 CH3 , 51.97 CH3 , 102.97 C, 109.74 CH(C-6), 116.20 
CH(=CH), 128.66 CH, 128.73 CH, 128.88 CH, 129.05 CH, 129.52 CH, 130.60 C, 131.19 CH, 
132.40 C, 135.15 CH(=CH), 146.26 C, 148.56 C, 157.15 C, 160.80 C, 168.81C(C=O). 
 
HRMS( EI ) calcd for C23H19N3O2 (M+) 369.14773, found 369.14773. 
 
Anal. Calcd. for C23H19N3O2: C 74.78; H, 5.18; N, 11.37. 
                                    Found: C, 74.89; H, 5.33; N, 11.17. 
 
 
3-[2-(4-Chloro-phenyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidin-3-yl]-acrylic acid methyl 
ester (106b) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (2/1) as eluting solvent , and a yellow solid was obtained, yield 93 %, mp 149-51 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.73 (s, 3 H, CH3), 3.81 (s, 3 H, CH3), 6.93 (s, 1 H, H-6), 7.30 (d, 1 
H, J = 15.4Hz, =C-H), 7.92 (d, 1 H, J = 15.4Hz, =C-H), 7.48-8.21 (m, 9 H, Ar-H) 
13C-NMR(CDCl3),δ(ppm): 25.08 CH3, 51.44 CH3 , 102.99 C, 106.38 CH(C-6), 116.59 
CH(=CH), 128.70 CH, 128.83 CH, 129.49 CH, 130.73 CH, 130.90 C, 131.27 CH, 134.58 
CH(=CH),  135.28 C, 146.28 C, 148.25 C, 155.86 C, 161.00 C, 168.68 C(C=O). 
 
Anal. Calcd. for C23H19ClN3O2: C, 68.40; H, 4.49; Cl, 8.78; N, 10.40. 
                                        Found: C, 68.41; H, 4.56; Cl, 9.15; N, 10.34. 
 
 
 
3-(2-Methyl-5,7-diphenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylic acid methyl ester (106c) 
 
The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (3/1) as eluting solvent; and a orange solid was obtained, yield 89 %, mp 164-5 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.60(s, 3H, CH3), 3.85(s, 3 H, CH3), 7.11(d, 1H, J =16Hz, =C-H),  
7.26(s, 1H, H-6), 7.97(d, 1H, J =16 Hz, =C-H), 7.40-8.24(m, 10H, Ar-H) 
13C-NMR(CDCl3),δ(ppm): 13.63 CH3, 51.44 CH3, 104.76 C, 105.50 CH(C-6), 114.87 
CH(=CH), 127.47 CH, 128.79 CH, 129.42 CH, 129.63 CH, 130.79 CH, 131.00 C, 131.29 CH, 
134.48 CH(=CH), 136.87 C, 146.85 C, 148.50 C, 156.54 C, 157.25 C, 168.76 C(C=O). 
 
Anal. Calcd. for C23H19N3O2 : C, 74.78; H, 5.18; N, 11.37. 
                                     Found: C, 74.30; H, 5.31; N, 11.35. 
 
 
3-[7-(4-Chloro-phenyl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-3-yl]-acrylic acid methyl 
ester (106d) 
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The crude product was purified by column chromatography on silica gel, using hexane:ethyl 
acetate (2/1) as eluting solvent; and a yellow solid was obtained, yield 94 %, mp 162-4 °C; 
 
1H-NMR(CDCl3), δ(ppm): 2.72 (s, 3 H, CH3), 3.80 (s, 3 H, CH3), 6.89 (s, 1 H, H-6), 7.30 (d, 1 
H, J = 16 Hz, =C-H), 7.97 (d, 1 H, J = 16 Hz, =C-H), 7.47-8.06 (m, 9 H, Ar-H). 
13C-NMR(CDCl3),δ(ppm): 25.07 CH3, 51.40 CH3, 103.09 C, 109.50 CH(C-6), 116.48 
CH(=CH), 128.77, 128.97, 128.90, 129.14, 129.46, 130.86, 132.25, 134.94 (=CH), 137.41, 
144.99, 148.48, 157.16, 160.75, 168.74 (C=O). 
 
Anal. Calcd. for C23H19ClN3O2: C, 68.40; H, 4.49; Cl, 8.78; N, 10.40. 
                                        Found: C, 68.44; H, 4.64; Cl, 8.53; N, 10.28. 
 
 
3-(2,5-Dimethyl-7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylic acid methyl ester (106e) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate(4/1) as eluting solvent; and a yellow solid was obtained, yield 90 %, mp 194-6 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.57 (s, 3 H, CH3), 2.58 (s, 3 H, CH3), 3.82 (s, 3 H, CH3), 6.81 (s, 1 
H, H-6), 7.01 (d, 1 H, J = 16 Hz, =C-H ), 7.91 (d, 1 H, J = 16Hz, =C-H), 7.57-8.01 (m, 5 H, 
Ar-H). 
13C-NMR(CDCl3),δ(ppm): 13.58 CH3, 24.96 CH3, 51.39 CH3, 103.68 C, 109.11 CH(C-6), 
114.43 CH(=C-H), 128.71CH, 129.35 CH, 130.83 C, 131.16 CH, 134.56 CH(=C-H), 146.04 C, 
148.37 C, 155.36 C, 160.70 C, 168.85 C(C=O). 
 
Anal. Calcd. for C18H17N3O2: C, 70.34; H, 5.58; N, 13.67. 
                                    Found: C, 70.23; H, 5.57; N, 13.76. 
 
 
3-(2,5,7-Trimethylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylic acid methyl ester (106f) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (4/1) as eluting solvent; and a light yellow solid was obtained, yield 62 %, mp 171-3 
°C; 
 
1H-NMR(CDCl3), δ(ppm): 2.58 (s, 3 H, CH3), 2.60 (s, 3 H, CH3), 2.70 (s, 3 H, CH3), 3.81 (s, 3 
H, CH3), 6.60 (s, 1 H, H-6), 6.98 (d, 1 H, J = 16 Hz, =C-H), 7.86 (d, 1 H, J = 16 Hz, =C-H). 
13C-NMR(CDCl3), δ(ppm): 13.38 CH3, 17.06 CH3, 24.80 CH3, 51.37 CH3, 103.71 C, 109.27 
CH(C-6), 114.30 CH(=C-H), 134.60 CH(=C-H), 145.29 C, 147.43 C, 155.06 C, 160.40 C, 
168.83 C(C=O). 
 
Anal. Calcd. for C13H15N3O2: C, 63.66; H, 6.16; N, 17.13. 
                                    Found: C, 63.40; H, 6.21; N, 17.05. 
 
 
 
 
Chapter7: Experimental 
_________________________________________________________________________________________________________________________________ 
 
130
3-(2,5,7-Triphenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylic acid methyl ester (106g) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (2/1) as eluting solvent; and a yellow solid was obtained, yield 90 %, mp 215-6 °C; 
 
1H-NMR(CDCl3), δ(ppm): 3.83 (s, 3 H, CH3), 7.26 (s, 1H, H-6), 7.54 (d, 1 H, J = 19Hz, =C-
H), 8.05 (d, 1 H, J = 19 Hz, =C-H), 7.59-8.27 (m, 15 H, Ar-H). 
13C-NMR(CDCl3),δ(ppm): 51.43 CH3, 104.03 C(C-3), 106.16 CH(C-6), 116.66 CH(=CH), 
127.90 CH, 128.76 CH, 128.80 CH, 129.20 CH, 129.55 CH, 129.58 CH, 129.81 CH, 130.41 
CH, 130.64 C, 130.91 CH, 132.34 C, 135.04 CH(=CH), 136.86 C, 147.07 C, 148.71 C, 157.34 
C, 157.40 C, 168.82 C(C=O). 
 
Anal. Calcd. for C28H21N3O2: C, 77.94; H, 4.91; N, 9.74. 
                                    Found: C, 77.33; H, 5.01; N, 9.58. 
 
 
3-(5,7-Diphenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylic acid methyl ester (106h) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate(6/1) as eluting solvent, and a yellow solid was obtained, yield 86 %, mp.134-5 °C. 
 
1H-NMR(CDCl3), δ(ppm): 3.77 (s, 3 H, CH3), 6.87 (d, 1 H, J = 16 Hz, =C-H), 7.39 (s, 1H, H-
6), 7.95 (d, 1 H, J = 16 Hz, =C-H), 7.47-8.15 (m, 10 H, Ar-H), 8.23 (s, 1 H, H-2). 
13C NMR(CDCl3), δ(ppm): 51.50 CH3, 106.11 CH(H-6), 107.20 C(C-3), 105.74 CH(C-6), 
115.49 CH(=CH), 127.52 CH, 128.84 CH, 129.07 CH, 129.11 C, 129.34 CH, 130.95 CH, 
131.34 CH, 134.42 CH(=CH), 136.70 C, 145.58 CH(C-2), 147.55 C, 157.55 C, 168.39 
C(C=O). 
 
Anal. Calcd. for C22H17N3O2: C, 74.35; H, 4.82; N, 11.82. 
                                     Found: C, 74.17; H, 4.92; N, 11.71. 
 
 
Substituted pyrazolo[1,5-a]pyrimidin-3-yl-acrylonitrile (107a-107c) 
 
N
N N
R3
R2
R1
CN
107a-107c
 
 
3-(5-Methyl-2,7-diphenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylonitrile (107a) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (2/1) as eluting solvent; and a yellow solid was obtained, yield 52 %, mp 206-8 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.73( s, 3 H, CH3), 6.85(d, 1H, J =16.2 Hz, =C-H ), 6.96 (s, 1 H, H-
6 ), 7.59 (d, 1 H, J = 16.2 Hz, =C-H), 7.48-8.10 (m, 10 H, Ar-H). 
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13C-NMR(CDCl3),δ(ppm): 25.06 CH3 , 93.95 C, 102.56 CH(=CH), 110.04 CH(C-6), 120.26 C, 
127.49 C, 128.72 CH, 128.84 CH, 129.38 CH, 129.41 CH, 129.54 CH, 130.29 C,  131.39 CH, 
140.48 CH(=CH), 146.56 C, 148.62 C, 156.68 C, 161.44 C(CN). 
 
HRMS( EI ) calcd for C22H16N4 (M+) 336.13750, found 369.13753. 
 
Anal. Calcd. for C22H16N4: C, 78.55; H, 4.79; N, 16.66. 
                                Found: C, 78.80; H, 4.82; N, 16.38. 
 
 
3-[2-(4-Chloro-phenyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidin-3-yl]-acrylonitrile (107b) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (2/1) as eluting solvent, and a yellow solid was obtained, yield 43 %, mp180-2 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.74(s, 3 H, CH3), 6.86(d, 1 H, J =15.6 Hz, =C-H), 6.98(s, 1H, H-
6), 7.49(d, 1 H, J = 15.6 Hz, =C-H), 7.46-8.07 (m, 9 H, Ar-H). 
13C-NMR(CDCl3),δ(ppm): 25.08 CH3, 94.46 CH(=CH), 102.56 C, 110.23 CH (C-6), 120.08 C, 
128.77 CH, 129.13 CH, 129.52 CH, 130.19 C, 130.3, 130.62 CH, 131.49 CH, 135.67 C, 139.96 
CH(=CH),  146.61C, 148.62 C, 155.41 C, 161.67 C(CN). 
 
Anal. Calcd. for C22H15ClN4: C, 71.75; H, 4.08; Cl, 9.56; N, 15.11. 
                                    Found: C, 72.29; H, 4.17; Cl, 9.21; N, 14.92. 
 
 
3-(2-Methyl-5,7-diphenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylonitrile (107c) 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (2/1) as eluting solvent; and a orange solid was obtained, yield 79 %, mp 164-5 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.56 (s, 3 H, CH3), 6.73 (d, 1 H, J = 16.2 Hz, =C-H), 7.44 (s, 1 H, 
H-6), 7.54 (d, 1 H, J = 16.2 Hz, =C-H), 7.56-8.19 (m, 10 H, Ar-H). 
13C-NMR(CDCl3),δ(ppm): 13.15 CH3 , 92.75 CH(=CH), 104.41 C, 105.83 CH(C-6), 120.33 C, 
127.45 CH, 128.86 CH, 129.13 CH, 129.46 CH, 130.71 C, 131.10 CH, 131.49 CH, 136.59 C, 
139.71CH(=CH), 147.18 C, 148.48 C, 155.45 C, 157.88 C(CN). 
 
Anal. Calcd. for C22H16N4 : C, 78.55; H, 4.79; N, 16.66. 
                                 Found: C, 78.71; H, 4.86; N, 16.52. 
 
 
5,7-Diphenyl-3-styrylpyrazolo[1,5-a]pyrimidine (108) 
 
108
N
N N
Ph
Ph
Ph  
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The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate(4/1) as eluting solvent , and a red solid was obtained, yield 36 %, mp 174-6 °C. 
 
1H-NMR(CDCl3), δ(ppm): 7.30 (s, 1 H, H-6), 7.41 (d, 1 H, J = 16.2 Hz, =C-H), 7.55 (d, 1 H, J 
= 16.2 Hz, =C-H), 7.19-8.21 (m, 15 H, Ar-H), 8.29 (s, 1 H, H-2). 
13C-NMR(CDCl3),δ(ppm): 105.26 CH(C-6), 109.68 C(C-3), 117.68(=CH), 126.03 CH, 126.87 
CH, 127.25 CH, 128.57 CH, 128.70 CH, 128.89 CH, 129.20 CH, 130.39 CH, 130.98CH(=CH), 
131.25 CH, 137.20 C, 138.19 C, 143.13 CH (C-2) , 143.15 C, 146.22 C, 146.84 C, 155.71 C 
Anal. Calcd. for C26H19N3: C, 83.62; H, 5.13; N, 11.25. 
                                Found: C, 83.84; H, 5.15; N, 11.07. 
 
 
3-(5,7-Diphenylpyrazolo[1,5-a]pyrimidin-3-yl)-acrylic acid 2-dimethylamino-ethyl ester (109) 
 
N
N N
Ph
Ph
CO2CH2CH2NMe2
109
 
 
The crude product was purified by column chromatography on silica gel, using ethyl 
acetate:methanol (5/1) as eluting solvent and provided a yellow glass material, yield 57 %. 
 
1H-NMR(CDCl3), δ(ppm): 2.26(s, 3H, CH3), 2.61(t,2H, J=5.9 Hz), 4.25 (t, 2H, J=5.9 Hz , 
CH2), 6.81(d, 1H, J=15.8Hz, =CH), 7.30(s, 1H, H-6), 7.39-7.48(m, 6H, Ph-H),  7.89-7.92(dd, 
2H, Ph-H),  7.91(d, 1H, J=15.8Hz, =CH), 8.16(s, 1H, H-2). 
13C-NMR(CDCl3), δ(ppm): 45.00 CH3, 57.83 CH2, 61.83 CH2, 105.97 CH, 107.16 C, 115.45 
CH, 127.43 CH, 128.73 CH, 128.95 CH, 129.31 CH, 130.87 CH, 131.26 CH, 134.46 CH, 
136.54 C, 145.35 C, 145.37 CH,  147.36, 147.53 C, 157.39 C, 167.84 C. 
 
HRMS (EI) calcd for C19H15N3 (M+) 412.18993, found 412.18964. 
 
 
3-(2,5-Dimethyl-7-phenylpyrazolo[1,5-a]pyrimidin-3-yl)-2-methyl-acrylic acid methyl ester 
(110) 
N
N N
Ph
110
H
O
O
 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (4/1) as eluting solvent; and provided a yellow solid, yield 27 %, mp. 122-3 °C; 
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1H-NMR(CDCl3), δ(ppm): 2.08 (d, 3 H, J = 1.5Hz, =C-CH3 ), 2.43 (s, 3 H, CH3), 2.61 (s, 3 H, 
CH3), 3.80 (s, 3 H, O-CH3), 6.72 (s, 1 H, H-6), 7.51-7.54(m, 3 H, Ph-H), 7.71 (d, 1 H, J = 1.5 
Hz, =C-H), 7.98 (dd, 2 H, Ph-H). 
13C-NMR(CDCl3), δ(ppm): 13.95 CH3, 15.79 CH3, 24.95 CH3, 51.87 CH3, 10438 C, 108.33 
CH(C-6), 128.17 C, 128.66 CH, 128.71 CH, 129.29 CH, 130.99 CH(=C-H), 131.27 C, 145.76 
C, 146.93 C, 154.24 C, 159.04 C, 169.12 C. 
 
Anal. Calcd. for C19H19N3O2: C, 71.01; H, 5.96; N, 13.08. 
                                     Found: C, 71.13; H, 6.00; N, 13.00. 
 
 
2-(5,7-Diphenylpyrazolo[1,5-a]pyrimidin-3-ylmethylene)-succinic acid dimethyl ester (111) 
 
111
N
N N
Ph
Ph
H
CH2CO2Me
O
O
 
 
The crude product was purified by column chromatography on silica gel using hexane:ethyl 
acetate (6/1) as eluting solvent; and get yellow solid, yield: 14 %, mp. 128-9 °C; 
 
1H-NMR(CDCl3), δ(ppm): 3.63 (s, 3 H, CH3), 3.80 (s,3 H, CH3), 3.82 (s, 2 H, CH2), 7.39 (s, 
1H, H-6), 7.46-7.54 (m, 6 H, Ph-H), 7.96 (dd, 2 H, Ph-H), 8.12 (dd, 2 H, Ph-H), 8.27 (s, 1H, 
=C-H), 8.29 (s, 1H, H-2). 
13C-NMR(CDCl3), δ(ppm): 34.45 CH2, 52.15 CH3, 52.21 CH3, 106.36 CH(C-6), 106.98 C, 
120.71C, 127.50 CH, 128.83 CH, 129.02 CH, 129.32 CH, 130.76 C, 130.94 CH, 131.13 CH, 
131.36 CH(=C-H), 136.74 C, 144.90 CH(C-3), 147.37 C, 148.20 C, 157.39 C, 168.37 C, 
171.62 C. 
 
Anal. Calcd. for C25H21N3O4: C, 70.25; H, 4.95; N, 9.83. 
                                    Found: C, 70.38; H, 5.09; N, 9.75. 
 
 
 
 
7.2.4 Synthesis of 3-alkynylpyrazolo[1,5-a]pyrimidines and related 
compounds (Sonogashira cross-coupling reaction) 
 
(1) Pd/C catalyzed Sonogashira reaction 
 
Synthesis of substituted 3-alkynylpyrazolo[1,5-a]pyrimidines (113a-k, 114) 
 
General Procedure: 
A 25ml Schlenk flask was charged with 3-iodopyrazolo[1,5-a]pyrimidine (104a-d, or 104h) 
(0.5 mmol), K2CO3 (166 mg, 1.2 mmol), CuI (10 mg, 0.05 mmol), 10% Pd/C (22 mg, 0.02 
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mmol ), and PPh3 (21 mg, 0.08 mmol) in DME (5 ml) and water (5 ml). Argon was passed 
through the flask 3 times and the mixture was stirred at 25 °C for 0.5 h, then the alkyne (0.6 
mmol) was added via syringe. The mixture was heated at 80 °C for 24 h, then cooled to RT, 
and filtered through a pad of celite, washing with EtOAc, the combined crude solution was 
washed with water (2 × 30 ml) twice. The organic layer was dried with anhydrous MgSO4, 
concentrated in vacuo, and the residue was purified by flash column chromatography on silica 
gel, eluting with EtOAc:MeOH (1:0→6:1) for products 113a-113e, with hexane:EtOAc 
(1:1→0:1) for products 113f-113k. 
 
N
N N
R3
R1
R2
         R1      R2       R3 
a       H       Ph       Ph
b      Me      Ph       Ph
c      Ph       Me      Ph
d      Ph       Me   4-ClPh
e    4-ClPh  Me      Ph
NMe2113a-e  
 
 
3-(5,7-Diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-prop-2-ynyl]-dimethylamine (113a) 
 
Yellow solid, yield 91 %, mp 102-3 °C 
 
1H-NMR (CDCl3), δ(ppm): 2.41 (s, 6 H, 2CH3), 3.58 (s, 2 H, CH2), 7.32 (s, 1 H, H-6), 7.43-
8.13 (m, 10 H, Ph-H), 8.15 (s, 1H, H-2). 
13C-NMR (CDCl3), δ(ppm): 44.15 CH3, 49.03 CH2, 76.23 C, 87.69 C, 93.99 C, 105.89 CH(H-
6), 127.50 CH, 128.79 CH, 128.93 CH, 129.26 CH, 129.36 C, 130.71 CH,130.92 C, 131.24 
CH, 136.93 C, 147.34 CH(C-2), 150.11 C, 157.01 C. 
 
Anal. Calcd. for C23H20N4 (352.43): C, 78.38; H, 5.72; N, 15.66. 
                                              Found: C, 78.50; H, 5.94; N, 15.66. 
 
 
Dimethyl-[3-(2-methyl-5,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-prop-2-ynyl]-amine 
(113b) 
 
Yellow solid, yield 76 %, mp 109-11 °C 
 
1H NMR (CDCl3), (ppm): 2.50 (s, 3 H, CH3), 2.64 (s, 6 H, 2CH3), 3.87(s, 2 H, CH2), 7.27 (s, 1 
H, H-6), 7.43-7.52 (m, 6 H, Ph-H), 7.96-8.00 (dd, 2 H, Ph-H), 8.08-8.11 (dd, 2 H, Ph-H). 
13C NMR (CDCl3) (ppm): 13.87 CH3, 42.91 CH3, 48.62 CH2, 85.26 C, 92.14 C, 105.58 CH 
(C-6), 127.41 CH, 128.78 CH, 128.94 CH, 129.33 CH, 130.70 CH, 130.91 C, 131.29 CH, 
136.95 C, 146.91 C, 150.94 C, 157.10 C, 157.65 C . 
 
Anal. Calcd. for C24H22N4 (366.46): C, 78.68; H, 6.05; N, 15.29. 
                                               Found: C, 78.44; H, 6.25; N, 15.01. 
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Dimethyl-[3-(5-methyl-2,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-prop-2-ynyl]-amine 
(113c): 
 
Yellow solid, yield 70 %, mp 152-4 °C 
 
1H-NMR (CDCl3), δ(ppm): 2.44 (s, 6 H, 2CH3), 2.63 (s, 3 H, CH3), 3.70 (s, 2 H, CH2), 6.77 (s, 
1 H, H-6), 7.35-7.51 (m, 6 H, Ph-H), 8.04 (dd, 2 H, Ph-H), 8.21 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 25.03 CH3, 43.96 CH3, 49.18 CH2, 77.93 C, 88.79 C, 89.93 C, 
109.50 CH(H-6), 127.81 CH, 128.41 CH, 128.59 CH, 129.18 CH, 129.47 CH, 130.53 C, 
131.19 CH, 132.52 C, 146.09 C, 151.75 C, 155.56 C, 160.22 C. 
 
HRMS (EI) calcd for C24H22N4 (M+) 366.18445, found, 366.18447. 
 
Anal. Calcd. for C24H22N4 (366.46): C, 78.68; H, 6.05; N, 15.29. 
                                              Found: C, 78.65; H, 6.28; N, 15.05. 
 
 
{3-[7-(4-Chloro-phenyl)-5-methyl-2-phenyl-pyrazolo[1,5-a]pyrimidin-3-yl]-prop-2-ynyl}-
dimethylamine (113d) 
 
Yellow solid, yield 54 %, mp 177-8 °C; 
 
1H-NMR (CDCl3), δ(ppm): 2.44 (s, 6 H, 2CH3), 2.71 (s, 3 H, CH3), 3.68 (s, 2 H, CH2), 6.84 (s, 
1 H, H-6), 7.40-7.59 (m, 5 H, Ph-H), 8.09 (dd, 2 H, Ph-H), 8.26 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 25.03 CH3, 44.35 CH3, 49.26 CH2, 76.50 C, 90.34 C, 90.66 C, 
109.62 CH(H-6), 128.58 CH, 128.61 CH, 129.03 CH, 129.43 CH, 130.51 C, 131.16 C, 131.20 
CH, 134.98 C, 146.04 C, 151.65 C, 154.20 C, 160.23 C. 
 
Anal. Calcd. for C24H21ClN3 (400.90): C, 71.90; H, 5.28; Cl, 8.84; N, 13.86. 
                                                  Found: C, 71.82; H, 5.42; Cl, 8.89; N, 13.58. 
 
 
{3-[2-(4-Chloro-phenyl)-5-methyl-7-phenyl-pyrazolo[1,5-a]pyrimidin-3-yl]-prop-2-ynyl}-
dimethylamine (113e) 
 
Yellow solid, yield 69 %, mp 80-2 °C 
 
1H-NMR (CDCl3), δ(ppm): 2.50 (s, 6 H, 2CH3), 2.68 (s, 3 H, CH3), 3.79 (s, 2 H, CH2), 6.81 (s, 
1 H, H-6), 7.43-7.54 (m, 5 H, Ph-H), 8.06 (dd, 2 H, Ph-H), 8.26 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 24.97 CH3, 43.12 CH3, 48.32 CH2, 77.94 C, 88.41 C, 90.03 C, 
109.30 CH(H-6), 127.74 CH, 128.45 CH, 128.88 CH, 129.27 CH, 130.70 C, 130.79 CH, 
132.33 C, 137.32 C, 144.82 C, 151.68 C, 155.59 C, 160.21 C. 
 
Anal. Calcd. for C24H21ClN3 (400.90): C, 71.90; H, 5.28; Cl, 8.84; N, 13.86. 
                                                  Found: C, 72.18; H, 5.38; Cl, 9.02; N, 13.57. 
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N
N N
Ph
R2
OH
R1 113f,  R1 = H, R2 = Ph
113g,  R1 = Ph, R2 = Me
 
 
3-(2-Methyl-5,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-prop-2-yn-1-ol (113f) 
 
Yellow solid, yield 78 %, mp 152-4 °C; 
 
1H-NMR (CDCl3), δ(ppm): 4.58 (s, 2 H, CH2), 7.37 (s, 1 H, H-6), 7.50-7.61 (m, 6 H, Ph-H), 
8.01 (dd, 2 H, Ph-H), 8.17 (dd, 2 H, Ph-H), 8.22(s, 1H, H-2). 
13C-NMR (CDCl3), δ(ppm): 51.99 CH2, 76.10 C, 91.51 C, 93.48 C, 106.13 CH(H-6), 127.58 
CH, 128.77 CH, 128.93 CH, 129.29 CH, 130.77 CH, 131.29 CH, 136.83, 147.45 CH(C-2), 
150.04 C, 157.45 C. 
 
Anal. Calcd. for C21H15N3O (325.30):C, 77.52; H, 4.65; N, 12.91. 
                                                 Found: C, 77.40; H, 4.80; N, 12.67. 
 
 
3-(5-Methyl-2,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-prop-2-yn-1-ol (113g) 
 
Yellow solid, yield 72 %, mp 85-6 °C 
 
1H-NMR (CDCl3), δ(ppm): 2.56 (s, 3 H, CH3), 4.56 (s, 2 H, CH2), 6.67 (s, 1 H, H-6), 7.33-7.48 
(m, 6 H, Ph-H), 7.96 (dd, 2 H, Ph-H), 8.15 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 24.78 CH3, 51.94 CH2, 77.17 C, 89.56 C, 93.58 C, 109.52 CH(H-
6), 127.58 CH, 128.43 CH, 128.59 CH, 129.19 CH, 129.50 CH, 130.36 C, 131.22 CH, 132.33 
C, 146.14 C, 151.62 C, 155.17 C, 160.32. 
 
Anal. Calcd. for C22H17N3O (339.39):C, 77.86; H, 5.05; N, 12.38. 
                                                Found: C, 77.64; H, 5.20; N, 12.11 
 
 
113h, R1 = Ph, R2 = Me
113i,  R1 = H, R2 = Ph
113j,  R1 = Me, R2 = Ph
N
N N
Ph
R2
R1
OH  
 
4-(5-Methyl-2,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-but-3-yn-1-ol (113h) 
 
Yellow solid, yield 71 %, mp 182-3 °C 
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1H-NMR (CDCl3), δ(ppm): 2.66 (s, 3 H, CH3), 2.86 (t, 2 H, J = 6.4 Hz, CH2), 3.91 (t, 2 H, J = 
6.4 Hz, CH2), 7.06 (s, 1 H, H-6), 7.31-7.44 (m, 6 H, Ph-H), 8.05 (dd, 2 H, Ph-H), 8.22 (dd, 2 H, 
Ph-H). 
13C-NMR (CDCl3), δ(ppm): 24.68 CH2, 24.91 CH3, 61.18 CH2, 74.25 C, 91.47 C, 92.37 C, 
106.08 CH(C-6), 127.48 CH; 127.59 CH, 128.52 CH, 128.87 CH, 129.14 CH, 130.47 CH, 
132.69 C, 137.02 C, 146.24 C, 150.72 C, 155.49 C, 156.49 C. 
 
Anal. Calcd. for C23H19N3O (353.42):C, 73.16; H, 5.42; N, 11.89. 
                                                Found: C, 73.28; H, 5.59; N, 11.68. 
 
 
4-(5,7-Diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-but-3-yn-1-ol (113i) 
 
Yellow solid, yield 75 %, mp 132-3 °C 
 
1H-NMR (CDCl3), δ(ppm): 2.74 (t, 2 H, J = 6.4 Hz, CH2), 3.80 (t, 2 H, J = 5.7 Hz, CH2), 7.30 
(s, 1 H, H-6), 7.44-7.52 (m, 6 H, Ph-H), 7.94 (dd, 2 H, Ph-H), 8.10 (dd, 2 H, Ph-H), 8.13 (s, 
1H, H-2). 
13C-NMR (CDCl3), δ(ppm): 24.42 CH2, 61.18 CH2, 72.75 C, 90.35 C, 94.26 C, 105.94 CH(C-
6), 127.54 CH; 128.78 CH, 128.96 CH, 129.28 CH, 130.71 CH, 130.94 C, 131.24 CH, 136.94 
C, 147.17 CH(C-2), 147.36 C, 150.01 C, 157.07 C. 
 
Anal. Calcd. for C22H17N3O (339.39):C, 77.86; H, 5.05; N, 12.38. 
                                                Found: C, 77.91; H, 5.19; N, 12.23 
 
 
4-(2-Methyl-5,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-but-3-yn-1-ol (113j) 
 
Yellow solid, yield 70 %, mp 128-9 °C 
 
1H-NMR (CDCl3), δ(ppm): 2.56 (s, 3 H, CH3), 2.84 (t, 2 H, J = 6.4 Hz, CH2), 3.88 (t, 2 H, J = 
5.8 Hz, CH2), 7.29 (s, 1 H, H-6), 7.50-7.60 (m, 6 H, Ph-H), 8.06 (dd, 2 H, Ph-H), 8.18 (dd, 2 H, 
Ph-H). 
13C-NMR (CDCl3), δ(ppm): 13.72 CH3, 24.53 CH2, 61.29 CH2, 73.10 C, 91.64 C, 93.37 C, 
105.31 CH(C-6), 127.46 CH; 128.73 CH, 128.87 CH, 129.32 CH, 130.49 CH, 131.04 C, 
131.16 CH, 137.13 C, 146.69 C, 150.46 C, 156.66 C, 157.34 C. 
 
Anal. Calcd. for C23H19N3O (353.42):C, 73.16; H, 5.42; N, 11.89. 
                                                Found: C, 73.32; H, 5.50; N, 11.74. 
 
 
Toluene-4-sulfonic acid 4-(5-methyl-2,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-but-3-ynyl 
ester (113k) 
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N
N N
Ph
Ph
OTs
113k, Ts = p-toluenesulfonyl
 
 
Brown solid, yield 18 %, mp 158-9 °C; 
 
1H-NMR (CDCl3), δ(ppm): 2.36 (s, 3 H, CH3), 2.67 (s, 3 H, CH3), 2.95 (t, 2 H, J = 7.1 Hz, 
CH2), 4.26 (t, 2 H, J = 7.1 Hz, CH2), 6.81(s, 1 H, H-6), 7.25 (d, 2 H, J = 8.3 Hz, Ph-H), 7.42-
7.45 (m, 6 H, Ph-H), 7.79 (d, 2 H, J = 8.3 Hz, Ph-H), 8.09 (dd, 2 H, Ph-H), 8.24 (dd, 2 H, Ph-
H). 
13C-NMR (CDCl3), δ(ppm):14.18 CH3, 21.17 CH2, 24.96 CH3, 67.99 CH2, 74.30 C, 89.33 C, 
89.83 C, 109.44 CH(C-6), 127.56 CH, 127.97 CH, 128.49 CH, 128.55 CH, 129.17 CH, 129.45 
CH, 129.85 CH, 130.44 C, 131.17 CH, 132.42 C, 132.78 C, 144.86 C, 146.02 C, 151.46 C, 
155.49 C, 160.16 C. 
 
Anal. Calcd. for C30H25N3O3S (507.60):C, 70.98; H, 4.96; N, 8.28, S, 6.32. 
                                                    Found: C, 70.84; H, 5.17; N, 8.05, S, 6.17. 
 
 
3-(But-3-en-1-ynyl)-5-methyl-2,7-diphenyl-pyrazolo[1,5-a]pyrimidine (114) 
N
N N
Ph
Ph
114
 
The crude product was purified by flash column chromatography on silica, eluting with 
cyclohexane:EtOAc (4:1→2:1) to provide a yellow solid 123 mg, yield 36 %, mp. 186-8 °C; 
 
1H NMR(CDCl3, 300 MHz), δ(ppm): 2.71 (s, 3 H, CH3), 5.53 (dd, 1 H, J1 = 11.3 Hz, J2 = 2.3 
Hz, CH=CH2), 5.77 (dd, 1 H, J1 = 17.9 Hz, J2 = 2.3Hz, CH=CH2), 6.19 (dd, 1H, J1 = 17.9 Hz, 
J2 = 11.3 Hz, CH=CH2), 6.85 (s, 1 H, H-6), 7.40-7.58 (m, 6 H, Ph-H), 8.11 (dd, 2 H, Ph-H), 
8.29 (dd, 2 H, Ph-H). 
13C NMR (CDCl3), δ(ppm): 25.0 CH3, 81.7 C, 90.3 C, 93.9 C, 109.6 CH(C-6), 117.9 
CH(CH=), 125.6 CH2(=CH2), 127.8 CH, 128.4 CH, 128.6 CH, 129.2 CH, 129.5 CH, 130.5 C, 
131.2 CH, 132.5 C, 146.1 C, 151.3 C, 155.5 C, 160.3 C. 
 
Anal. Calcd. for C23H17N3 (335.40):C, 82.32; H, 5.11; N, 12.53. 
                                              Found: C, 82.07; H, 5.30; N, 12.28. 
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Using the same procedure, 104h reacted with 3-amino-phenylacetylene, no desired coupling 
product was obtained, but a nearly quantitative homo-coupling product 115 was isolated. 
 
2-[4-(2-Amino-phenyl)-1,3-butadiynyl]phenyl-amine (115) 
H2N NH2
115  
 
The crude product was purified by flash column chromatography on silica gel, eluting with 
cyclohexane:EtOAc (3:1 → 1:1) to afford a grey-green solid, yield: 100 %, mp.124-5°C. 
 
1H-NMR (CDCl3, 300MHz), δ(ppm): 3.70 (s, br, 4 H, 2NH2), 6.69 (m, 2 H, Ph-H), 6.81 (t, 2 
H, J = 1.9 Hz, Ph-H), 6.93 (dt, 2 H, J1 = 7.5 Hz, J2 = 1.2 Hz, Ph-H), 7.11 (t, 2 H, J = 7.9 Hz, 
Ph-H). 
13C NMR (CDCl3, 75MHz), δ(ppm): 73.4 C, 81.7 C, 116.3 CH, 118.4 CH, 122.4 C(C-3), 123.0 
CH, 129.4 CH, 146.3 C(C-1). 
 
Anal. Calcd. for C16H12N2 ( 232.28): C, 82.73; H, 5.21; N, 12.06. 
                                                Found: C, 82.84; H, 5.40; N, 12.01. 
 
 
(2) Catalytic hydrogenation of 113a and 113b 
 
General Procedure: 
A 25 ml Schlenk-flask was charged with 113a or 113b 0.3 mmol, 10 % Pd/C (67 mg, 0.06 
mmol, 0.2 equiv) and EtOH (15ml). The mixture was stirred under hydrogen at atmospheric 
pressure (balloon) and room temperature for 16h. It was filtered through a pad of Celite, 
washed with EtOAc. The solvent was evaporated and the residue was purified by flash column 
chromatography on standard neutral Al2O3, eluting with EtOAc:MeOH(1:0→10:1) to provide 
the product 116a or 116b. 
N
N N
Me2N
Ph
Ph
R1
116a (R1=Me)
116b (R1=H)
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[3-(5,7-Diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-propyl]-dimethylamine (116a): 
 
Yellow solid, Yield 37 %, mp 72-74 °C; 
 
1H-NMR(CDCl3, 300 MHz), δ(ppm,): 1.95-2.06 (m, 2 H, CH2), 2.28 (s, 6 H, 2CH3), 2.44 (t, 2 
H, J = 7.5 Hz, CH2), 2.95 (t, 2H, J = 7.9Hz, CH2), 7.31 (s, 1 H, H-6), 7.50-8.05 (m, 10 H, Ph-
H), 8.07 (s, 1 H, H-2). 
13C NMR (CDCl3, 75MHz), δ(ppm): 21.0 CH2, 28.3 CH2, 45.5 CH3, 59.4 CH2, 104.7 CH(C-6), 
110.8 C, 127.2 CH, 128.7 CH, 128.9 CH, 129.2 CH, 130.1 CH, 130.8 CH, 131.7 C, 137.7 C, 
144.5 CH, 146.5 C, 147.1 C, 154.5 C. 
 
Anal. Calcd. for C23H24N4(356.46): C, 77.50; H, 6.79; N, 15.72. 
                                              Found: C, 77.62; H, 6.95; N, 15.48. 
 
 
N,N-Dimethyl-[3-(2-methyl-5,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-propyl]-amine 
(116b) 
 
Yellow solid, Yield 40 %, mp 93-4 °C; 
 
1H NMR (CDCl3, 300 MHz), (ppm): 1.82-1.91 (m, 2 H, CH2), 2.18 (s, 6 H, CH3), 2.32 (t, 2 H, 
J = 7.5 Hz, CH2), 2.40 (s, 3 H, CH3), 2.81 (t, 2 H, J = 7.5 Hz, CH2), 7.13 (s, 1 H, H-6), 7.40-
7.49 (m, 6 H, Ph-H), 7.99-8.02 (dd, 2 H, Ph-H), 8.06-8.09 (dd, 2 H, Ph-H). 
13C NMR (CDCl3, 75MHz), (ppm): 13.2 CH3, 20.6 CH2, 28.3 CH2, 45.6 CH3, 59.6 CH2, , 
103.8 CH (C-6), 108.3 C, 127.1 CH, 128.7 CH, 128.8 CH, 129.2 CH, 129.9 CH, 130.7 CH, 
131.9 C, 137.9 C, 145.7 C, 147.9 C, 153.6 C, 154.2 C. 
 
Anal. Calcd for C24H26N4 (370.49): C, 77.80; H, 7.07; N, 15.12. 
                                             Found: C, 77.92; H, 7.14; N, 15.07. 
 
(3) Other Sonogashira reaction 
 
Synthesis of dimethyl-[4-(5-methyl-2,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-ylethynyl)-
phenyl]-amine (117) 
N
N N
Ph
Ph
NMe2
117
 
 
A 25 ml flask was charged with 3-iodo-5-methyl-2, 7-diphenylpyrazolo[1, 5]pyrimidine 104a 
(206 mg, 0.5 mmol), Pd(PPh3)2Cl2 (14 mg, 0.02 mmol), (4-ethynyl-phenyl)dimethylamine (73 
mg, 0.5 mmol), and piperdine 2 ml Argon was passed three times and the mixture was heated at 
80 °C for 24 h, the solvent was evaporated in vacuum, the residue was purified by column 
Chapter7: Experimental 
_________________________________________________________________________________________________________________________________ 
 
141
chromatography on silica gel, eluting with cyclohehane:ethyl acetate (6/1→1/1), and 94 mg 
brown solid was obtained, yield 44 %, mp 150-2 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.86 (s, 3 H, CH3), 2.98 (s, 6 H, 2CH3), 6.69 (d, 2 H, J = 9.0 Hz, 
Ph-H), 7.18 (s, 1 H, H-6), 7.48-8.21 (m, 10 H, Ph-H), 8.44 (d, 2 H, J = 9.0 Hz, Ph-H). 
13C NMR (CDCl3), δ(ppm): 26.90 CH3, 40.28 CH3, 78.96 C, 92.42 C, 95.98 C, 105.84 CH(C-
6), 111.87 CH, 127.46 CH, 127.74 CH, 128.47 CH, 128.61 C, 128.79 C, 128.99 CH, 130.34 
CH, 132.57 CH, 132.94 C, 137.13 C, 146.08 C, 149.86 C, 149.98 C, 155.41 C, 155.99 C. 
 
Anal. Calcd. for C30H24N4 (428.53): C, 81.28; H, 5.65; N, 13.07. 
                                               Found: C, 81.40; H, 6.71; N, 13.18. 
 
 
 
Synthesis of 2-[3-(2-Methyl-5,7-diphenyl-pyrazolo[1,5-a]pyrimidin-3-yl)-prop-2-ynyl]-
isoindole-1,3-dione (118) 
N
N N
Ph
Ph
NPhth
118
 
 
 
A 25 ml flask was charged with 3-iodo-2-methyl-5, 7-diphenylpyrazolo[1, 5]pyrimidine 104c 
(206 mg, 0.5 mmol), Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10 mg, 0.05 mmol), TEA 5 ml, 
DMF 5 ml and N-propargyl-phthalamide 111 mg (0.6 mmol), Argon was passed three times 
and the mixture was heated at 50 °C for 24 h, the solvent was evaporated in vacuum, the 
residue was purified by column chromatography on silica gel, eluting with cyclohehane:ethyl 
acetate (5/1→1/1), and 89 mg light brown solid was obtained, yield 38 %, mp 163-5 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.47 (s, 3 H, CH3), 4.77 (s, 2 H, CH2), 7.24 (s, 1 H, H-6), 7.42-8.14 
(m, 14 H, Ph-H). 
13C NMR (CDCl3), δ(ppm): 13.74 CH3, 28.61 CH2, 74.24 C, 88.07 C, 92.46 C, 105.37 CH(C-
6), 123.49 CH, 127.52 CH, 128.73 CH, 128.80 C, 128.88 CH, 129.32 CH, 130.54 CH, 131. 16 
CH, 132.22 C, 134.07 CH, 134.32 C, 137.01 C, 146.72 C, 156.89 C, 158.23 C, 167.22 C(C=O). 
 
Anal. Calcd. for C30H20N4O2(468.50): C, 76.91; H, 4.30; N, 11.96. 
                                                  Found: C, 76.78; H, 4.51; N, 11.78. 
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7.2.5 Synthesis of substituted pyrazolo[1,5-a]pyrimidines via Suzuki cross-
coupling reaction 
 
Synthesis of 5-chloro-3,7-diphenylpyrazolo[1,5-a]pyrimidine (120) 
 
N
N N
Ph
Cl
Ph 
 
 
A 50 ml Schlenk flask was charged with 5,7-dichloro-3-phenylpyrazolo[1,5-a]pyrimidine 101 
(528 mg, 2 mmol), phenylboronic acid (244 mg, 2 mmol), anhydrous K2CO3 (331 mg, 2.4 
mmol), Pd(PPh3)4 (70 mg, 0.06 mmol), and toluene 30 ml. Argon was passed inside the flask 
and the mixture was heated at 100 °C for 20 h, after cooled, the solid was filtered out, the 
filtrate was evaporated and the residue was separated by column chromatography on silica gel, 
eluting with hexane and then hexane:ethyl acetatate (10/1), the coupling product 5-chloro-3,7-
diphenylpyrazolo[1,5-a]pyrimidine 120 347 mg (54 %) was first isolated, eluting with 
hexane:ethyl acetatate (5/1) and isolated 7-chloro-3,5-diphenylpyrazolo[1,5-a]pyrimidine 98 
(138 mg yield 23 %). 
 
Orange solid, yield 54 %, mp 121-3 °C; 
 
1H-NMR (CDCl3), δ(ppm): 6.80 (s, 1 H, H-6), 7.18-7.96 (m, 10 H, Ph-H), 8.38 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 108.20 CH(C-6), 110.82 C, 126.42 CH, 126.68 CH, 128.84 CH, 
129.31 CH, 129.98 C, 131.23 C, 131.66 CH, 143.48 CH(C-2), 144.70 C, 148.35 C, 150.47 C. 
 
Anal. Calcd for C18H12ClN3 (305.76): C, 70.71; H, 3.96; Cl, 11.60; N, 13.74 
                                                  Found: C, 70.77; H, 4.06; Cl, 11.62; N, 13.53. 
 
Using the same conditions, 101 was coupled with 3 equiv. of phenylboronic acid, 3,5,7-
triphenylpyrazolo[1,5-a]pyrimidine (89c) was obtained in 86 % yield. 100 or 104h was coupled 
with 1.5 equiv. of phenylboronic acid, 89c was obtained in 99 % and 62 % respectively. 
 
Attempt to undergo regioselective Suzuki coupling, and chose Pd(PPh3)4 (0.05 equiv.) as 
catalyst, DME as solvent, 2 M aqueous (2 equiv.) Na2CO3 as base, and at 80 °C 16 h, 101 was 
treated with equal equivalent of phenylboronic acid, 5-chloro-3,7-diphenylpyrazolo-
[1,5a]pyrimidine 120 was obtained in 72 % yield 
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7.2.6 Synthesis of substituted pyrazolo[1,5-a]pyrimidines by Nucleophilic 
substitution 
 
3,7-Diphenylpyrazolo[1,5-a]pyrimidin-5-ylamine (127) 
 
N
N N
Ph
Ph
H2N
127
 
 
A 500 ml autoclave was charged 5-Chloro-3,7-diphenylpyrazolo[1,5-a]pyrimidine 120 (162 
mg, 0.53 mmol) and liquid ammonia 20ml, the mixture was heated at 100 °C for 24 h, after 
cooled the autoclave was opened, the residue was dissolve in 60 ml CH2Cl2, washed with water 
(2 × 30 ml), and dried with anhydrous MgSO4, the solvent was evaporated and the residue was 
purified by column chromatography on silica gel, eluting with cyclohexane:ethyl acetate (1/1), 
and provided a yellow solid 126 mg, yield 83 %, mp 214-5 °C. 
 
1H-NMR(CDCl3), δ(ppm): 4.88 (s, 2 H, NH2), 6.09 (s, 1 H, H-6), 7.11-7.93 (m, 10 H, Ph-H), 
8.16 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ (ppm): 98.10 CH(H-6), 106.56 C, 125.38 CH, 125.87 CH, 128.59 CH, 
128.63 CH, 129.15 CH,130.72 CH, 131.42 C, 142.61 CH(H-2), 145.74 C, 148.00 C, 156.17 C. 
 
Anal. Calcd. for C18H14N4: C,75.50; H, 4.93; N, 19.57. 
                                Found: C, 75.43; H, 5.04; N, 19.55. 
 
 
N'-(3,7-Diphenyl-pyrazolo[1,5-a]pyrimidin-5-yl)-N,N-dimethyl-propane-1,3-diamine (128) 
N
N N
Ph
Ph
Me2N(H2C)3HN
128
 
 
A solution of 5-chloro-3,7-diphenylpyrazolo[1,5-a]pyrimidine 47 (58 mg, 0.19 mmol) in N,N-
dimethyl-propane-1,3-diamine 3 ml was heated at 100 °C for 24 h, the mixture was evaporated 
in vacuum, 30 ml water was added, the solution was extracted with chloroform (3 × 30 ml), the 
extract was washed with 10 % NaOH 30 ml and water 30 ml, then dried with anhydrous 
MgSO4, the solvent was evaporated and the residue was purified by flash column 
chromatography on standard neutral Al2O3 gel, eluting with EtOAc:MeOH(10:1), yellow solid 
61 mg was obtained, yield 87 %, mp 195-7 °C. 
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1H-NMR (CDCl3), δ(ppm): 1.76 (m, 2 H, CH2), 2.18 (s, 6 H, CH3), 2.38 (t, 2 H, J = 6.8Hz, 
CH2), 3.54(m, 2 H, CH2), 5.94 (s, 1 H, H-6), 6.31 (br, 1H, NH), 7.09-8.02 (m, 10 H, Ph-H), 
8.14 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 24.27 CH2, 38.26 CH2, 43.30 CH3, 56.13 CH2, 99.35 CH(C-6), 
105.81 C, 125.22 CH, 125.38 CH, 128.48 CH, 128.59 CH, 129.12 CH, 130.44 CH, 131.47 C, 
133.54 C, 141.81 CH(C-2), 145.93 C, 146.85 C, 155.95 C. 
 
HRMS (EI) calcd for C23H25N5 (M+) 371.21100, found 371.21108. 
 
Anal. Calcd. for C23H25N5 (371.48): C, 74.36; H, 6.78  N, 18.85. 
                                               Found: C, 74.46; H, 6.90; N, 18.61. 
 
 
 
N'-(3,7-Diphenyl-pyrazolo[1,5-a]pyrimidin-5-ylmethyl)-N,N-dimethyl-propane-1,3-diamine 
(129) 
N
N N
Ph
Ph
Me2N(H2C)3HN 129
 
 
A solution of 5-bromomethyl-3,7-diphenylpyrazolo[1,5-a]pyrimidine 105 (146 mg, 0.4 mmol) 
in N,N-dimethyl-propane-1,3-diamine 2 ml was stirred at RT for 12 h, then the solution was 
treated with saturated aq. NaHCO3 30 ml, the mixture was extracted with ethyl acetate (3 × 30 
ml), the extract was dried with anhydrous MgSO4, the solvent was evaporated and the residue 
was purified by flash column chromatography on standard neutral Al2O3 gel, eluting with 
EtOAc:MeOH(10:1) and provided a brown glass material 50 mg, yield 33 %. 
 
1H-NMR(CDCl3), δ(ppm): 1.76 (m, 2 H, CH2), 2.22 (s 6 H, 2CH3), 2.38 (t, 2 H, J = 7.5Hz, 
CH2), 2.49 (br, 1 H, NH), 2.80 (t, 2 H, J = 6.9Hz, CH2), 4.05 (s, 2 H, CH2), 6.99 (s, 1 H, H-6), 
7.26-8.12 (m, 10 H, Ph-H), 8.43 (s, 1 H, H-2). 
13C-NMR(CDCl3), δ(ppm): 28.13 CH2, 45.53 CH3, 48.13 CH2, 54.99 CH2, 57.95 CH2, 107.00 
CH(C-6), 109.86 C, 126.10 CH, 126.31 CH, 128.67 CH, 129.23 CH, 130.94 CH, 131.20 CH, 
132.31 C, 142.59 CH(C-2), 145.62 C, 146.66 C, 160.67 C. 
 
HRMS(EI) calcd for C24H26N5( M+ ) 385.22665, found 385.22662. 
 
 
 
7.2.7 Synthesis of pyrazolo[1,5-a]pyrimidine derivatives by ring-chain-
transformation 
 
2-(Dihydro-furan-2-ylidene)-1-phenyl-ethanone (130) 
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OO
Ph
130 
 
 
A 250 ml flask was charged with 95 % NaH (1.01 g, 0.04 mol), and dry ether 120 ml, ethanol 
0.1 ml was added dropwise(as catalyst), 4-butyrolactone (1.80 g, 0.02 mol) was added inside in 
one portion, and the mixture was cooled to 15 °C, then a solution of acetophenone (2.40 g, 0.02 
mol) in 20 ml ether was added dropwise over 1 h, the resulting mixture was stirred at RT for 24 
h,  and cooled to 0°C, 2 ml ethanol was added to destroy the excess NaH, then cold 10 % aq. 
ammonium sulphate 40 ml was added,  and separated, the ether solution was dried with 
anhydrous sodium sulphate, evaporated the solvent, the residue was purified by column 
chromatography on silica gel, eluting with cyclohexane:ethyl acetate (4/1→1/1), and provided 
a yellow solid 1.05 g, yield 28 %, mp 36-8 °C. 
 
1H-NMR(CDCl3), δ(ppm): 1.95 (m, 2 H, CH2), 2.58 (t, 2 H, J = 6.1 Hz, CH2), 3.73 (t, 2 H, J = 
7.3 Hz, CH2), 6.21 (s, 1 H, C=CH), 7.42-7.90 (m, 5 H, Ph-H). 
13C-NMR (CDCl3), δ (ppm): 28.34 CH2, 36.13 CH2, 62.08 CH2, 96.31 CH, 126.98 CH, 128.64 
CH, 132.34 CH, 134.60 C, 182.45 C, 197.59 C. 
 
Anal. Calcd. for C12H16O2: C, 76.57; H, 6.43; 
                                Found: C, 76.34; H, 6.60; 
 
3-(3,7-Diphenyl-pyrazolo[1,5-a]pyrimidin-5-yl)-propan-1-ol (131) 
 
N
N N
Ph
Ph
55HO
 
 
A 50ml flask was charged with 2-(dihydro-furan-2-ylidene)-1-phenyl-ethanone 130 (395 mg, 
2.1 mmol, 3-amino-4-phenylpyrazole (320 mg, 2 mmol), ethanol 15 ml and 37 % HCl 1 ml, the 
mixture was heated at reflux for 6 h, ethanol was evaporated and neutralized with aq. Na2CO3, 
the mixture was extracted with ethyl acetate (3 × 30 ml), and dried with anhydrous MgSO4, the 
solvent was evaporated and the residue was purified by column chromatography on silica gel, 
eluting with CH2Cl2:ethyl acetate (4/1), and provided a yellow solid 546 mg, yield 83 %, mp 
147-8 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.13-2.21 (m, 2 H, CH2), 2.24 (br, 1 H, OH), 3.07 (t, 2 H, J = 7.4 
Hz, CH2), 3.83 (t, 2 H, J = 6.0 Hz, CH2), 6.82 (s, 1 H, H-6), 7.26-8.07 (m, 10 H, Ph-H), 8.42 (s, 
1 H, H-2) 
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13C-NMR(CDCl3), δ (ppm): 30.81 CH2, 34.80 CH2, 62.15 CH2, 108.34 CH(C-6), 109.83 C, 
126.19 CH, 126.42 CH, 128.72 CH, 128.75 CH, 129.22 CH, 131.00 CH, 131.13 C, 142.76 
CH(C-2), 145.59 C, 146.65 C, 162.07 C, . 
 
Anal. Calcd. for C21H19N3O: C,76.57; H, 5.81; N, 12.76 
                                   Found: C, 76.27; H, 6.12; N, 12.59. 
 
 
 
7.3 Synthesis of purine derivatives 
 
7.3.1 Synthesis of 2,6-dichloropurine 
2,6-Dichloropurine was prepared from commercial available adenine. The synthetic route is as 
below (Scheme 7.7): 
 
N
N N
H
N
NH2
Adenine
N
N N
H
N
NH2
N
N N
H
N
Cl
O N
N N
H
N
OH
O
Cl
H2O2
60%
181 182 179
NaNO2
HOAc
50%
POCl3
PhNMe2
reflux 3h
28%
 
Scheme 7.7 
 
Adenine 1-N-oxide (181) 
Adenine (20.0 g, 0.15mol) was suspended in 120 ml of acetic acid and the mixture was heated 
at reflux for 1 h. After the solid was dissolved completely, the solution was cooled to room 
temperature. To this solution, 74 ml of 30 % H2O2 was added dropwise and then the solution 
was allowed to stand for 3 days at room temperature. The precipitate was collected and washed 
with water to give 51 as a white solid 13.60 g, yield 60 %, mp>300 °C.  
 
Hypoxanthine 1-N-oxide (182) 
Adenine 1-N-oxide (181) (7.19 g, 0.053 mol) was suspended in a solution containing NaNO2 
(33.07 g, 0.48 mol) in 500 ml water. The mixture was cooled to 10 °C in an ice bath, and 300 
ml of 30 % aqueous was added dropwise with stirring over a period of 30 min. After the 
addition of acid was complete, the solution was heated at 70-80 °C for 2 h, then cooled to room 
temperature and allowed to stand for 4 days. The precipitate was collected and washed with 
water, alcohol, and ether to afford 52 as a yellow solid 4.0 g, yield 50 %, mp>300 °C. 
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2,6-dichloropurine (179) 
Hypoxanthine 1-N-oxide (182) (3.6 g, 0.024 mol) was suspended in a mixture of 180 ml of 
phosphoryl chloride and 6 ml N,N-dimethylaniline and was was heated at reflux for 3 h under 
Argon. After the mixture was cooled to room temperature, excess phosphoryl chloride was 
distilled off under reduced pressure. The residue was dissolved in 100 ml water and extracted 
with CH2Cl2 (3 × 100 ml), the solvent was evaporated in vacuum to give a crude oil, which was 
chromatography on silica gel, eluting with ethyl acetate: hexane (1/1→1/0) to give a white 
solid 1.28 g, yield 28 %, mp 184-6 °C.  
 
Anal. Calcd. for C5H2Cl2N4: C, 31.77; H, 1.07; Cl, 37.52; N, 29.64. 
                                  Found: C, 31.79; H, 1.13; Cl, 36.72; N, 29.35. 
 
 
7.3.2 Benzylation of 2,6-dichloropurine and 6-chloropurine 
 
(1) Benzylation of 2,6-dichloropurine 
 
N
N N
H
N
Cl
N
N N
N
Cl
Cl
Bn
Cl
N
N
N
N
Cl
Cl
Bn
BnCl, K2CO3
 DMF
RT, 24 h +
179
137 183(44 %) (21 %)  
 
Scheme 7.8 
 
A flask was charged with 2,6-dichloropurine (1.27 g, 6.6 mmol), anhydrous potassium 
carbonate (2.72 g, 20 mmol), and dry DMF 40 ml, Argon was passed, the mixture was stirred 
for 30 min, then benzylchloride (1.27 g, 16 mmol) was added, and stirred at room temperature 
for 2 days.The solid was filtered off, the filtratet was evaporated, and the residue was purified 
by column chromatography on silica gel. 
 
 
9-Benzyl-2,6-dichloro-purine (137) 
 
Eluting with hexane:ethyl acetate (2/1), and provide 0.81 g white solid, yield 44 %, mp 125-7 
°C.  
 
1H-NMR (CDCl3), δ(ppm): 5.34 (s, 2 H, CH2), 7.30-7.56 (m, 5 H, Ph-H), 7.98 (s, 1 H, H-8) 
13C-NMR (CDCl3), δ(ppm): 48.04 CH2, 127.84 C, 128.09 CH, 129.03 C,129.09 CH, 129.39 
CH, 133.99 C, 145.54 CH(H-8), 151.89 C, 153.02 C. 
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Anal. Calcd. for C12H8Cl2N4 (279.13): C, 51.64; H, 2.89; Cl, 25.40; N, 20.07. 
                                                   Found: C, 51.58; H, 2.94; Cl, 25.27; N, 19.96. 
 
 
7-Benzyl-2,6-chloro-purine (183) 
 
Eluting with hexane:ethyl acetate (1/1), and obtain 0.36 g white solid, yield 21 %, mp 144-6 
°C. 
 
1H-NMR(CDCl3), δ(ppm): 5.74 (s, 2 H, CH2), 7.23-7.45 (m, 5 H, Ph-H), 9.06 (s, 1 H, H-8). 
13C-NMR(CDCl3), δ(ppm): 49.8 CH2, 121.9 C(C-5), 126.8 CH, 128.0 CH, 128.9 CH, 136.3 C, 
143.4 C, 151.2 C, 152.8 CH(C-8), 163.4 C. 
 
Anal. Calcd. for C12H8Cl2N4 (279.13): C, 51.64; H, 2.89; Cl, 25.40; N, 20.07. 
                                                   Found: C, 51.50; H, 2.98; Cl, 25.21; N, 19.99. 
 
 
(2) Benzylation of 6-chloropurine 
 
N
N N
H
N
Cl
N
N N
N
Cl
Bn
N
N
N
N
Cl Bn
BnBr, K2CO3
 DMSO
RT, 2 d +
132 155(50 %) (23 %)180  
 
Scheme 7.9 
 
A mixture of 6-chloropurine (2.47 g, 16 mmol), anhydrous potassium carbonate (2.76 g, 20 
mmol), DMSO 40 ml and benzylbromide (2.74 g, 16 mmol) was stirred at room temperature 
for 2 days. 
The reaction solution was decanted from the solid, ice water 50 ml was poured inside, the 
solution was acidified to PH = 5 with formic acid, the mixture was extracted with ethyl acetate 
(4 × 80ml), the combined extract was washed with water 100 ml, dried with anhydrous 
MgSO4, evaporated the solvent, the residue was separated by column chromatography on silica 
gel. 
 
9-Benzyl-6-chloro-purine (132) 
 
Eluting with hexane:ethyl acetate (2/1), 1.98 g white solid was obtained, yield 50 %, mp 80-2 
°C.  
 
1H-NMR (CDCl3), δ(ppm): 5.46 (s, 2 H, CH2), 7.30-7.39 (m, 5 H, Ph-H), 8.10 (s, 1 H, H-8), 
8.19 (m, 1 H, H-2) 
13C-NMR (CDCl3), δ(ppm): 47.91 CH2, 127.96 CH, 128.90 CH, 129.30 CH, 131.55 C, 134.52 
C, 144.96 CH(C-8), 151.19 C, 151.88 C, 152.21 CH(C-2). 
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Anal. Calcd. for C12H9ClN4 (244.69): C, 58.91; H, 3.71; Cl, 14.49; N, 22.90. 
                                                 Found: C, 58.74; H, 3.86; Cl, 14.35; N, 22.71. 
 
 
7-Benzyl-6-chloro-purine (155) 
 
Eluting with hexane:ethyl acetate (1/1), and get 0.91 g white solid, yield 23 %, mp 144-6°C.  
 
1H-NMR (CDCl3), δ(ppm): 5.71 (s, 2 H, CH2), 7.17-7.38 (m, 5 H, Ph-H), 8.25 (s, 1 H, H-8), 
8.89 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 50.74 CH2, 122.56 C, 127.08 CH, 128.94 CH, 129.39 CH, 134.64 
C, 143.24 C, 149.16 CH(C-8), 152.62 CH(C-2), 162.05 C. 
 
Anal. Calcd. for C12H9ClN4 (244.69): C, 58.91; H, 3.71; Cl, 14.49; N, 22.90. 
                                                 Found: C, 58.74; H, 3.86; Cl, 14.35; N, 22.71. 
 
 
 
7.3.3 Suzuki cross-coupling of halopurines 
 
General procedure: 
A flask was charged with halopurine (137, 183, or 132) 0.6 mmol, phenboronic acid (79 mg, 
0.6 mmol), K2CO3 (100 mg, 0.72 mmol), Pd(PPh3)4 (35 mg, 0.03 mmol), and dry toluene 10 
ml. Argon was passed three times and heated at 100 °C for 20 h, the solvent was evaporated, 
and the residue was purified by column chromatography on silica gel. 
 
9-Benzyl-2-chloro-6-phenylpurine (140) 
 
N
N N
N
Ph
Cl
140
Bn  
 
Eluting with hexane:ethyl acetate (1:1), and a white solid 112 mg was obtained, yield 70 %, mp 
141-3 °C.  
 
1H-NMR (CDCl3), δ(ppm): 5.36 (s, 2 H, CH2), 7.30-7.49 (m, 8 H, Ph-H), 7.96 (s, 1 H, H-8), 
8.72-8.78 (dd, 2H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 47.41 CH2, 128.01 CH, 128.72 CH, 128,80 CH, 129.25 CH, 
130.06 CH, 131.74 CH, 134.49 C, 134.76 C, 144.67 CH(C-8), 154.39 C, 154.43 C, 156.77 C, 
160.11 C. 
 
Anal. Calcd for C18H13ClN4 (320.78): C, 67.40; H, 4.08; Cl, 11.05; N, 17.47 
                                                 Found: C, 67.67; H, 4.36; Cl, 10.92; N, 17.23. 
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7-Benzyl-2-chloro-6-phenylpurine (184) 
 
N
N
N
N
Ph
Cl
Bn
184
 
 
 
Eluting with hexane:ethyl acetate (1:3), and a white solid was obtained, yield 66 %, mp 154-5 
°C.  
 
1H-NMR (CDCl3), δ(ppm): 5.12 (s, 2 H CH2), 6.45-7.45 (m, 10 H, Ph-H), 8.22 (s, 1 H, H-8). 
13C-NMR (CDCl3), δ(ppm): 51.31 CH2, 122.02 C, 126.46 CH, 128.53 CH, 128.63 CH, 128.98 
CH, 130.43 CH, 133.98 C, 134.47 C, 150.70 CH(C-8), 154.41 C, 154.66 C, 164.04 C. 
 
Anal. Calcd for C18H13ClN4 (320.78): C, 67.40; H, 4.08; Cl, 11.05; N, 17.47 
                                                  Found: C, 67.34; H, 4.33; Cl, 10.87; N, 17.52. 
 
 
9-Benzyl-6-phenylpurine (134a) 
N
N N
N
Ph
134a
Bn  
 
Eluting with hexane:ethyl acetate (1:1), and a white solid was obtained, yield 75 %, mp 124-5 
°C.  
 
1H-NMR (CDCl3), δ(ppm): 5.43 (s, 2 H, CH2), 7.26-7.50 (m, 8 H, Ph-H), 8.04 (s, 1 H, H-8), 
8.71 (dd, 2 H, Ph-H), 8.99 (s, 1 H, H-2) 
13C-NMR (CDCl3), δ(ppm): 47.32 CH2, 127.83 CH, 128.61 CH, 128.70 CH, 129.17 CH, 
129.80 CH, 130.93 C, 131.06 CH, 135.16 C, 135.48 C, 144.21CH(C-8), 149.45 C, 151.34 C, 
152.55 CH(C-2). 
 
Anal. Calcd for C18H14N4 (286.33): C, 75.50; H, 4.93; N, 19.57 
                                              Found: C, 75.44; H, 5.14; N, 19.64. 
 
 
9-Benzyl-8-iodo-6-chlorol-purine (152) 
 
A 50 ml flask was charged with 9-Benzyl-6-chloro-purine (132) (367 mg, 1.5 mmol), NIS 
(1.01 g, 4.5 mmol), and THF 20 ml. The flask was draped with aluminium-foil, and the mixture 
was heated at reflux under Ar for 3 days. The solvent was evaporated, 60 ml CH2Cl2 was added 
inside, the solution was washed with sat. aq. Na2S2O3 (2 × 30 ml), and water 30 ml, then dried 
with anhydrous MgSO4, evaporated the solvent, the residue was separated by flash column 
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chromatography on silica gel, eluting with hexane:ethyl acetate (2/1), to provide a white solid 
254 mg, yield 46 %, mp 135-6 °C. 
N
N N
N
Cl
Bn
I
152
 
 
 
1H-NMR (CDCl3), δ(ppm): 5.47 (s, 2 H, CH2), 7.32-7.34 (m, 5 H, Ph-H), 8.71 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 49.69 CH2, 108.17 C, 127.89 CH, 128.62 CH, 128.99 CH, 133.81 
C, 134.27 C, 149.36 C, 152.09 CH(H-2), 153.06 C. 
 
Anal. Calcd for C12H8ClIN4 (370.58): C, 38.89; H, 2.18; N, 15.12 
                                                  Found: C, 39.00; H, 2.20; N, 15.01 
 
 
 
7.3.4 Sonogashira cross-coupling of halo-purines 
(1) 9-Benzyl-8-bromo-6-phenylpurine (185) 
 
 
N
N N
N
Ph
Bn
185Br
 
 
A 50 ml flask was charged with 9-benzyl-6-phenylpurine 134a (358 mg, 1.25 mmol), NBS 
(1.35 g, 7.5 mmol), and THF 20 ml. The mixture was heated at reflux for 2 days. The solvent 
was evaporated, the residue was separated by flash column chromatography on silica gel, 
eluting with hexane:ethyl acetate (3/1) to provide a white solid 255 mg, yield 56 %, mp 112-4 
°C. 
 
1H-NMR (CDCl3), δ(ppm): 5.43 (s, 2 H, CH2), 7.23-8.69 (m, 10 H, Ph-H), 8.91 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 47.64 CH2, 127.84 CH, 128.43 CH, 128.74 CH, 128.94 CH, 
129.72 CH, 131.20 CH, 131.31 C, 133.07 C, 134.77 C, 135.13 C, 152.09 CH(H-2), 153.59 C, 
153.73 C. 
 
Anal. Calcd for C18H13BrN4 (365.23): C, 59.19; H, 3.59; Br, 21.88; N, 15.12 
                                                  Found: C, 59.02; H, 3.75; Br, 22.03; N, 15.00 
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(2) [3-(9-Benzyl-6-phenyl-purin-8-yl)-prop-2-ynyl]-dimethylamine (186) 
 
N
N N
N
Ph
Bn
186NMe2
 
 
A 25 ml schlenk flask was charged 9-Benzyl-8-bromo-6-phenylpurine 185 (182 mg, 0.5 
mmol), Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10 mg, 0.05 mmol), triethylamine 10 ml, and 
N, N-dimethylpropargylamine (83 mg, 1.0 mmol), Argon was passed three times and the 
mixture was heated at 80 °C for 24 h. The mixture was concentrated, the residue was purified 
by column chromatography on silica gel, eluting with ethyl acetate:methanol (1/0→8/1), and 
provided a brown solid 158 mg, yield 86 %, mp 134-6 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.34 (s, 6 H, 2CH3), 3.63 (s, 2 H, CH2), 5.58 (s, 2 H, CH2), 7.29-
8.80 (m, 10 H, Ph-H), 9.03 (s, 1 H, H-2). 
13C-NMR (CDCl3), δ(ppm): 44.21 CH3, 46.90 CH2, 47.64 CH2, 75.13 C, 94.23 C, 127.60 CH, 
128.22 CH, 128.69 CH, 128.80 C, 128.86 CH, 129.87 CH, 130.88 C, 131.08 CH, 135.46 C, 
138.42 C, 152.32 C, 152.09 CH(H-2), 154.61 C. 
 
Anal. Calcd for C23H21N5 (367.45): C, 75.18; H, 5.76; N, 19.06. 
                                              Found: C, 75.05; H, 5.98; N, 19.01 
 
 
(3) [3-(9-Benzyl-6-phenyl-purin-8-yl)-propyl]-dimethylamine (187) 
 
A mixture of [3-(9-benzyl-6-phenyl-purin-8-yl)-prop-2-ynyl]-dimethylamine 186 (100 mg, 
0.27 mmol), 10 % palladium on charcoal (65mg, 0.054 mmol on Pd, 0.2 equiv) in ethanol (15 
mL)  were stirred under hydrogen at room temperature and atmosphere 16 hours. After 
complete conversion (TLC monitoring), the catalyst was filtered off through a pad of celite, 
washed with ethyl acetate, the solvents were removed under reduced pressure, and the residue 
was purified by column chromatography on neutral Al2O3 gel, eluting with cyclohexane:ethyl 
acetate (1:1) to provide a white solid 71 mg, yield 70 %, mp 81-3 °C. 
N
N N
N
Ph
Bn
187NMe2
 
 
1H-NMR (CDCl3), δ(ppm): 1.94-2.02 (m, 2 H, CH2), 2.13 (s, 6 H, 2CH3), 2.27 (t, 2 H, J = 
7.2Hz, CH2), 2.82 (t, 2 H, J = 7.4 Hz, CH2), 5.45 (s, 2 H, CH2), 7.07-8.78 (m, 10 H, Ph-H), 
8.91 (s, 1 H, H-2). 
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13C-NMR (CDCl3), δ(ppm): 25.01 CH2, 25.54 CH2, 45.42 CH3, 45.51 CH2, 58.68 CH2, 126.85 
CH, 128.08 CH, 128.60 CH, 129.00 C, 129.73 CH, 130.64 CH, 130.88 C, 132.16 C, 135.80 C, 
151.76 CH(H-2), 152.86 C, 154.09 C, 157.42 C. 
 
Anal. Calcd for C23H25N5 (371.48): C, 74.36; H, 6.78; N, 18.85. 
                                              Found: C, 74.56; H, 6.91; N, 18.77. 
 
 
 
7.3.5 Nucleophilic substitution of halopurines 
 
(a) Introducing Me2N(CH2)3NH to 2-position of purines 
 
General procedure: 
 
A solution of 2-Cl-substituted purine 0.3 mmol in 3 ml N,N-dimerhyl-1,3-propan-diamine was 
heated at 150 °C for 18 h, then evaporated in vacuum, the residue was dissolved in 50 ml 
chloroform, washed with aq. 10 % NaOH 30 ml and water 30 ml, dried with anhydrous 
MgSO4, evaporated the solvent, and purified by column chromatograph on standard neutral 
Al2O3 gel. 
 
 
N'-(9-Benzyl-6-phenyl--purin-2-yl)-N,N-dimethyl-propane-1,3-diamine (190) 
 
N
N N
N
Ph
N
H
190
Bn
N
 
 
 
Eluting with chloroform:methol (50/1) to provide a light brown solid, yield 98 %, mp 81-2 °C. 
 
1H-NMR (CDCl3), δ(ppm): 1.73 (m, 2 H, CH2), 2.14 (s, 6 H, 2CH3), 2.31 (t, 2 H, J = 7.6 Hz, 
CH2), 3.48 (m, 2 H, CH2), 5.17 (s, 2 H, CH2), 5.60 (t, 1 H, J = 5.3 Hz, NH), 7.19-7.60 (m, 8 H, 
Ph-H), 7.62 (s, 1 H, H-8), 8.59-8.62 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 27.46 CH2, 40.68, 45.54 CH3, 46.54 CH2, 57.81 CH2, 124.70 C, 
127.77 CH, 128.26 CH, 128.39 CH, 128.90 CH, 129.48 CH, 130.43 CH, 136.08 CH, 140.72 
CH(C-8), 154.56, 155.44 C, 159.72 C. 
 
Anal. Calcd. for C23H26N6 : C, 71.48; H, 6.78; N, 21.74. 
                                 Found: C, 71.36; H, 6.87; N, 21.51. 
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N'-(7-Benzyl-6-phenyl-7H-purin-2-yl)-N,N-dimethyl-propane-1,3-diamine (189) 
 
N
N
N
N
Ph
N
H
Bn
189
N
 
 
Eluting with ethyl acetate:methol (5/1) to give a light brown oil, yield 98 %. 
 
1H-NMR (CDCl3), δ(ppm): 2.17 (m, 2 H, CH2), 2.71 (s, 6 H, 2CH3), 3.07 (t, 2 H, J = 7.5 Hz, 
CH2), 3.59 (m, 2 H, CH2), 5.04 (s, 2 H, CH2), 6.07 (br, 1 H, NH), 6.52 (dd, 2 H, J = 6.7 Hz, Ph-
H), 7.12-7.40 (m, 8 H, Ph-H), 8.05 (s, 1 H, H-8) 
13C-NMR (CDCl3), δ(ppm): ): 24.90 CH2, 40.68 CH2, 43.03 CH3, 50.96 CH2, 555.78 CH2, 
116.86 C, 126.42 CH, 128.11 CH, 128.44 CH, 128.58 CH, 128.75 CH, 129.74 CH, 134.82 C, 
136.37 C, 148.44 CH(C-8), 154.01 C, 159.70 C, 163.88 C, 175.94 C. 
 
HRMS (EI) calcd for C23H26N6 (M+) 386.22189; found 386.22182. 
 
 
(b) Introducing Me2N(CH2)3O- to 2 position of purine 
 
[2-(9-Benzyl-6-phenyl-purin-2-yloxy)-ethyl]-dimethylamine (191) 
 
A 10 ml flask was charged with 9-benzyl-2-chloro-6-phenylpurine 141 (51 mg, 0.16 mmol), t-
BuOK (23 mg, 0.2 mmol) and 2-dimethylamino-ethanol 3 ml. Argon was passed and the 
mixture was heated at 150 °C for 16 h, evaporated in vacuum, the residue was dissolved in 60 
ml chloroform, washed with sat. aq. NaHCO3 30 ml, then water 30 ml, dried with anhydrous 
MgSO4, evaporated the solvent, and purified by column chromatograph on standard neutral 
Al2O3 gel, eluting with ethyl acetate:methol (10/1) to give a light brown oil 41 mg, yield 68 %. 
N
N N
N
Ph
O
191
Bn
N
 
 
1H-NMR (CDCl3), δ(ppm): 2.48 (s, 6 H, 2CH3), 3.00 (t, 2 H, J = 6.0 Hz, CH2), 4.73 (t, 2 H, J = 
6.0 Hz, CH2), 5.38 (s, 2 H, CH2), 7.32-7.52 (m, 8 H, Ph-H), 7.93 (s, 1 H, H-8), 8.78 (dd, 2 H, 
Ph-H). 
13C-NMR (CDCl3), δ(ppm): 45.13 CH3, 47.01 CH2, 57.29 CH2, 64.84 CH2, 127.85 CH, 128.47 
CH, 128.54 CH, 129.08 CH, 129.79 CH, 131.17 CH, 135.35 C, 135.45 C, 143.12 CH(C-8), 
154.78 C, 155.97 C, 161.18 C, 175.72 C. 
 
HRMS (EI) calcd for C22H23N5O (M+) 373.19026, found 373.19029. 
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7.4 Synthesis of pyrido[2,3-b]pyridazine derivatives 
 
7.4.1 Synthesis of 7-bromo-2,3-diphenylpyrido[2,3-b]pyrazine (193) 
 
A 100ml flask was charged with 2,3-diamino-5-bromopyridine (965mg, 5.0 mmol), benzil 
(1.26g, 6.0 mmol), ethanol 30 ml and 3 drops of hydrochloric acid, the mixture was heated at 
reflux for 12 h, the alcohol was evaporated, the solid was dissolve in 60 ml dichloromethane, 
and washed with water (2 × 30 ml), dried with anhydrous MgSO4, evaporated the solvent, the 
residue was purified by column chromatography on silica gel, eluting with cyclohexane:ethyl 
acetate (4/1) and afforded a yellow solid 1.33 g, yield 73 %, mp 149-50 °C. 
 
N
Br
N
N
Ph
Ph
193
 
 
 
1H-NMR (CDCl3), δ(ppm): 7.27-7.63 (m, 10 H, Ph-H), 8.67 (d, 1 H, J6,8 = 2.6 Hz, H-8), 9.15 
(d, 1 H, J6,8 = 2.6 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 120.92 C(C-7), 128.24 CH, 128.45 CH, 129.60 CH, 129.68 CH, 
129.83 CH, 130.19 CH, 136.40 C, 137.78 C, 138.09 C, 139.37 CH(C-8), 148.25 C, 155.11 
CH(C-6), 155.47 C, 156.48. 
 
Anal. Calcd. for C19H12 BrN3 (362.22): C, 63.00; H, 3.34; Br, 22.06; N, 11.60. 
                                                    Found: C, 62.83; H, 3.45; Br, 22.29; N, 11.63. 
 
 
7.4.2 Synthesis of 7-alkynyl-2,3-diphenylpyrido[2,3-b]pyrazine  
 
General procedure of Sonogashira reaction: 
A 25 ml Schlenk flask was charged with 7-bromo-2,3-diphenylpyrido[2,3-b]pyrazine (181 mg, 
0.5 mmol), Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10 mg, 0.05 mmol), dry TEA 5 ml, dry 
DMF 5 ml and alkyne (1.0 mmol), Argon was passed three times and the mixture was heated at 
100 °C for 24 h, the solvent was evaporated in vacuum, and the residue was purified by column 
chromatography on silica gel. 
 
4-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-but-3-yn-1-ol (194a) 
 
N N
N
Ph
PhHO
194a
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The residue was purified by column chromatography on silica gel, eluting with ethyl acetate: 
and provided a yellow solid 172 mg, yield 98 %, mp 165-7 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.06 (br, 1 H, OH), 2.79 (t, 2 H, J = 6.4 Hz, CH2), 3.90 (t, 2 H, J = 
6.4 Hz, CH2), 7.29-7.61 (m, 10 H, Ph-H), 8.44 (d, 1 H, J = 3.0 Hz, H-8), 9.09 (d, 1 H, J = 3.0 
Hz, H-6).  
13C-NMR (CDCl3), δ(ppm): 24.00 CH2, 60.81 CH2, 78.59 C, 93.42 C, 128.20 CH, 128.43 CH, 
129.44 CH, 129.59 CH, 129.81CH, 130.23 CH, 135.33 C, 137.84 C, 138.27 C, 139.53 CH (C-
8), 148.46 C, 155.32 C, 156.09 C, 156.24 CH(C-6). 
 
Anal. Calcd. For C23H17N3O: C, 78.61; H, 4.88; N, 11.96. 
                                    Found: C, 78.90; H, 5.12; N, 11.65. 
 
 
[3-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-prop-2-ynyl]-dimethylamine (194b) 
 
N N
N
Ph
Ph
N
194b
 
 
 
The residue was purified by column chromatography on silica gel, eluting with ethyl acetate: 
methanol (4/1), and get light yellow solid 133 mg, yield 76 %, mp 101-3 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.32 (s, 6 H, 2CH3), 3.47 (s, 2 H, CH2), 7.20-7.7.53 (m, 10 H, Ph-
H), 8.40 (d, 1 H, J = 2.3 Hz, H-8), 8.40 (d, 1 H, J = 2.3 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 44.34 CH3, 48.64 CH2, 81.67 C, 91.01 C, 121.71 C, 128.13 CH, 
128.37 CH, 129.37 CH, 129.52 CH, 129.77 CH, 129.77 CH, 130.21 CH, 135.25 C, 137.86 C, 
138.27 C, 139.61 CH(C-8), 148.60 C, 155.22 C, 156.07 CH(C-6). 
 
Anal. Calcd. for C24H20N4(364.44): C, 79.10; H, 5.53; N, 15.73. 
                                              Found: C, 78.94; H, 5.69; N, 15.46. 
 
 
N'-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-N,N-dimethyl-propane-1,3-diamine (195) 
 
A solution of [3-(2,3-diphenyl-imidazo[1,2-a]pyridin-6-yl)-prop-2-ynyl]-dimethylamine (81 
mg, 0.22 mmol), ethanol (15 ml) and 10 % palladium on charcoal (46 mg, 0.044 mmol on Pd, 
0.2 equiv) was stirred under hydrogen at room temperature and atmosphere for 16 hours. After 
complete conversion (TLC monitoring), the catalyst was filtered off through a pad of celite, 
washed with ethyl acetate, the solvent was removed under reduced pressure, and the residue 
was purified by column chromatography on neutral Al2O3 gel, eluting with ethyl 
acetate:methanol (10:1) to provide 44 mg brown liquid, yield, 54 %. 
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N N
N
Ph
Ph
N
195
 
 
 
1H-NMR (CDCl3), δ(ppm): 1.85-1.92 (m, 2 H, CH2), 2.18 (s, 6 H; 2CH3), 2.30 (t, 2 H, J = 7.2 
Hz, CH2), 2.88 (t, 2 H, J = 7.2 Hz, CH2), 7.26-7.30 (m, 6 H, Ph-H), 7.46 (dd, 2 H, Ph-H), 7.51 
(dd, 2 H, Ph-H), 8.21 (d, 1 H, J6,8 = 2.3 Hz, H-8), 8.96 (d, 1 H, J6,8 = 2.3 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 28.71 CH2, 30.70 CH2, 45.43 CH3, 58.67 CH2, 128.11 CH, 
128.39 CH, 129.17, CH, 129.24 CH, 129.79 CH, 130.23 CH, 135.84 CH(C-8), 136.04 C, 
138.23 C, 138.72 C, 140.24 C, 148.44 C, 154.52 C, 155.31 C, 155.84 CH(C-6). 
 
HRMS (EI) calcd for C24H24N3 (M+) 368.2001, found 368.2001. 
 
Anal. Calcd. for C24H24N4(368.47): C, 78.23; H, 6.57; N, 15.21. 
                                              Found: C, 78.32; H, 6.75; N, 15.09. 
 
 
7.4.3 Buchwald-Hartwig amination of 7-bromo-2,3-diphenylpyrido[2,3-b]pyrazine 
 
General procedure: 
A 25 ml schlenk flask was charged with 7-bromo-2,3-diphenylpyrido[2,3-b]pyrazine (181 mg, 
0.5 mmol), Pd2(dba)3 (10 mg, 0.01 mmol), BINAP (19 mg, 0.03mmol), t-BuONa (68 mg, 
0.7mmol), appropriate substituted amine1.0 mmol, dry toluene 5 ml, Argon was passed three 
times and the mixture was heated at 110 °C for 20 h, after cooled, 50 ml water was added, the 
mixture was extracted with ethyl acetate (3 × 40ml), the extract was washed with water (2 × 40 
ml), dried with anhydrous MgSO4, evaporated the solvent, the residue was purified by column 
chromatography 
 
7-(4-Methyl-piperazin-1-yl)-2,3-diphenylpyrido[2,3-b]pyrazine (198) 
 
N N
N
Ph
PhN
N
198
 
 
The crude product was purified by flash column chromatography on silica gel, eluting with 
CH2Cl2:MeOH(10:1)and provided a brown sold 122 mg, yield 68 %, mp.164-6 °C; 
 
1H-NMR (CDCl3), δ(ppm): 2.28 (s, 3 H, CH3), 2.55 (t, 4 H, J = 4.9 Hz, 2CH2), 3.38 (t, 4 H, J 
= 4.9 Hz, 2CH2), 7.20-7.51 (m, 11 H, 10Ph-H and H-8), 8.94 (d, 1H, J6,8 = 3.0 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 46.05 CH3, 48.05 CH2, 54.45 CH2, 116.13 CH(C-8),128.00 CH, 
128.29 CH, 128.73 CH, 128.92 CH, 129.73 CH, 130.11 CH, 137.25 C, 138.98 C, 138.98 C, 
144.27 C, 147.29 CH(H-6), 147.80 C, 152.22 C, 154.54 C. 
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Anal. Calcd. for C24H23N5(381.47) C, 75.56; H, 6.08; N, 18.36. 
                                             Found: C, 75.44; H, 6.32; N, 18.07. 
 
 
 
N'-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-N,N-dimethyl-propane-1,3-diamine (199) 
 
N N
N
Ph
Ph
H
NN
199
 
 
 
The crude product was purified by flash column chromatography on standard neutral Al2O3 gel, 
eluting with ethyl acetate:methanol (10/1) and provided a brown solid 140 mg, yield:73 %, mp 
150-2°C. 
 
1H-NMR (CDCl3), δ(ppm):1.83 (m, 2 H, CH2), 2.25(s, 6H, 2CH3), 2.43 (t, 2 H, J = 5.7 Hz, 
CH2), 3.30 (m, 2 H, CH2), 6.42 (s, 1 H, NH), 7.20 (d, 1 H, J = 3.0 Hz, H-8), 7.27-7.57 (m, 10 
H, Ph-H), 8.68 (d, 1 H, J = 3.0 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 25.37 CH2, 43.26 CH2, 45.47 CH3, 58.49 CH2, 108.36 CH(C-8), 
127.92 CH, 128.21 CH, 128.34 CH, 128.68 CH, 129.76 CH, 130.07 CH, 138.54 C, 138.76 C, 
139.29 C, 143.64 C, 145.91 C, 147.86 CH(C-6), 150.02 C, 154.03 C. 
 
Anal. Calcd. for C24H25N5(383.49) C, 75.17; H, 6.57; N, 18.26. 
                                             Found: C, 75.21; H, 6.72; N, 17.99. 
 
 
7.4.4 Synthesis of 7-alkenyl-2,3-diphenylpyrido[2,3-b]pyrazine (Heck reaction) 
 
General procedure: 
 
A 25 ml schlenk flask was checked with 7-bromo-2,3-diphenylpyrido[2,3-b]pyrazine (181 mg, 
0.5 mmol), Pd(OAc)2 (11 mg, 0.05 mol), P(o-tolyl)3 (15 mg, 0.05 mmol), TEA (200 mg, 2 
mmol), and MeCN 10 ml, Argon was passed inside, appropriate alkene 1.5 mmol was added 
inside with a syringe, the mixture was heated at 100 °C for 20 h, the solvent was evaporated 
and the residue was purified by column chromatography on silica gel. 
 
3-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-acrylic acid methyl ester (200) 
 
N N
N
Ph
Ph
O
O
200
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The crude product was purified by flash column chromatography on silica gel, eluting with 
cyclohexane:ethyl acetate (5/1→1/1), and provided a yellow solid 176 mg, yield 96 %, mp 
197-8°C; 
 
1H-NMR (CDCl3), δ(ppm): 3.88 (s, 3 H, CH3), 6.77 (d, 1 H, J = 16.2 Hz, =C-H), 7.34-7.65 (m, 
10 H, Ph-H), 7.91 (d, 1 H, J = 16.2 Hz, =C-H), 8.58 (d, 1 H, J = 2.6 Hz, H-8), 9.32 (d, 1 H, J = 
2.6 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 52.14 CH3, 121.99 CH(=C-H), 128.23 CH, 128.49, 129.54, 
129.74 CH, 129.79 CH, 130.30 CH, 131.64 C, 135.65 C, 136.37 CH(=C-H), 137.80 C, 138.26 
C, 140.00 CH(C-8), 150.32 C, 153.06 CH(C-6), 155.58 C, 156.79 C, 166.47 C(C=O). 
 
Anal. Calcd. for C23H17N3 O2 (367.40): C, 75.19; H, 4.66; N, 11.44. 
                                                    Found: C, 75.19; H, 4.85; N, 11.28. 
 
 
3-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-acrylonitrile (201) 
 
N N
N
Ph
Ph
N
201
 
 
 
The crude product was purified by flash column chromatography on silica with cyclo-
hexane:ethyl acetate (3/1-1/1) as eluting solvent and provided a yellow solid 109 mg, yield: 65 
%, mp.188-9 °C; 
 
1H-NMR (CDCl3), δ(ppm): 6.23 (d, 1 H, J = 17.0 Hz, =C-H), 7.60 (d, 1 H, J = 17.0 Hz, =C-H), 
7.32-7.66 (m, 10 H, Ph-H), 8.53 (d, 1 H, J = 2.3 Hz, H-8), 9.32 (d, 1 H, J = 2.3 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm):100.84 CH(=C-H), 117.07 C, 128.29 CH, 128.52 CH, 129.72 CH, 
129.95 CH, 130.28 CH, 130.52 C, 135.34 C, 136.00 CH(=C-H), 137.62 C, 138.04 C,145.84 
CH(C-8), 150.64 C, 151.93 CH(C-6), 155.94 C, 157.36 C. 
 
Anal. Calcd. for C22H14N4 (334.37): C, 79.02; H, 4.22; N, 16.76. 
                                               Found: C, 79.14; H, 4.35; N, 16.67 
 
 
 
2-[3-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-allyl]-isoindole-1,3-dione (202) 
 
N N
N
Ph
Ph
N
O
O  
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The crude product was purified by flash column chromatography on silica, eluting with 
cyclohexane:ethyl acetate (3/1→1/1) and provided a light yellow solid 78 mg, yield:33 %, mp 
89-91 °C; 
 
1H-NMR (CDCl3), δ(ppm): 4.57 (dd, 2 H, J1 = 6.3 Hz, J2 = 1.1 Hz, CH2), 6.63 (dt, 1 H, J1 = 
16.0 Hz, J2 = 6.3 Hz, =C-H), 6.87 (d, 1 H, J = 16.0 Hz, 7.31-7.63 (m, 10 H, Ph-H), 7.75 (dd, 2 
H, J1 = 5.7 Hz, J2 = 3.0 Hz, Ph-H), 7.90 (dd, 2 H, J1 = 5.7 Hz, J2 = 3.0 Hz, Ph-H), 8.37 (d, 1H, 
J = 2.3 Hz, H-8), 9.19 (d, 1 H, J = 2.3 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm):39.54 CH2, 123.52 CH(=C-H), 127.95 CH, 128.13 CH, 128.39 
CH, 129.10 CH, 129.29 CH, 129.41 CH, 129.81 CH, 130.26 CH, 132.04 C, 133.57 C, 
133.93CH(=C-H), 134.21(C-8), 135.94 C, 138.01 C, 138.50 C, 149.25 C, 152.92 (C-6), 155.04 
C, 155.70 C, 167.89 C. 
 
Anal Calcd for C30H20N4O (468.50): C, 76.91; H, 4.30; N, 11.96. 
                                                Found: C, 76.70; H, 4.48; N, 11.83. 
 
 
7.4.5 Synthesis of 7-aryl-2,3-diphenylpyrido[2,3-b]pyrazine (Suzuki reaction) 
 
General procedure of Suzuki reaction: 
A 25ml schlenk flask was charged with 7-bromo-2,3-diphenylpyrido[2,3-b]pyrazine (181 mg, 
0.5 mmol), K2CO3 (97 mg, 0.7 mmol), arylbronic acid (0.7 mmol), Pd(PPh3)4 (29 mg, 0.025 
mmol), and dry toluene 10 ml, Argon was passed three times and the mixture was heated at 100 
°C for 16 h, the solvent was evaporated in vacuum, the residue was dissolved in 50 ml CH2Cl2, 
washed with water (2 × 30 ml), the solution was dried with anhydrous MgSO4. The solvent was 
evaporated, and the residue was purified by column chromatography. 
 
2,3,7-Triphenylpyrido[2,3-b]pyrazine (203) 
 
N N
N
Ph
PhPh
203
 
 
The crude product was purified by flash column chromatography on silica gel, eluting with 
cyclohexane:ethyl acetate (6/1→2/1),and provide yellow solid 172 mg, yield 96 %, mp: 172-3 
°C. (lit. [9], 282-4 °C) 
 
1H-NMR (CDCl3), δ(ppm): 7.31-7.82 (m, 15 H, Ph-H), 8.67 (d, 1 H, J = 2.6 Hz, H-8), 9.45 (d, 
1 H, J= 2.6 Hz, H-6). 
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13C-NMR (CDCl3), δ(ppm): 127.56 CH, 128.16 2CH, 128.45 CH, 128.95 CH, 129.32 CH, 
129.44 CH, 129.81 CH, 130.29 CH, 134.50 CH, 136.01 C, 136.50 C, 138.11 C, 138.60 C, 
149.06 C, 153.61 CH, 155.12 C, 155.90 C. 
 
HRMS (EI) calcd for C25H17N3 (M+) 359.14225, found 359.14226. 
 
Anal. Calcd. for C25H17N3: C, 83.54; H, 4.77; N, 11.69. 
                                Found: C, 83.69; H, 4.83; N, 11.48. 
 
 
1-[4-(2,3-Diphenyl-pyrido[2,3-b]pyrazin-7-yl)-phenyl]-ethanone (204) 
N N
N
Ph
Ph
O
204
 
 
The crude product was purified by flash column chromatography on silica gel, eluting with 
cyclohexane:ethyl acetate (4/1→1/1), and provided a yellow solid 101 mg, yield 50 %, mp 
273-4 °C; 
 
1H-NMR (CDCl3), δ(ppm): 2.66 (3, 3 H, CH3), 7.32-7.65 (m, 10 H, Ph-H), 7.88 (d, 2 H, J = 
10.3 Hz, Ph-H), 8.13 (d, 2 H, J = 10.3 Hz, Ph-H), 8.69 (d, 1 H, J6,8 = 2.6 Hz, H-8), 9.43 (d, 1 H, 
J6,8 = 2.6 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 26.79 CH3, 127.71 CH, 128.21 CH, 128.48 CH, 129.39 CH, 
129.46 CH, 129.61 CH, 129.80 CH, 130.28 CH, 135.16 CH(C-8), 135.78 C, 136.75 C, 137.04 
C, 137.94 C, 138.41 C, 140.88 C, 149.40 C, 153.09 CH(C-6), 155.41 C, 156.42 C, 197.45 
C(C=O). 
 
HRMS (EI) calcd for C27H19N3O(M+) 401.15285, found 401.15281. 
 
Anal. Calcd. for C27H19N3O: C, 80.78; H, 4.77; N, 10.47. 
                                   Found: C, 81.01; H, 4.92; N, 10.24. 
 
 
 
7.5 Synthesis of imidazo[1,2-a]pyridine derivatives 
 
7.5.1 Synthesis of 6-bromo-2,3-diphenyl-imidazo[1,2-a]pyridine (218) 
 
A 50 ml flask was charged 2-amino-5-bromopyridine (892 mg, 5 mmol), 2-bromo-2-phenyl-
acetophenone (desyl bromide) (1.70 g, 6 mmol), NaHCO3 (491 mg (6 mmol), and iso-propanol 
15 ml, the mixture was heated at reflux for 12 h, the alcohol was evaporated, then 30 ml water 
and 60 ml dichloromethane were added, the mixture was separated and the organic phase was 
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washed with water (2 × 30 ml), dried with anhydrous MgSO4, evaporated the solvent, the 
residue was purified by column chromatography on silica gel, eluting with cyclohexane:ethyl 
acetate(3/1) and provided white solid 1.17 g, yield 67 %, mp 198-9 °C. 
 
6-Bromo-2,3-diphenylimidazo[1,2-a]pyridine (218) 
 
N
N
Br
Ph
Ph
218
 
 
1H-NMR (CDCl3), δ(ppm): 7.23-7.66 (m, 12 H, Ph-H H-7 and H-8), 8.05 (dd, 1 H, J1 = 1.8 Hz, 
J2 = 0.8 Hz, H-5) 
13C-NMR (CDCl3), δ(ppm): 107.11 C, 118.20 CH(C-8), 121.44 C(C-7), 123.32 CH(C-5), 
127.77 CH, 128.03 CH, 128.06 CH, 128.34 CH, 129.20 C, 129.30 CH, 129.75 CH, 130.64 
CH(C-5), 133.62 C, 143.17 C. 
 
Anal. Calcd. for C19H13BrN2 (349.22): C, 65.35; H, 3.75; Br, 22.88 N, 8.02. 
                                                   Found: C, 65.09; H, 3.97; Br, 23.17; N, 7.91. 
 
 
 
7.5.2 Synthesis of [3-(2,3-diphenyl-imidazo[1,2-a]pyridin-6-yl)-prop-2-ynyl]-
dimethylamine and related compounds (Sonogashira reaction) 
 
[3-(2,3-Diphenyl-imidazo[1,2-a]pyridin-6-yl)-prop-2-ynyl]-dimethylamine (220) 
 
A 25 ml flask was charged with 6-bromo-2,3-diphenylimidazo[1,2-a]pyridine 218 (153 mg, 0.5 
mmol), Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10 mg, 0.5 mmol), TEA 5 ml, DMF 5 ml and 
N,N-dimethylpropargylamine 83 mg (1.0 mmol), Argon was passed and the mixture was 
heated at 100 °C for 24 h, the solvent was evaporated in vacuum, the residue was purified by 
column chromatography on silica gel, eluting with ethyl acetate: methanol (4/1), and afforded a 
light yellow solid 130 mg, yield 74 %, mp 136-7 °C. 
 
N
N Ph
Ph
Me2N
220
 
 
 
1H-NMR (CDCl3), δ(ppm): 2.27 (s, 6 H, CH3), 3.34 (s, 2 H, CH2), 7.15-7.59 (m, 12 H, Ph-H, 
H-7 and H-8), 7.98 (s, 1 H, H-5). 
13C-NMR (CDCl3), δ(ppm): 44.43 CH3, 48.57 CH2, 81.43 C, 86.28 C, 108. 91 C, 117.2 CH(C-
8), 126.22 CH(C-7), 127.66 CH, 127.83 CH, 128.02 CH, 128.30 CH, 129.15 CH, 129.67 CH, 
130.73 CH(C-5)132.02 C, 132.15 C, 133.76 C, 143.09 C, 143.62. 
 
Anal. Calcd. for C24H21N3 (351.44): C, 82.02; H, 6.02; N, 11.96. 
                                               Found: C, 82.06; H, 6.26; N, 11.78. 
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[3-(2,3-Diphenyl-imidazo[1,2-a]pyridin-6-yl)-propyl]-dimethylamine (221) 
 
A solution [3-(2,3-diphenyl-imidazo[1,2-a]pyridin-6-yl)-prop-2-ynyl]-dimethylamine 220 (84 
mg, 0.24 mmol), ethanol (15 ml) and 10 % palladium on charcoal (52 mg, 0.048 mmol on Pd, 
0.2 equiv) was stirred under hydrogen at room temperature and atmosphere 16 hours. After 
complete conversion (TLC monitoring), the catalyst was filtered off through a pad of celite, 
washed with ethyl acetate, the solvents were removed under reduced pressure, and the residue 
was purified by column chromatography on neutral Al2O3 gel, eluting with ethyl 
acetate:methanol (10:1) to give 40 mg light brown solid, yield, 47 %, mp 70-1 °C. 
 
N
N Ph
Ph
Me2N
221
 
 
 
1H-NMR (CDCl3), δ(ppm): 1.67 (m, 2 H, CH2), 2.12 (s, 3 H, CH3), 2.19 (t, 2 H, J = 7.2 Hz, 
CH2), 2.49(t, 2 H, J = 7.7 Hz, CH2), 7.01 (dd, 1 H, J1 = 9.0 Hz, J2 = 1.5 Hz , H-7), 7.16-7.58 
(m, 11 H, Ph-H and H-8), 7.67 (s, 1 H, H-5) 
13C-NMR (CDCl3), δ(ppm): 28.74 CH2, 30.39 CH2, 45.44 CH3, 58.70 CH2, 117.9 CH, 120.81 
CH, 126.26 C, 126.85 CH, 127.31 CH, 128.01 CH, 128.21 CH, 128.77 Ch, 129.52 CH, 130.08 
C,130.74 CH,132.15 C, 134.34 C, 142.38 C, 142.38 C, 144.06 C. 
 
HRMS (EI) calcd for C24H25N3 (M+) 355.2048, found 355.2045. 
 
 
 
7.5.3 Buchwald-Hartwig amination of 6-bromo-2,3-diphenylimidazo[1,2-a]pyridine 
 
General procedure: 
A schlenk 25ml flask was charged with 6-bromo-2,3-diphenyl-imidazo[1,2-a]pyridine 218 (175 
mg, 0.5 mmol), Pd2(dba)3 (10 mg, 0.01 mmol), BINAP (19 mg, 0.03 mmol), t-BuONa 68 mg 
(0.7 mmol), appropriate substituted amine 1.0 mmol, dry toluene 5 ml, Argon was passed three 
times and the mixture was heated at 110 °C for 20 h, after cooled, 50 ml water was added, the 
mixture was extracted with ethyl acetate (3 × 40 ml), the extract was washed with water (2 × 40 
ml), dried with anhydrous MgSO4, evaporated the solvent, the residue was purified by column 
chromatography. 
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6-Morpholin-4-yl-2,3-diphenylimidazo[1,2-a]pyridine (225) 
 
N
N
N
Ph
Ph
O
225
 
 
The crude product was purified by column chromatography on silica gel, eluting with ethyl 
acetate, and provided a grey needle crystal 142 mg, yield 80 %, mp 201-2 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.90 t, 4 H, J = 4.6 Hz, 2CH2), 3.76 (t, 4 H, J = 4.6 Hz, 2CH2), 
7.01 (dd, 1 H, J1 = 9.8 Hz, J2 = 2.2 Hz, Ar-H), 7.14-7.22 m, 3 H, Ph-H), 7.29 (d, 1 H, J = 1.9 
Hz, Ar-H), 7.37-7.53 (m, 7 H, Ph-H), 7.56 (d, 1 H, J = 1.9 Hz, Ar-H). 
13C-NMR (CDCl3), δ(ppm): 50.66 CH2, 66.68 CH2, 108.74 CH(C-8), 117.55 CH(C-7),121.07 
CH(C-5), 121.71 C, 127.24 CH, 127.88CH, 128.22 CH, 128.82 CH, 129.60 CH, 130.16 C, 
130.60 CH, 134.34 C, 139.90 C, 142.01 C, 142.45 C. 
 
Anal. Calcd. for C23H31N3O (355.439): C, 77.72; H, 5.96; N, 11.82. 
                                                    Found: C, 77.62; H, 6.22; N, 11.50. 
 
 
6-(4-Methyl-piperazin-1-yl)-2,3-diphenylimidazo[1,2-a]pyridine (226) 
 
N
N
N
Ph
Ph
N
226
 
 
The product was purified by column chromatography on silica gel, eluting with ethyl 
acetate:methanol:TEA (10/1/0.2), and get grey needle crystal 112 mg, yield 61 %, mp 229-230 
°C. 
 
1H-NMR (CDCl3), δ(ppm): 2.33 (s, 3 H, CH3), 2.56 (t, 4 H, J = 4.5 Hz, 2CH2), 3.01 (t, 4 H, J = 
4.5 Hz, 2CH2), 7.10 (dd, 1 H, J1 = 9.4 Hz, J2 = 2.2 Hz, Ar-H), 7.21-7.29 (m, 3 H, Ph-H), 7.38 
(d, 1 H, J = 1.9 Hz, Ar-H), 7.44-7.60 (m, 7 H, Ph-H), 7.62 (d, 1 H, J = 1.9Hz, Ar-H). 
13C-NMR (CDCl3), δ(ppm): 46.07 CH3, 50.38 CH2, 54.86 CH2,108.83CH(C-8),117.38 
CH(C-7), 121.48 CH(C-5), 121.66 C, 127.17 CH, 127.89 CH, 128.19 CH, 128.73 CH, 129.55 
CH, 130.22 C, 130.60 C, 134.45 C, 139.88 C, 141.98 C, 142.37 C. 
 
Anal. Calcd. for C24H24N4 (368.47): C, 78.23; H, 6.57; N, 15.21. 
                                               Found: C, 78.22; H, 6.58; N, 15.22. 
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N'-(2,3-Diphenyl-imidazo[1,2-a]pyridin-6-yl)-N,N-dimethyl-propane-1,3-diamine (227) 
 
N
N
Me2N(H2C)3HN
Ph
Ph
227 
 
 
The product was purified by column chromatography on neutral Al2O3 gel, eluting with ethyl 
acetate:methanol 20:1 to give 40 mg brown solid, yield 22 %, mp 125-6 °C 
1H-NMR (CDCl3), δ(ppm): 1.70-1.79 (m, 2 H, CH2), 2.21 (s, 6H, 2CH3), 2.37 (t, 2H, J = 6.4 
Hz, CH2), 2.97 (t, 2 H, J = 6.4 Hz, CH2), 6.75 (dd, 1 H, Ar-H), 7.11 (s, 1 H, N-H), 7.19-7.62 
(m, 12 H, Ph-H and Ar-H). 
13C-NMR (CDCl3), δ(ppm): 26.22 CH2, 43.99 CH2, 45.54 CH3, 58.48 CH2, 102.21 CH(C-
8),117.41 CH(C-7), 120.24 CH(C-5), 121.31 C, 126.93 CH, 127.79 CH, 128.13 CH, 128.52 
CH, 129.43 C, 129.44 CH, 130.65 CH, 134.69 C, 136.98 C. 141.47 C, 141.61. 
 
Anal. Calcd. for C24H26N4 (370.49): C, 77.80; H, 7.07; N, 15.12. 
                                               Found: C, 77.81; H, 6.98; N, 15.03. 
 
 
 
7.6 Synthesis of imidazo[1,2-b]pyridazine derivatives 
 
7.6.1 Synthesis of 6-chloro-2,3-diphenylimidazo[1,2-b]pyridazine (219) 
 
A 50 ml flask was charged with 3-amino-6-chloropyridazine (1.30 g, 10 mmol), 2-bromo-2-
phenyl-acetophenone (desyl bromide) (3.40 g, 12 mmol), NaHCO3 (982 mg, 12 mmol), and 
iso-propanol 30 ml, the mixture was heated at reflux for 12 h, the alcohol was evaporated, then 
50 ml water and 100 ml dichlomethane was added inside, separated and the organic phase was 
washed with water (2 × 30 ml), dried with anhydrous MgSO4, evaporated the solvent, the 
residue was purified by column chromatography on silica gel, eluting with cyclohexane:ethyl 
acetate(2/1) and provided a yellow needle crystal 2.35 g, yield 77 %, mp 207-8 °C. 
 
6-Chloro-2,3-diphenylimidazo[1,2-b]pyridazine (219) 
N
N
N
Cl
Ph
Ph
219 
 
 
1H-NMR (CDCl3), δ (ppm): 7.07 (d, 1 H, J = 9.0 Hz, H-7), 7.31-7.67 (m,10 H, Ph-H), 7.94 (d, 
1 H, J = 9.0 Hz, H-8) 
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13C-NMR (CDCl3), δ (ppm): 118.83 CH, 126.56 CH, 128.03 C, 128.24 CH, 128.39 CH, 
128.47 CH, 128.78 CH, 128.95 CH, 130.41 CH, 133.63 C, 137.29 C, 144.09 C, 146.49. 
 
Anal. Calcd. for C18H12ClN3 (305.76): C, 70.71; H, 3.96; Cl, 11.60; N, 13.74. 
                                                  Found: C, 70.64; H, 3.93; Cl, 11.80; N, 13.63. 
 
 
7.6.2 Synthesis of [3-(2,3-diphenyl-imidazo[1,2-b]pyridazin-6-yl)-prop-2-ynyl]-dimethylamine 
(223) 
 
A 25ml flask was charged with 6-Chloro-2,3-diphenylimidazo[1,2-b]pyridazine 219 (153mg, 
0.5mmol), Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10mg, 0.5mmol), TEA 5 ml, DMF 5 ml 
and N,N-dimethylpropargylamine (83 mg, 1.0 mmol), Argon was passed three times and the 
mixture was heated at 100 °C for 24 h, the solvent was evaporated in vacuum, the residue was 
purified by column chromatography on silica gel, eluting with ethyl acetate:methanol (6/1), and 
provided a light yellow solid 160 mg, yield 86 %, mp 144-5 °C. 
N
N
N
Ph
Ph
Me2N
223 
 
 
1H-NMR (CDCl3), δ (ppm): 2.38 (s, 6 H, CH3), 3.50 (s, 2 H, CH2), 7.15 (d, 1 H, J = 9.3 Hz, H-
7), 7.28-7.66 (m, 10 H, Ph-H), 7.98 (d, 1 H, J = 9.1 Hz, H-8) 
13C-NMR (CDCl3), δ (ppm): 44.47 CH3, 48.53 CH2, 81.66 C, 88.59 C, 120.99 CH, 124.70 
CH, 125.32 C, 128.06, 128.34 CH, 128.45 CH, 128.67 CH, 128.71 CH, 130.55 CH, 133.71 C, 
137.59 C, 138.01, 143.88 C, 146.57 C. 
 
Anal. Calcd. for C23H20N4 (352.43): C, 78.38; H, 5.72; N, 15.90. 
                                               Found: C, 78.22; H, 5.91; N, 15.86. 
 
 
7.6.3 Synthesis of [3-(2,3-diphenyl-imidazo[1,2-b]pyridazin-6-yl)-propyl]-dimethylamine 
(224) 
 
A solution [3-(2,3-Diphenyl-imidazo[1,2-b]pyridazin-6-yl)-prop-2-ynyl]-dimethylamine 223 
(130 mg, 0.37 mmol), ethanol (15 ml) and 10 % palladium on charcoal (82 mg, 0.074 mmol on 
Pd, 0.2 equiv) was stirred under hydrogen at room temperature and atmosphere 16 hours. After 
complete conversion (TLC monitoring), the catalyst was filtered off through a pad of Celite, 
washed with ethyl acetate, the solvent was removed under reduced pressure, and the residue 
was purified by column chromatography on neutral Al2O3 gel, eluting with ethyl 
acetate:methanol (10:1) to give 96 mg of light brown solid, yield, 73 %, mp 112-3 °C 
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N
N
N
Ph
Ph
Me2N
224
 
 
 
1H-NMR (CDCl3), δ (ppm): 1.80 (m, 2 H, CH2), 2.11 (s, 3 H, CH3), 2.23 (t, 2 H, J = 7.3 Hz, 
CH2), 2,73 (t, 2 H, J = 7.7 Hz, CH2), 6.85 (d, 1 H, J = 9.1 Hz, H-7), 7.19-7.60 (m, 10 H, Ph-H), 
7.79 (d, 1 H, J = 9.0 Hz, H-8). 
13C-NMR (CDCl3), δ ( ppm): 26.64 CH2, 33.30 CH2, 45.46 CH3, 58.86 CH2, 118.50 CH, 
124.89 CH, 127.74 CH, 128.29 CH, 128.34 CH, 128.40 CH, 128.44 CH, 129.05 C, 130.53 
CH,134.38 C, 137.92 C, 142.85 C, 154.92 C. 
 
Anal. Calcd. for C23H24N4 (356.46): C, 77.50; H, 6.79; N, 15.72. 
                                               Found: C, 77.52; H, 6.82; N, 15.62. 
 
 
 
 
7.7 Synthesis of pyrimidine derivatives 
 
7.7.1 Synthesis of aryl substituted chloro- or iodopyrimidine 
 
7.7.1.1 Using general methods and starting with benzamidine 
 
2,6-Diphenyl-3H-pyrimidin-4-one (249) 
 
HN
NPh
O
Ph
249
 
 
 
Benzamidine hydrochloride hydrate (10.48 g, 0.067mol) and ethyl benzolacetate (14.82 g, 
0.074 mol) were added to a solution of sodium (1.8 g, 0.077 mol ) in 80 ml dry ethanol, the 
mixture was heated at reflux for 16 hours. Ethanol was evaporated in vacuum to dryness and 
the residue was dissolve in 100 ml water, the mixture was acidified with concentrated 
hydrochloric acid (pH = 3), the precipitate was collected, washed with water, the crude product 
was recrystallized with ethanol and provided a white solid 12.70 g, yield 76 %, mp 296-7 °C. 
 
4-Chloro-2,6-diphenylpyrimidine (250) 
 
N
N
Cl
Ph Ph
250
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A 100 ml flask was charged with 2,6-diphenyl-3H-pyrimidin-4-one 249 (12.70 g, 0.051 mol), 
phosphoryl chloride (36.0 ml, 59.20 g, 0.38 mol), phosphorpentachloride (10.20 g, 0.049 mol). 
The mixture was heated at reflux for 3 h, the excess of phosphoryl chloride was evaporated in 
vacuum, then 100 g ice was added slowly and carefully, the solid was collected and washed 
with water completely. The crude product was recrystallized with petroether (40-60 °C), and 
provided a white solid 10.20 g, yield 75 %, mp 103-4 °C. 
 
1H-NMR (CDCl3), δ(ppm): 7.43-7.49 (m, 6 H, Ph-H), 7.55 (s, 1 H, H-5), 8.11-8.14 (dd, 2 H, 
Ph-H), 8.48-8.52 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 114.47 CH(C-5), 127.40 CH, 128.58 CH, 128.65 CH, 129.01 CH, 
131.42 CH, 131.51 CH,135.90 C, 136.48 C, 162.22 C, 165.21 C, 165.67 C. 
 
Anal. Calcd for C16H11ClN2 (266.72): C, 72.05; H, 4.16; Cl, 13.29; N, 10.50 
                                                 Found: C, 72.15; H, 4.29; Cl, 13.14; N, 10.36 
 
 
4-Iodo-2,6-diphenylpyrimidine (251) 
 
N
N
I
Ph Ph 251 
 
 
A mixture of 4-Chloro-2,6-diphenylpyrimidine 250 (3.0 g, 8.3 mmol) and 57 % HI (30 ml, 0.23 
mol) was stirred at room temperature for 20 h, then 100 ml cold 10 % NaOH was added, the 
precipitate was collected and washed with cold water, the crude product was recrystallized with 
petroether (40-60 °C), and provided a light brown solid 1.70 g, yield 42 %, mp 98 °C. 
 
1H-NMR (CDCl3), δ(ppm): 7.41-7.48 (m, 6 H, Ph-H), 7.95 (s, 1 H, H-5), 8.06-8.10 (dd, 2 H, 
Ph-H), 8.44-8.48 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 125.57 CH(C-5), 127.33 CH, 128.52 CH, 128.57 CH, 128.99 CH, 
130.80 (C-4) 131.32 CH, 131.40 CH,135.46 C, 136.34 C, 163.44 C, 164.60 C. 
 
Anal. Calcd for C16H11IN2 (358.18): C, 53.65; H, 3.10; I, 35.43; N, 7.82. 
                                               Found: C, 53.79; H, 3.24; I, 35.27; N, 7.58. 
 
 
2-Phenyl-1H-pyrimidine-4,6-dione (252) 
 
HN
NPh
O
O
252
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Benzamidine hydrochloride hydrate (10.90 g, 0.070mol) and diethyl malonate (11.20 g, 
0.070mol) were added to a solution of sodium (4.30 g, 0.19mol) in 70 ml dry ethanol, the 
mixture was heated at reflux for 3 hours. Ethanol was evaporated in vacuum to dryness and the 
residue was dissolve in 80 ml warm water, the mixture was acidified with concentrated 
hydrochloric acid (pH = 3), the precipitate was collected, washed with water, the crude product 
was recrystallized with DMF/water and afforded a white solid 6.90 g, yield 52 %, mp 324-5 °C. 
 
 
4,6-Dichloro-2-phenylpyrimidine (253) 
 
N
N
Cl
Ph Cl
253
 
 
A mixture of 2-Phenyl-pyrimidine-4,6-dione (2-phenyl-4,6-dihydroxypyrimidine) 252 (6.90 g, 
0.037 mol), phosphoryl chloride (18 ml, 0.19 mol), N,N-dimethylaniline (4.4 g, 0.036 mol), 
was heated at reflux for 2 h, the excess POCl3 was evaporated in vacuum, then 50 g ice was 
added inside slowly and carefully, the solid was collected and washed with water completely. 
The crude product was recrystallized with ethanol, and provided a light yellow solid 7.5 g, 
yield 89 %, mp 93-4°C. 
 
1H-NMR (CDCl3), δ(ppm): 7.20 (s, 1 H, H-5), 7.42-7.46 (m, 3 H, Ph-H), 8.35-8.38 (dd, 2 H, 
Ph-H). 
13C-NMR (CDCl3), δ(ppm): 118.8 CH(C-5), 128.73 CH, 128.87 CH, 132.26 CH, 134.87 C, 
162.03 C, 165.76. C. 
 
Anal. Calcd for C10H6Cl2N2 (225.07): C, 53.36; H, 2.69; Cl, 31.50; N, 12.45. 
                                                 Found: C, 53.24; H, 2.86; Cl, 31.75; N, 12.32. 
 
 
4,6-Diiodo-2-phenylpyrimidine (254) 
 
N
N
I
Ph I
254
 
 
 
A mixture of 2-phenyl-4,6-dichloropyrimidine 254 (2.0 g, 9.0 mmol), NaI (2.7 g, 18 mmol) and 
57 % HI 40 ml was stirred at 40 °C under Argon for 24 h, 50 g ice was added, the mixture was 
neutralizd with 40 % NaOH, and extracted with CH2Cl2 (3 × 40 ml), the extract was washed 
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with water, dried with anhydrous MgSO4, the solvent was evaporated, and the crude product 
was recrystallized with with petroether (40-60 °C), and provided a yellow solid 3.30 g, yield 91 
%, mp 103-5 °C. 
 
1H-NMR (CDCl3), δ(ppm): 7.38-7.46 (m, 3 H, Ph-H), 8.05 (s, 1 H, H-5), 8.28-8.33 (dd, 2 H, 
Ph-H). 
13C-NMR (CDCl3), δ(ppm): 128.67 CH, 128.84 CH, 132.07 CH, 134.73 C, 139.67 CH(C-5), 
164.94. C. 
 
Anal. Calcd for C10H6I2N2 (407.98): C, 29.44; H, 1.48; I, 62.21; N, 6.87. 
                                               Found: C, 29.60; H, 1.63; I, 62.01; N, 6.72. 
 
 
 
7.7.1.2 Using Suzuki cross-coupling and starting with 2,4,6-trichloropyrimidine 
 
(a) 2-Chloro-4,6-diarylpyrimidine 
General procedure: 
To a solution of 2,4,6-trichloropyrimidine (1.0 g, 5.5 mmol) in 50 ml DME, appropriate 
arylboronic acid (11.0 mmol, 2.0 equiv), sodium carbonate (3.61 g, 34.1 mmol, 6.2 equiv, 
dissolve in a minimium amount of water) was added. The active catalyst was generated by the 
addition of palladium acetate (31 mg, 0.14 mmol, 2.5 % equiv), and triphenylphosphine (72 
mg, 0.28 mmol, 5 % equiv) to the mixture. Argon was passed, and the mixture was heated at 70 
°C for 24 h. The solvent was removed by rotary evaporation and the product was extracted with 
methylene chloride (3 × 50 ml), the organics washed with water (2 × 50 ml), and dried over 
anhydrous magnesium sulphate. The solvent was evaporated, and the residue was purified by 
column chromatography on silica gel, eluting with cyclohexane:ethyl acetate(15/1→6/1). 
 
2-Chloro-4,6-diphenylpyrimidine (240a) 
 
N
N
Ph
PhCl  
 
White solid, yield 67 %, mp 106-8 °C; 
 
1H-NMR(CDCl3), δ(ppm): 7.53-7.55 (m, 6 H, Ph-H), 8.01 (s, 1 H, H-5), 8.12-8.16 (m, 4 H, 
Ph-H). 
13C-NMR(CDCl3), δ(ppm): 110.93 CH(H-5), 127.46 CH, 129.09 CH, 131.66 CH, 135.65 C, 
162.07 C,  167.64 C. 
 
Anal. Calcd. for C16H11ClN2(266.73): C, 72.05; H, 4.16; Cl, 13.29; N, 10.50. 
                                                  Found: C, 72.21; H, 4.30; Cl, 13.47; N, 10.50. 
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2-Chloro-4,6-bis-(4-chloro-phenyl)-pyrimidine 
 
N
N
Ph-Cl-4
Ph-Cl-4Cl  
 
 
White solid, yield: 82%; mp.151-3°C; 
 
1H-NMR(CDCl3), δ(ppm): 7.42 (dd, 4 H, J = 8.7 Hz. Ph-H), 7.85 (s, 1 H, H-5), 8.01 (dd, 4 H, 
J = 8.7 Hz, Ph-H). 
13C-NMR(CDCl3), δ(ppm): 110.31CH(H-5), 128.73 CH, 129.41 CH, 133.83 C, 138.19 C, 
162.17 C, 166.52 C. 
 
Anal. Calcd. for C16H9Cl3N2(335.62): C, 57.26; H, 2.70; Cl, 31.69; N, 8.35. 
                                                  Found: C, 57.23; H, 2.61; Cl, 31.80; N, 8.44. 
 
 
(b) 2,4-dichloro-6-arylpyrimidine 
 
General procedure: 
To a solution of 2,4,6-trichloropyrimidine (1.0 g, 5.5 mmol) in 50 ml DME, appropriate 
arylboronic acid (5.5 mmol, 1.0 equiv), sodium carbonate (1.80 g, 17.0 mmol, 3.1 equiv, 
dissolve in a minimium amount of water) was added. The active catalyst was generated by the 
addition of palladium acetate (31 mg, 0.14 mmol, 2.5 % equiv), and triphenylphosphine (72 
mg, 0.28 mmol, 5 % equiv) to the mixture. Argon was passed, and the mixture was heated at 70 
°C for 24 h. The solvent was removed by rotary evaporation and the product was extracted with 
methylene chloride (3 × 50 ml), the organic layer was  washed with water (2 × 50 ml), and 
dried over anhydrous magnesium sulphate. The solvent was evaporated, and the residue was 
purified by column chromatography on silica gel, eluting with cyclohexane:CH2Cl2 (5/1→1/1). 
 
 
2,4-dichloro-6-phenylpyrimidine (239a) 
 
N
N
Cl
Cl Ph 
 
 
White solid, yield: 81 %; mp 83-4 °C; 
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1H-NMR(CDCl3), δ(ppm): 7.44-7.48 (m, 3 H, Ph-H), 7.59 (s, 1 H, H-5), 7.96-8.01 (dd, 2 H, J 
= 8.7 Hz, Ph-H). 
13C-NMR(CDCl3), δ(ppm): 115.33 CH(H-5), 127.61 CH, 129.24 CH, 132.48 CH, 134.09 C, 
160.97 C, 162.93 C, 168.20 C. 
 
Anal. Calcd. for C10H6Cl2N2(225.08): C, 53.36; H, 2.69; Cl, 31.50; N, 12.45. 
                                                  Found: C, 53.41; H, 2.51; Cl, 31.20; N, 12.68. 
 
 
2,4-Dichloro-6-(4-chloro-phenyl)-pyrimidine (239b) 
 
N
N
Cl
Cl
Cl 
 
White solid, yield: 78 %; mp.123-5 C; 
 
1H-NMR(CDCl3), δ(ppm): 7.41-7.45 (dd, 2 H, Ph-H), 7.57 (s, 1 H, H-5), 7.93-7.96 (dd, 2 H, 
Ph-H). 
13C-NMR(CDCl3), δ(ppm): 115.12CH(H-5), 128.87 CH, 129.56 CH, 132.49 C, 138.97 C, 
161.07 C, 163.17 C, 166.88 C. 
 
Anal. Calcd. for C10H5Cl3N2(259.52): C, 46.28; H, 1.94; Cl, 40.98; N, 10.79. 
                                                  Found: C, 46.32; H, 2.04; Cl, 40.70; N, 10.48. 
 
 
(c) 2-Chloro-4-(4-chloro-phenyl)-6-phenylpyrimidine (255) 
 
N
N
Ph
Cl
Cl 
 
 
To a solution of 2,4-dichloro-6-(4-chloro-phenyl)-pyrimidine 239b (290 mg, 1.1 mmol) in 15 
ml DME, phenyllboronic acid (134 mg, 1.1 mmol, 1.0 equiv), sodium carbonate (360 mg, 3.4 
mmol, 3.1 equiv, dissolve in a minimium amount of water) was added. The active catalyst was 
generated by the addition of palladium acetate (12 mg, 0.055 mmol, 5 % equiv), and 
triphenylphosphine (29 mg, 0.11 mmol, 10 % equiv) to the mixture. Argon was passed, and the 
mixture was heated at 70 °C for 24 h. The solvent was removed by rotary evaporation and the 
product was extracted with methylene chloride (3 × 20 ml), the organic layer was washed with 
water (2 × 20 ml), and dried over anhydrous MgSO4. The solvent was evaporated, the residue 
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was purified by flash column chromatography on silica gel, eluting with cyclohexane:CH2Cl2 
(5/1→1/1), and provided a white solid 274 mg, yield 82 %, mp 97-9 °C; 
 
1H-NMR (CDCl3), δ(ppm): 7.39-7.46 (m, 5 H, Ph-H), 7.87 (s, 1 H, H-5), 7.98-8.05 (m, 4 H, 
Ph-H). 
13C-NMR (CDCl3), δ(ppm): 110.63 CH(C-5), 127.46 CH, 128.73 CH, 129.12 CH, 129.35 CH, 
131.80 CH, 134.05 C, 135.84 C, 138.02 C, 162.13 C, 166.31 C, 167.86 C. 
 
Anal. Calcd. for C16H10Cl2N2: C, 63.81; H, 3.35; Cl, 23.54; N, 9.30. 
                                      Found: C, 63.71; H, 3.46; Cl, 23.66; N, 9.13. 
 
 
 
7.7.2 Sonogashira cross-coupling of halopyrimidines 
 
7.7.2.1 From 4-iodo-2,6-diphenylpyrimidine 251 
 
General procedure: 
 
A 25 ml flask was charged with 4-iodo-2,6-diphenylpyrimidine 251 (358 mg, 1.0 mmol), 
Pd(PPh3)2Cl2 (35 mg, 0.05 mmol), cuprous iodide (19 mg, 0.10 mmol), dry triethylamine 10 
ml, and appropriate alkyne 1.5 mmol. Argon was passed inside and the mixture was stirred at 
room temperature for 24 h, the solvent was evaporated under reduced pressure and the residue 
was purified by column chromatography on silica gel. 
 
[3-(2,6-Diphenyl-pyrimidin-4-yl)-prop-2-ynyl]-dimethylamine (256) 
 
N
N
Ph
Ph
NMe2
92
 
 
 
The product was purified by column chromatography on silica gel, eluting with ethyl 
acetate:methanol (8:1) and provided 237 mg brown solid, yield 76 %, mp 62-3 °C. 
 
1H-NMR (CDCl3), δ (ppm): 2.29 (s, 6 H, CH3), 3.44 (s, 2 H, CH2), 7.35-7.37 (m, 6 H, Ph-H), 
7.51 (s, 1 H, H-5), 8.05 (dd, 2 H, Ph-H), 8.48 (dd, 2 H, Ph-H). 
13C-NMR (CDCl3), δ (ppm): 44.47 CH3, 48.59 CH2, 84.19 C, 89.11 C, 116.91 CH(H-5), 
127.20 CH, 128.46 CH, 128.52 CH, 128.92 CH, 130.89 CH, 132.15 CH, 136.44 C, 137.44 C, 
151.39 C, 164.01 C, 164.70 C. 
 
Anal. Calcd. for C21H19N3 (313.4): C, 80.48; H, 6.11; N, 13.41. 
                                             Found: C, 80.30; H, 6.35; N, 13.24. 
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2-[3-(2,6-Diphenyl-pyrimidin-4-yl)-prop-2-ynyl]-isoindole-1,3-dione (258) 
 
N
N
Ph
Ph
N
O
O
 
 
 
The product was purified by column chromatography on silica gel, ethyl acetate:cyclohexane 
(1:1) was as eluting solvent and provided a brown solid, yield 84 %, mp 221-2 °C. 
 
1H-NMR (CDCl3), δ (ppm): 4.71 (s, 2 H, CH2), 7.40-7.46 (m, 6 H, Ph-H), 7.60 (s, 1 H, H-5), 
7.67-7.70 (dd, 2 H, Ph-H), 7.83-7.86 (dd, 2 H, Ph-H), 8.10-8.13 (dd, 2 H, Ph-H), 8.46-8.49 (dd, 
2 H, Ph-H) 
13C-NMR (CDCl3), δ (ppm): 27.73 CH2, 81.42 C, 86.28 C, 117.12 CH(C-5), 123.70 CH, 
127.24 CH, 128.49 CH, 128.95 CH, 130.92 CH, 131.24 CH, 131.99 C, 134.35 CH, 136.34 C, 
137.27 C, 150.74 C, 164.17 C, 164.78 C, 166.94 C. 
 
Anal. Calcd. for C27H17N3 O (415.44): C, 78.06; H, 4.12; N, 10.11. 
                                                   Found: C, 78.16; H, 4.28; N, 10.05 
 
 
[3-(2,6-Diphenyl-pyrimidin-4-yl)-propyl]-dimethylamine (257) 
 
A solution [3-(2,6-diphenyl-pyrimidin-4-yl)-prop-2-ynyl]-dimethylamine 256 (126 mg, 0.4 
mmol), ethanol (15 ml) and 10 % palladium on charcoal (89 mg, 0.08 mmol on Pd, 0.2 equiv) 
was stirred under hydrogen at room temperature and atmosphere 16 hours. After complete 
conversion (TLC monitoring), the catalyst was filtered off through a pad of Celite, washed with 
ethyl acetate, the solvents were removed under reduced pressure, and the residue was purified 
by column chromatography on neutral Al2O3 gel, using ethyl acetate:Methanol (10:1) as eluting 
solvent to provide 96 mg light brown oil, yield 76 %. 
 
N
N
Ph
Ph
NMe2
257
 
 
1H-NMR (CDCl3), δ(ppm): 1.91-2.01 (m, 2 H, CH2), 2.17(s, 3 H, CH3), 2.31 (t, 2 H, J = 7.3 
Hz, CH2), 2.79 (t, 2 H, J = 7.5 Hz, CH2), 7.35 (s, 1 H, H-5), 7.38-7.41 (m, 6 H, Ph-H), 8.11 dd, 
2 H, Ph-H), 8.51 (dd, 2 H, Ph-H) 
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13C-NMR (CDCl3), δ(ppm): 26.46 CH2, 35.77 CH2, 45.35 CH3, 58.99 CH2, 113.54 CH(C-5), 
127.10 CH, 128.38 CH, 128.42 CH, 128.85 CH, 130.46 CH, 130.65 CH, 137.34 C, 138.21 C, 
163.71 C, 164.22 C, 171.00 C. 
 
HRMS (EI) calcd for C21H23N3 (M+) 317.18920, found 317.18920. 
 
 
7.7.2.2 From 2-chloro-4,6-diarylsubstituted pyrimidine 
 
General procedure: 
 
A 25 ml flask was charged with appropriate 2-chloro-4,6-diarylpyrimidine (0.5 mmol), 
Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10 mg, 0.05 mmol), TEA 5 ml, DMF 5 ml and N,N-
dimethylpropargylamine 83 mg (1.0 mmol), Argon was passed three times and the mixture was 
heated at 100 °C for 24 h, the solvent was evaporated in vacuum, the residue was purified by 
column chromatography on silica gel, eluting with ethyl acetate: methanol (5/1), 
 
[3-(4,6-Diphenyl-pyrimidin-2-yl)-prop-2-ynyl]-dimethylamine (259a) 
N
N
Ph
Ph
NMe2
 
 
Brown solid 60 mg was obtained, yield 38 %, mp 101-3 °C. When using KOAc as base, 112 
mg brown solid was obtained, yield 70 %. 
 
1H-NMR(CDCl3), δ(ppm): 2.39 (s, 6 H, CH3), 3.54(s, 2 H, CH2),  7.43-7.46 (m, 6 H, Ph-H), 
7.93 (s, 1 H, H-5), 8.06-8.10 (dd, 4 H, Ph-H). 
13C-NMR(CDCl3), δ(ppm): 44.35 CH3, 48.44 CH2, 83.07 C, 85.40 C, 111.55CH(H-5), 127.37 
CH, 128.96 CH, 131.08 CH, 136.56C, 153.09C, 165.16 C 
 
HRMS ( EI ) calcd for C21H19N3 (M+) 313.15790, found , 313.15785 
 
Anal. Calcd. for C21H19N3 (313.40) C, 80.48; H, 6.11; N, 13.41. 
                                              Found: C, 80.14; H, 6.12; N, 13.37. 
 
 
{3-[4,6-Bis-(4-chloro-phenyl)-pyrimidin-2-yl]-prop-2-ynyl}-dimethylamine (259b) 
 
N
N
p-Cl-Ph
Ph-Cl-p
NMe2
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Brown solid 98 mg was obtained, yield: 51 %, mp 112-4 °C. 
 
1H-NMR (CDCl3), δ(ppm): 2.35 (s, 6 H, CH3), 3.50 (s, 2 H, CH2), 7.37 (d, 4 H, J = 8.7 Hz), 
7.80 (s, 1 H, H-5), 7.98 (d, 4 H, J = 8.7 Hz) 
13C-NMR (CDCl3), δ(ppm): 44.38 CH3, 48.40 CH2, 83.72 C, 85.06 C,  111.77 CH(H-5), 
128.63 CH, 129.18 CH, 134.67 CH, 137.47 C, 153.09 C, 163.97 C 
 
Anal. Calcd. for C21H17Cl2N3 (382.28): C, 65.98; H, 4.48; Cl, 18.55; N, 10.99. 
                                                    Found: C, 65.84; H, 4.61; Cl, 18.73; N, 10.81. 
 
 
{3-[4-(4-Chloro-phenyl)-6-phenyl-pyrimidin-2-yl]-prop-2-ynyl}-dimethylamine (259c) 
 
N
N
Ph
NMe2
Cl
 
 
Brown solid 88 mg was obtained, yield 51 %, mp 86-8 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.35 (s, 6 H, CH3), 3.50 (s, 2 H, CH2), 7.36-7.42(m, 5 H, Ph-H), 
7.84 (s, 1 H, H-5), 7.97-8.05 (m, 4 H, Ph-H). 
13C-NMR(CDCl3), δ (ppm): 44.39 CH3, 48.44 CH2, 83.45 C, 85.22 C,  111.13CH(H-5), 127.34 
CH, 128.64 CH,  128.96 CH, 129.16 CH, 131.20 CH, 134.89 C, 136.32 C, 137.33 C, 153.10C, 
163.80 C, 165.30 C 
 
Anal. Calcd. for C21H18 ClN3 (347.84): C, 72.51; H, 5.22; Cl, 10.19; N, 12.08. 
                                                   Found: C, 72.66; H, 5.41; Cl, 10.26; N, 11.94. 
 
 
[3-(4,6-Diphenyl-pyrimidin-2-yl)-propyl]-dimethylamine (260) 
 
N
N
Ph
Ph
NMe2
 
 
 
A solution [3-(4,6-diphenyl-pyrimidin-2-yl)-prop-2-ynyl]-dimethylamine 259a (76mg, 0.24 
mmol) in ethanol (15 ml) and 10 % palladium on charcoal (51 mg, 0.048 mmol on Pd, 
0.2equiv) was stirred under hydrogen at room temperature and atmosphere 16 hours. After 
complete conversion (TLC monitoring), the catalyst was filtered off through a pad of Celite, 
washed with ethyl acetate, the solvents were removed under reduced pressure, the residue was 
purified by column chromatography on neutral Al2O3 gel, using ethyl acetate:cyclohexane (1:1) 
as eluting solvent to provide 55 mg light brown oil, yield 72 %. 
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1H-NMR (CDCl3), δ(ppm): 2.04-2.14 (m, 2 H, CH2), 2.20 (s, 2 × 3 H, CH3), 2.37 (t, 2 H, J = 
7.5 Hz, CH2), 3.03 (t, 2 H, J = 7.7 Hz, CH2), 7.41-7.44 (m, 6 H, Ph-H), 7.81 (s, 1 H, H-5), 8.05-
8.08 (m, 4 H, Ph-H), 
13C-NMR (CDCl3), δ(ppm): 26.53 CH2, 37.52 CH2, 45.61 CH3, 59.56CH2, 110.03 CH(C-5), 
127.25 CH, 128.91 CH, 130.62 CH, 137.56 C, 164.66 C, 171.27 C. 
 
HRMS (EI) calcd for C21H23N3 (M+) 317.18920, found 317.18920. 
 
259b and 259c were hydrogenated with hydrogen, using the same conditions, only 260 was 
obtained, and the yields were 37 % and 44 %, respectively. 
 
 
7.7.3 Nucleophilic substitution of 2-chloropyrimidine 
 
7.7.3.1 To introduce 3-dimethylamino-propylamino group 
 
N'-(4,6-Diphenyl-pyrimidin-2-yl)-N,N-dimethyl-propane-1,3-diamine (262) 
 
N
N
Ph
Ph
H
N NMe2
 
 
A mixture of 2-chloro-4,6-diphenylpyrimidine (107 mg, 0.4 mmol) in N,N-dimethyl-
propanediamine 3 ml was heated at 110 °C for 16 h, then evaporated the solvent to dryness in 
high vacuum, the residue was dissolved in 20 ml 2 N HCl, and washed with dichloromethane 
(2 × 20 ml), the aqueous layer was basified with solid potassium carbonate (ph > 10), then 
extracted with dichloromethane (4 × 20 ml), the organic phase was dried with anhydrous 
MgSO4, evaporated the solvent, and provide yellow solid 105 mg, yield 79 %, mp 62-4 °C; 
 
1H-NMR (CDCl3), δ(ppm): 1.73 (m, 2 H, CH2), 2.14 (s, 3 H, CH3), 2.31 (t, 2 H, J = 7.2 Hz, 
CH2), 3.51 (dt, 2 H, J1 = 6.0 Hz, J2 = 6.7 Hz, CH2), 5.73 (t, 1 H, J = 6.0 Hz, NH), 7.29 (s, 1 H, 
H-5), 7.35-7.38 (m, 6 H, Ph-H), 7.99 (dd, 4 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 27.50 CH2, 40.32 CH2, 45.57 CH3, 57.82 CH2, 102.67 CH(C-5), 
127.10 CH, 128.66 CH, 130.28 CH, 138.12 C, 163.11 C, 165.57 C. 
 
HRMS (EI) calcd for C21H24N4 (M+) 332.20010, found 332.20014. 
 
 
7.7.3.2 To introduce 2-dimethylamino-ethoxy group 
 
[2-(4,6-Diphenyl-pyrimidin-2-yloxy)-ethyl]-dimethylamine (263) 
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A mixture of 2-chloro-4,6-diphenylpyrimidine 240a (107 mg, 0.4 mmol) and t-BuOK (56 mg, 
0.5 mmol) in 2-(dimethylamino)-ethanol 3 ml was heated at 110 °C for 16 h, then evaporated to 
dryness in high vacuum, the residue was dissolved in 20 ml 2 N HCl, and washed with 
dichloromethane (2 × 20 ml), the aqueous layer was basified with solid potassium carbonate 
(pH > 10), then extracted with dichloromethane (4× 20 ml), the organic phase was dried with 
anhydrous MgSO4, evaporated the solvent, and provided a yellow glass 38 mg, yield 30 %. 
 
N
N
Ph
Ph
O
NMe2
 
 
1H-NMR (CDCl3), δ(ppm): 2.35 (s, 6 H, CH3), 2.84 (t, 2 H, J = 6.0 Hz, CH2), 4.62 (t, 2 H, J = 
6.0 Hz, CH2), 7.41-7.44 (m, 6 H, Ph-H), 7.70 (s, 1 H, H-5), 8.08 (dd, 4 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 45.81 CH3, 57.83 CH2, 65.01 CH2, 106.65 CH(C-5), 127.30 CH, 
128.83 CH, 130.98 CH, 136.87 C, 165.64 C, 167.05 C. 
 
HRMS (EI) calcd for C20H21N3O (M+) 319.16846, found 319.16852. 
 
 
7.7.3.3 To introduce 2-dimethylamino-ethylsulfanyl group 
 
General procedure: 
A 50 ml flask was charged with appropriate 2-chloro-4,6-diarylpyrimidine (0.4 mmol), 2-
(dimethylamino)-ethanethiol hydrochloride (N, N-dimethylamino-2-mercaptoethyl ammonium 
chloride) (63 mg, 0.42 mmol), sodium hydroxide (40 mg, 1.0 mmol) and ethanol 20 ml. The 
mixture was refluxed overnight (16 h), evaporated the solvent, 30 ml water was added, and 
neutralized the mixture with 2 N HCl. The mixture was extracted dichloromethane (3 × 30 ml), 
washed with water 30 ml, the organic phase was dried with anhydrous magnesium sulphate, 
evaporated the solvent, the residue was column chromatography on silica gel. 
 
[2-(4,6-Diphenyl-pyrimidin-2-ylsulfanyl)-ethyl]-dimethylamine (261a) 
 
N
N
Ph
Ph
S
NMe2
 
 
Eluting with ethyl acetate: methanol (9:1) to provide light yellow solid 47 mg, yield: 35 %, mp. 
86-8 °C; 
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1H-NMR (CDCl3), δ(ppm): 2.30 (s, 6 H, CH3), 2.71 (t, 2 H, J = 7.5 Hz, CH2), 3.35 (t, 2 H, J = 
7.5 Hz, CH2), 7.42-7.43 (m, 6 H, Ph-H), 7.68 (s, 1 H, H-5), 8.05 (dd, 4 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 28.52 CH2, 45.33 CH3, 58.80 CH2, 107.98 CH(C-5), 127.20 CH, 
128.84 CH, 130.95 CH, 136.78 C, 164.75 C, 172.06 C. 
 
HRMS (EI) calcd for C20H21N3S (M+) 335.14562, found 335.14558. 
 
 
{2-[4,6-Bis-(4-chloro-phenyl)-pyrimidin-2-ylsulfanyl]-ethyl}-dimethylamine (261b) 
 
N
N
p-Cl-Ph
Ph-Cl-p
S
NMe2
 
 
 
Eluting with ethyl acetate: methanol (10:1) to provide light yellow solid 54 mg, yield 33 %, mp 
131-2 °C; 
 
1H-NMR(CDCl3), δ(ppm): 2.29 (s, 6 H, CH3), 2.69 (t, 2 H, J = 7.5 Hz,CH2), 3.34 (t, 2 H, J = 
7.5 Hz,CH2), 7.40 (dd, 4 H, Ph-H), 7.60 (s, 1 H, H-5), 8.00 (dd, 4 H, Ph-H). 
13C-NMR (CDCl3), δ (ppm): 28.68 CH2, 45.37 CH3, 58.71 CH2, 107.38 CH(H-5), 128.52 CH, 
129.18 CH,135.04 C, 137.34 C, 163.70 C, 172.49. 
 
HRMS (EI) calcd for C20H19Cl2N3S (M+): 403.06767, found 403.06746. 
 
 
 
7.7.3.4 To introduce 3-hydroxypropylamino group 
 
A solution of 2,4,6-trichloropyrimidine (1.83 g, 10 mmol) in THF (10ml) was added dropwise 
to a stirred solution of propanlamine (1.50 g, 20 mmol) in THF 20ml at room temperature. The  
 
turbid mixture was allowed to stir at room temperature overnight (about 16 h). The solvent was 
removed by evaporation under vacuum to give a white solid. The crude product was separated 
by flash chromatograph on silica gel. 
 
3-(2,6-Dichloro-pyrimidin-4-ylamino)-propan-1-ol (264b) 
264b was eluted with hexane:ethyl acetate (1/2), a white solid 0.882 g was obtained, yield 40 
%, mp 91-2 °C. 
N
N
NH(CH2)3OH
ClCl
264b
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1H-NMR(CDCl3), δ(ppm): 1.81-1.90 (m, 2 H, CH2), 3.49-3.56(m, 2 H, CH2), 3.63-3.68 (m, 
2H, CH2), 4.85 (t, 1 H, J = 4.7 Hz, NH), 6.69(s, 1 H, H-6), 8.39 (br, 1 H, OH). 
13C-NMR(CDCl3), δ(ppm): 31.52 CH2, 37.76 CH2, 58.26 CH2, 102.70 CH(C-6), 156.74 C, 
159.17 C, 164.12 C. 
 
Anal. Calcd. for C7H9Cl2N2O (222.08): C, 37.86; H, 4.08; Cl, 31.93; N, 18.92. 
                                                      Found: C, 38.02; H, 4.03; Cl, 31.69; N, 18.95. 
 
 
 
3-(4,6-Dichloro-pyrimidin-2-ylamino)-propan-1-ol (264a) 
 
264a was eluted with ethyl acetate, a white solid 1.089 g was obtained, yield 49 %, mp 118-9 
°C. 
N
N
Cl
NH(CH2)3OHCl
264a
 
 
 
1H-NMR(CDCl3), δ(ppm): 1.36-1.45 (m, 2 H, CH2), 3.00-3.06(m, 2 H, CH2), 3.17-3.23 (m, 2 
H, CH2), 4.36 (t, 1 H, J = 4.9 Hz, NH), 6.57(s, 1 H, H-6), 7.81 (br, 1 H, OH). 
13C-NMR(CDCl3), δ(ppm): 31.63 CH2, 38.30 CH2, 58.49 CH2, 107.23 CH(C-6), 160.80 C, 
161.50 C. 
 
Anal. Calcd. for C7H9Cl2N2O (222.08): C, 37.86; H, 4.08; Cl, 31.93; N, 18.92. 
                                                     Found: C, 38.10; H, 4.08; Cl, 31.99; N, 19.04. 
 
 
 
 
7.8 Synthesis of pyridine derivatives 
7.8.1 Synthesis of 2-amino-3,5-diphenylpyridine (283): 
2-Amino-3,5-dibromopyridine (2.52 g, 10.0 mmol) and phenylboronic acid (2.53 g, 21.0 
mmol) were dissolved in methanol (20 ml). Na2CO3 (25 g, 0.24 mol) in water (50 ml) and then 
toluene (100 ml) were added, and the suspension was degassed with evaporating for 10 min 
and then passing Argon. Pd (PPh3)2Cl2 (177 mg, 0.25 mmol) was then added, and the mixture 
was heated under reflux under argon with vigorous stirring for 66 h. The organic solvents were 
removed under reduced pressure, followed by extraction with ethyl acetate (3 × 50 ml), washed 
with water (2 × 50 ml), and dried with anhydrous MgSO4, evaporated the solvents, the residue  
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was separated with column chromatography on silica ( eluting with diethyl ether) and provide 
1.37 g light brown solid, yield: 53 %, mp 106 °C. 
 
N NH2
PhPh
 
 
 
1H-NMR(CDCl3), δ(ppm): 4.83 (s, 2 H, NH2), 7.39-7.64 (m, 10 H, Ph-H), 7.69 (d, 1 H, J = 2.3 
Hz, H-4), 7.81 (d, 1 H, J = 2.3 Hz, H-6). 
13C-NMR(CDCl3), δ(ppm): 121.74 C, 126.29 CH, 126.94 CH, 127.86 CH, 127.94 CH, 128.76 
CH, 128.93 CH, 129.18 CH, 136.60 CH(C-4), 137.98 C, 138.20 C, 145.48 CH(C-6), 155.21 C. 
 
Anal. Calcd. for C17H14N2 (246.30): C, 82.90; H, 5.73; N, 11.37. 
                                               Found: C, 82.83; H, 5.93; N, 11.41. 
 
 
 
7.8.2 Synthesis of 2-iodo-3,5-diphenylpyridine (284): 
 
Aminopyridine 283 (1.00 g, 4.0 mmol) was dissolved in CH2I2 (13 ml), aided by ultrasound. 
tert-Butyl nitrite (0.65 g, 6.0 mmol) and I2 (1.02 g, 4.0 mmol) were then added, and the 
reaction mixture was stirred at room temperature for 24 h under exclusion of light. To complete 
the reaction (TLC monitoring), additional of tert-butyl nitrite (0.32 g 3.0 mmol) was added and 
the mixture was stirred for further 12 h. The reaction was stopped by addition of 30 ml of satd. 
Na2CO3 solution and an excess of solid Na2S2O3. The solvents were evaporated to dryness 
under reduced pressure, followed by addition of 40 ml water and extraction with ethyl acetate 
(3 × 40 ml). The combined organic layers were dried with MgSO4 and concentrated. The 
residue was purified by column chromatography on silica gel, eluting with cyclohexane:ethyl 
acetate (10:1-3:1), to provide 660 mg light brown solid, yield 46 %, mp 86-7 °C. 
N I
PhPh
 
 
1H-NMR (CDCl3), δ(ppm): 7.31-7.44 (m, 10 H, Ph-H), 7.54 (d, 1 H, J = 2.6 Hz, H-4), 8.43 (d, 
1 H, J = 2.6 Hz, H-4). 
13C-NMR (CDCl3), δ(ppm): 120.77 C, 127.08 CH, 128.40 CH, 128.53 CH, 128.67 CH, 129.31 
CH, 129.38 CH, 135.39 CH(C-4), 136.05 C, 136.27 C, 141.36 C, 144.05 C, 147.46 CH(C-6). 
 
Anal. Calcd. for C17H12IN (357.19): C, 57.16; H, 3.39; I, 35.53; N, 3.93. 
                                               Found: C, 57.48; H, 3.60; I, 35.30; N, 3.98. 
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3,5-Diphenyl-1H-pyridin-2-one (285): 
 
Further elution of the crude product described above with ethyl acetate, 161 mg light yellow 
solid was obtained, yield: 16 %, mp 192-3 °C. 
N
PhPh
O
H  
 
1H-NMR(CDCl3), δ(ppm): 7.30-7.46(m, 8H, Ph-H), 7.62(d, 1H, J=2.6Hz, H-4), 7.76-7.79(dd, 
2H, J=5.4Hz, Ph-H), 7.90(d, 1H, J=2.6Hz, H-6), 13.63(s, 1H, N-H). 
13C-NMR(CDCl3), δ(ppm): 121.32 C, 125.83 CH, 127.35 CH, 128.03 CH, 128.41 CH, 128.63 
CH, 129.10 CH, 131.29 CH(C-4), 131.35 C, 136.49 C, 139.50 CH(C-6), 163.45 C. 
 
Anal. Calcd. for C17H13NO (247.29): C, 82.57; H, 5.30; N, 5.66. 
                                                 Found: C, 82.68; H, 5.42; N, 5.57. 
 
 
 
7.8.3 Synthesis of 3-(3,5-diphenyl-pyridin-2-yl)-prop-2-ynyl]-dimethylamine(286): 
 
2-Iodo-3,5-diphenylpyridine 284 (250 mg, 0.7 mmol) CuI (13 mg, 0.10 equiv.), Pd(PPh3)2Cl2 
(25 mg, 0.05 equiv), N,N-dimethyl-propargylamine (116 mg, 1.4 mmol 2 equiv) was 
suspended in triethylamine (10 ml) and pass the Argon, the suspension was  stired at room 
temperature 24 hours, The solvent was evaporated under reduced pressure and the residue was 
purified by column chromatography on silica gel (ethyl acetate:methanol 6:1) and provided 196 
mg of 286 as a brown crystal yield, 89 %, mp 82-83 °C. 
 
 
N
PhPh
CH2NMe2 
 
 
1H-NMR(CDCl3), δ(ppm): 2.08 (s, 6 H, CH3), 3.35 (s, 2 H, CH2), 7.28-7.51 (m, 10 H, Ph-H), 
7.74 (d, 1H, J = 1.8 Hz, H-4), 8.70 (d, 1 H, J = 1.8 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 44.00 CH3, 48.47 CH2, 84.68 C, 88.34 C, 127.07 CH, 128.12 CH, 
128.29 CH, 128.42 CH, 129.16 CH, 129.26 CH, 135.06 CH(C-4), 135.54 C, 136.95 C, 138.29 
C, 139.60 C, 139.84 C, 146.97 CH(C-6). 
 
HRMS (EI) calcd for C22H20N2 (M+) 312.16265, found 312.16260. 
 
Anal. Calcd. for C22H20N2 (312.41): C, 84.58; H, 6.45; N, 8.97. 
                                               Found: C, 84.52; H, 6.50; N, 8.94. 
 
Chapter7: Experimental 
_________________________________________________________________________________________________________________________________ 
 
183
7.8.4 Synthesis of 3,5-diphenyl-2-(3-dimethylaminopropyl)-pyridine (287): 
A solution [3-(3,5-diphenyl-pyridin-2-yl)-prop-2-ynyl]-dimethylamine 286 (125 mg, 0.4 mmol) 
in ethanol (15 ml) and 10 % palladium on charcoal (89 mg, 0.08 mmol on Pd, 0.2 equiv) wase 
stirred under hydrogen at room temperature and atmosphere 16 hours. After complete 
conversion (TLC monitoring), the catalyst was filtered off through a pad of Celite, washed with 
ethyl acetate, the solvents were removed under reduced pressure, and the residue was purified 
by column chromatography on neutral Al2O3 gel (ethyl acetate and ethyl acetate:Methanol 10:1) 
to provide 90 mg of 287 as a light brown oil, yield 71%. 
N
PhPh
N
 
 
1H-NMR(CDCl3), δ(ppm): 1.73-1.83 (m, 2 H, CH2), 2.08 (s, 6 H, 2CH3), 2,20 (t, 2 H, J = 7.5 
Hz, CH2), 2.73 (t, 2 H, J = 7.9 Hz, CH2), 7.26-7.52 (m, 10 H, Ph-H), 7.61 (d, 1 H, J = 2.3 Hz, 
H-4), 8.70 (d, 1 H, J = 2.3 Hz, H-6). 
13C-NMR (CDCl3), δ(ppm): 27.39 CH2, 33.08 CH2, 45.02 CH3, 59.26 CH2, 127.00 CH, 127.59 
CH, 127.90 CH, 128.47 CH, 129.04 CH, 129.08 CH, 133.86 C, 135.89 C, CH(C-4), 136.83 C, 
137.59 C, 139.72 C, 146.45 CH(C-6), 157.97 C. 
 
HRMS (EI) calcd for C22H24N2 (M+) 316.1940, found 316.1937. 
 
Anal. Calcd. for C22H24N2 (316.44): C, 83.50; H, 7.64; N, 8.85. 
                                               Found: C, 83.40; H, 7.80; N, 8.85. 
 
 
3,5-Diphenyl-2-propylpyridine (288): 
The crude product described above was purified by column chromatography on neutral Al2O3 
gel, 17 mg of 288 was at first isolate (eluting with cyclohexane:ethyl acetate 1:1) as a light 
yellow liquid, yield 16 %. 
 
N
PhPh
 
 
 
1H-NMR(CDCl3), δ(ppm): 0.80 (t, 3 H, J= 7.3 Hz, CH3), 1.60-1.69 (m, 2 H, CH2), 2.71 (t, 2H, 
J = 7.9 Hz, CH2), 7.27-7.55 (m, 10 H, Ph-H), 7.63 (d, 1 H, J = 2.3 Hz, H-4), 8.72 (d, 1 H, J = 
2.3 Hz, H-6). 
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13C-NMR (CDCl3), δ(ppm): 14.11 CH3, 23.09 CH2, 37.16 CH2, 127.02 CH, 127.50 CH, 
127.87 CH, 128.39 CH, 129.04 CH, 129.12 CH, 133.69 C, 135.85 CH(C-4), 136.83 C, 137.70 
C, 139.95 C, 146.43 CH(C-6). 158.42 C. 
 
HRMS (EI) calcd for C20H19N (M+) 273.15175, found 273.15174. 
 
 
 
 
7.9 Synthesis of pyrazine derivatives 
 
7.9.1 Synthesis of 5-chloro-2,3-diphenylpyrazine 
 
5-Chloro-2,3-diphenylpyrazine was chosen as the starting diphenyl-haloheterocycle, 2-
hydroxy-5,6-diphenylpyrazine was prepared at first. 
 
2-Hydroxy-5,6-diphenylpyrazine (296) 
 
N
NPh
Ph OH 
 
To a stirring and refluxing mixture of glycine amide hydrochloride 6.6 g (0.06 mol) and benzyl 
12.6g (0.06 mol) in 150 ml methanol, a solution of 12 N aq. NaOH 9.6 ml (0.12 mol) was 
added dropwise over 20 min, the mixture was continue refluxing for 2 h and cooled, treated 
with 12 N hydrochloric acid 7.5 ml, follow by 6 g solid KHCO3, the yellow solid was filtered 
off, washed well with water and methanol, dried in air, recrystallized from butanol, and 
provided a yellow solid 10.56 g, yield 71 %, mp 225-7°C. 
 
1H-NMR(DMSO-d6), δ(ppm): 7.21-7.34 (m, 10 H, Ph-H), 8.13 (s, 1 H, H-3), 12.23 (s, 1 H, N-
H) 
13C-NMR(DMSO-d6), δ(ppm): 117.84 C, 127.04 CH, 127.68 CH, 128.05 CH, 128.78 CH, 
129.03 CH, 129.43 CH, 137.75 C, 156.68 C. 
 
Anal. Calcd. for C16H12N2O (248.28): C, 77.40; H, 4.87; N, 11.28. 
                                                  Found: C, 77.24; H, 4.94; N, 11.20. 
 
 
5-Chloro-2,3-diphenylpyrazine (297) 
 
N
NPh
Ph Cl 
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A solution of 2-hydroxy-5,6-diphenylpyrazine 296 (5.0 g, 0.02 mol), phosphoryl chloride 20 
ml, and one drop of sulphuric acid was refluxed for 16 h, after cooled, the mixture was poured 
slowly onto 200 g chopped ice, stirred to complete hydrolysis, then the mixture was neutralized 
with 28 % ammonia while keeping it below 10°C, the mixture was extracted with chloroform 
(3 × 50 ml), the extract was dried with anhydrous MgSO4, evaporated the solvent, the crude 
product was recrystallized with methanol, and provided a light yellow solid 4.94 g, yield 93 %, 
mp 124-5 °C. 
 
1H-NMR(CDCl3), δ(ppm): 7.30-7.47 (m, 10 H, Ph-H), 8.60 (s, 1 H, H-6). 
13C-NMR (CDCl3), δ(ppm): 128.38 CH, 128.40 CH, 128.96 CH, 129.23 CH, 129.59 CH, 
129.74 CH, 137.11 C, 137.47 C, 141.58 CH(C-6), 146.45 C, 150.78 C, 152.22 C. 
 
Anal. Calcd. for C16H11Cl N2 (266.72): C, 72.05; H, 4.16; Cl, 13.29; N, 10.50. 
                                                    Found: C, 72.05; H, 4.24; Cl, 13.33; N, 10.56. 
 
 
7.9.2 Synthesis of [3-(5,6-diphenyl-pyrazin-2-yl)-prop-2-ynyl]-dimethylamine (298): 
 
A 25 ml schlenk flask was charged with 5-chloro-2,3-diphenylpyrazine 297 267 mg (1.0 mmol), 
Pd(PPh3)2Cl2 36 mg (0.05 mmol), CuI 20 mg (0.1mmol), KOAc 147 mg (1.5 mmol), DMF 5 
ml and N,N-dimethylpropargylamine 125 mg (1.5 mmol), Argon was passed and the mixture 
was heated at 100 °C for 24 h, DMF was evaporated in vacuum, the residue was purified by 
column chromatography on neutral Al2O3 gel, eluting with cyclohexane:ethyl acetate (1/1) to 
give 165 mg light brown oil 163 mg, yield 52 %. 
N
NPh
Ph
NMe2 
 
 
1H-NMR(CDCl3), δ(ppm): 2.31 (s, 6 H, 2CH3), 3.48 (s, 2 H, CH2), 7.18-7.37 (m, 10 H, Ph-H), 
8.58 s, 1 H, H-3) 
13C-NMR(CDCl3), δ(ppm): 44.42 CH3, 48.61 CH2, 82.49 C, 89.23 C, 128.27 CH, 128.82 CH, 
128.86 CH, 129.64 CH, 129.74 CH, 136.95 C, 138.10 C, 138.13 C, 144.73 CH(C-3), 150.81 C, 
152.30 C. 
 
HRMS (EI) calcd for C21H19N3 (M+) 313.1579, found 317.1576. 
 
Anal. Calcd. for C21H19N3(313.40): C, 80.48; H, 6.11; N, 13.41. 
                                              Found: C, 80.65; H, 6.30; N, 13.37. 
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7.9.3 Synthesis of [3-(5,6-diphenyl-pyrazin-2-yl)-propyl]-dimethylamine (299): 
 
A solution 3-(5,6-diphenyl-pyrazin-2-yl)-prop-2-ynyl]-dimethylamine 298 (84 mg, 0.27 mmol) 
in ethanol (15 ml) and 10 % palladium on charcoal (67 mg, 0.06 mmol on Pd, 0.2 equiv) was 
stirred under hydrogen at room temperature and atmosphere 16 hours. After complete 
conversion (TLC monitoring), the catalyst was filtered off through a pad of Celite, washed with 
ethyl acetate, the solvents were removed under reduced pressure, and the residue was purified 
by column chromatography on neutral Al2O3 gel eluting with ethyl acetate:methanol 10:1) to 
provide 58 mg of brown oil, yield, 58 %. 
N
NPh
Ph
NMe2
 
 
1H-NMR(CDCl3), δ(ppm): 1.89-1.99 (m, 2 H, CH2), 2.18 (s, 6 H, 2CH3), 2.32 (t, 2 H, J = 7.3 
Hz, CH2), 2.86 (t, 2 H, J = 7.7Hz, CH2),7.20-7.36 (m, 10 H, Ph-H), 8.40 (s, 1 H, H-3). 
13C-NMR(CDCl3), δ(ppm): 27.31 CH2, 32.84 CH2, 45.49 CH3, 59.09 CH2, 128.21 CH, 128.31 
CH, 128.47 CH, 129.60 CH, 129.74 CH, 138.75 C, 138.85 C, 141.60 CH(C-3), 149.96 151.62 
C, 154.54 C. 
 
HRMS (EI) calcd for C21H23N3 (M+) 317.1892, found 317.1890. 
 
Anal. Calcd. for C21H23N3(317.43): C, 79.46; H, 7.30; N, 13.24. 
                                              Found: C, 79.66; H, 7.46; N, 13.12.. 
 
 
 
7.10 Synthesis of oxazole derivatives 
 
7.10.1 Synthesis of 4-bromo-2,5-diphenyloxazole (310): 
 
To a solution of 2,5-diphenyloxazole (2.21 g, 10 mmol), NBS (2.14 g, 12 mmol), in CCl4 20 
ml, a few (5~6) drops of hydrobromic acid was added as catalyst, the mixture was heated at 
reflux for 4 hours, cooled and filtered, the filtrate was evaporate, the crude product was purified 
by recrystallization from methanol, and provide white solid 1.30 g, yield 43 %, mp 64-5 °C. 
 
4-Bromo-2,5-diphenyloxazole (310) 
N
OPh Ph
Br
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1H-NMR(CDCl3), δ(ppm): 7.29-7.43 (m, 6 H, Ph-H), 7.93 (dd, 2 H, Ph-H), 8.00-8.03 (m, 2 H, 
Ph-H). 
13C-NMR (CDCl3), δ(ppm): 112.72 C, 124.27 C, 125.39 CH, 126.37 CH, 127.03 C, 128.79 
CH, 128.83 CH, 128.90 CH, 130.89 CH, 146.14 C, 160.07 C. 
 
Anal. Calcd. for C15H10BrNO(300.15): C, 60.02; H,3.36; Br, 26.62, N, 4.67. 
                                                    Found: C, 60.13; H, 3.52; Br, 25.81; N, 4.77. 
 
 
 
7.10.2 Synthesis of 4-alkyl-2,5-diphenyloxazole by Sonogashira reactions 
 
[3-(2,5-Diphenyl-oxazol-4-yl)-prop-2-ynyl]-dimethylamine (311) 
 
A 25ml flask was charged with 4-bromo-2,5-diphenyloxazole (150 mg, 0.5 mmol), 
Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10mg, 0.05mmol), TEA 5 ml, DMF 5 ml and N,N-
dimethylpropargylamine (83 mg, 1.0 mmol), Argon was passed and the mixture was heated at 
100 °C for 24 h, the solvent was evaporated in vacuum, the residue was purified by column 
chromatography on silica gel, eluting with ethyl acetate: methanol (6/1), and provided a brown 
glass material 63 mg, yield 42 %. When using TEA as base and solvent and reacted at 80 °C 24 
h, 311 was isolated in 10 %, When using KOAc as base and DMF as solvent and reacted at 100 
°C 24 h, 311 was isolated in 66 %. 
N
OPh Ph
NMe2
 
 
1H-NMR(CDCl3), δ(ppm): 2.35 (s, 6 H, CH3), 3.58 (s, 2 H, CH2), 7.37-8.02 (m, 10 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 44.07 CH3, 48.62 CH2, 77.86 C, 91.06 C, 119.23 C, 124.99 CH, 
126.55 CH, 128.79 CH, 128.97 CH, 130.79 CH, 132.01 CH, 133.08 C, 135.18 C, 151.78 C, 
159.64 C. 
 
HRMS (EI) calcd for C20H18N2O (M+) 302.14191, found 302.14193. 
 
 
[3-(2,5-Diphenyl-oxazol-4-yl)-propyl]-dimethylamine (312) 
 
A solution [3-(2,5-diphenyl-oxazol-4-yl)-prop-2-ynyl]-dimethylamine(112 mg, 0.37 mmol) in 
ethanol (15 ml) and 10 % palladium on charcoal (83 mg, 0.074 mmol on Pd, 0.2 equiv) was 
stirred under hydrogen at room temperature and atmosphere 16 h. After complete conversion 
(TLC monitoring), the catalyst was filtered off through a pad of Celite, washed with ethyl 
acetate, the solvents were removed under reduced pressure, and the residue was purified by 
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column chromatography on neutral Al2O3 gel, eluting with cyclohexane:ethyl acetate(1:1) to 
provide 66 mg of brown oil, yield, 58 %. 
 
N
OPh Ph
NMe2
313 
 
 
1H-NMR(CDCl3), δ(ppm): 1.78-1.88 (m, 2 H, CH2), 2.09(s, 6 H, CH3), 2.25 (t, 2 H, J = 7.4 
Hz, CH2), 2.70 (t, 2 H, J = 7.7 Hz, CH2),7.17-7.95 (m, 10 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 25.06 CH2, 26.81 CH2, 45.49 CH3, 59.16 CH2, 125.59 CH, 126.28 
CH, 127.57 C, 127.71 CH, 128.73 CH, 128.81 CH, 129.13 C, 130.11 CH, , 133.08 C, 137.54 
C, 145.39 C, 159.53 C. 
 
HRMS (EI) calcd for C20H22N2O (M+) 306.17321, found 306.17321. 
 
 
Synthesis of 3-(2,5-diphenyl-oxazol-4-ylethynyl)-phenylamine (313) 
 
A 25 ml flask was charged with 4-bromo-2,5-diphenyloxazole (150 mg, 0.5 mmol), 
Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10 mg, 0.05mmol), TEA 5 ml, and 3-ethynyl-
phenylamine (117 mg, 1.0 mmol), Argon was passed and the mixture was heated at 80 °C for 
24 h, the solvent was evaporated in vacuum, the residue was purified by column 
chromatography on silica gel, eluting with cyclohexane:ethyl acetate(2/1), and gave a light 
yellow solid 125 mg, yield 74 %, mp 195-6 °C. 
N
O
Ph
Ph NH2 
 
 
1H-NMR(CDCl3), δ(ppm): 3.74 (s, 2 H, NH2), 6.69-6.72 (dd, 1 H, J = 8.8 Hz, Ph-H), 6.93 (t, 1 
H, J = 1.9 Hz, Ph-H), 7.17 (t, 1 H, J = 7.9 Hz, Ph-H), 7.39 (t, 1 H, Ph-H), 7.47-7.52 (m, 5 H, 
Ph-H), 8.13-8.16 (m, 4 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 80.88 C, 95.66 C, 115.89 CH, 117.74 CH, 119.68 C, 122.13 CH, 
123.22 C, 125.06 CH, 126.61 CH,126.71 C, 127.75 C, 128.84 CH, 128.97 CH, 129.39 CH, 
130.81 CH, 146.37 C, 151.87 C, 159.81 C. 
 
Anal. Calcd. for C23H16N2O (336.39): C, 82.12; H,4.79; N,8.33. 
                                                 Found: C, 81.94; H, 4.90; N, 8.19. 
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7.10.3 Buchwald-hartwig amination of 4-bromo-2,5-diphenyloxazole 
 
Synthesis of 1-(2,5-diphenyl-oxazol-4-yl)-4-methyl-piperazine (314): 
 
A schlenk 25 ml flask was charge with 4-bromo-2,5-diphenyloxazole 310 (150 mg, 0.5 mmol), 
Pd2(dba)3 (10 mg, 0.01 mmol), BINAP (19 mg, 0.03 mmol), t-BuONa (68 mg, 0.7 mmol), 4-
methyl-piperazine (100 mg, 1.0 mmol), dry toluene 5 ml, Argon was passed three times and the 
mixture was heated at 110 °C for 20 h, evaporated the solvent, the residue was purified by 
column chromatography on neutral Al2O3 gel, eluting with ethyl acetate, and get light yellow 
solid 22 mg, yield 14 %, mp 110-2 °C; 
N
OPh Ph
N
N
 
 
1H-NMR(CDCl3), δ(ppm): 2.38 (s, 3 H, CH3), 2.60 (t, 4 H, J = 4.8 Hz, CH2), 3.20 (t, 4 H, J = 
4.8 Hz, CH2), 7.23-7.45 (m, 6 H, Ph-H), 7.84 (dd, 2 H, J1 = 8.2Hz, J2 = 1.0 Hz, Ph-H), 8.06 (dd, 
2 H, J1 = 8.4 Hz, J2 = 1.5 Hz, Ph-H), 
13C-NMR (CDCl3), δ(ppm): 46.38 CH3, 50.20 CH2, 55.28 CH2, 124.45 CH, 126.15 CH, 
126.74 CH, 127.70 C, 128.56 CH, 128.67 CH, 129.35 C, 129.97 CH, 135.93 C, 146.61 C, 
157.54. 
 
HRMS (EI) calcd for C20H21N3O ( M+ ) 319.16846, found 319.16845. 
 
 
 
 
7.11 Synthesis of Pyrazole derivatives 
 
7.11.1 Synthesis of 4-iodo-3-methyl-1,5-diphenylpyrazole 
 
4-Iodo-3-methyl-1,5-diphenylpyrazole was started from 3-methyl-1,5-diphenylpyrazole. 
 
3-Methyl-1,5-diphenylpyrazole (320) 
N
N
Ph
Ph
 
 
A 250ml flask was charged with phenylhydrazine (6.68 g, 0.06mol), sodium acetate (3.28 g, 
0.04mol), benzoylacetone (9.74 g, 0.06mol), ethanol 80 ml and water 40 ml, the mixture was 
heated at reflux for 3 h and concentrated the solvent in vacuum, 40 ml ether and 40 ml water 
were added inside the flask, separated, the aqueous layer was extracted with ether (40 2 × 40 
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ml), the combined extracts were washed with 1 N NaOH 30 ml, brine 30 ml, and dried with 
anhydrous MgSO4, the solvent was evaporated in vacuum and provided an orange oil 13.03 g, 
yield 93 %. 
 
1H-NMR(CDCl3), δ(ppm): 2.56 (s, 3 H, CH3), 6.48 (s 1 H, H-4), 7.39-7.46 (m, 10 H, Ph-H). 
13C-NMR(CDCl3), δ (ppm): 13.63 CH3, 107.79 CH(C-4), 125.13 CH, 127.09 CH, 128.08 CH, 
128.42 CH, 128.65 CH, 128.86 CH, 130.77 C, 140.19 C, 143.69 C, 149.45 C. 
 
HRMS (EI) calcd for C16H14N2(M+) 234.11570, found 234.11575. 
 
 
4-Iodo-3-methyl-1,5-diphenylpyrazole (321) 
N
N
Ph
Ph
I
 
 
A 100ml flask was charged with 4-methyl-1,2-diphenylpyrrole 320 (2.34 g,10 mmol), 50 ml 
DMF, the solution was cooled to 0 °C and passed Argon, NIS (2.70 g, 12 mmol) was added and 
stirred at room temperature overnight (16 h), then the solution cooled again to 0°C, NIS (0.13 
g, 0.5 mmol) was added and continue to stir at RT for another 12 h, 250 ml water was added 
inside, the mixture was extracted with ether (2 × 120 ml), ethyl acetate 100 ml and hexane 100 
ml, the combined extract was washed with water 50 ml, 10 % aq. Na2S2O3 50ml, water 50 ml, 
and dried with anhydrous MgSO4, the solvent was concentrated and provided a brown solid 
2.12 g, yield 59 %, mp 94-6 °C. 
 
1H-NMR(CDCl3), δ(ppm): 2.33 (s, 3 H, CH3), 7.08-7.19 (m, 10 H, Ph-H). 
13C-NMR(CDCl3), δ(ppm): 14.39 CH3, 66.23 C, 124.64 CH, 127.27 CH, 128.27 C, 128.44 
CH, 128.79 CH, 128.85 CH, 130.15 CH, 139.93 C, 144.02 C, 151.64 C. 
 
HRMS (EI) calcd for C16H13IN2 (M+) 360.01235, found 360.01241. 
 
 
7.11.2 Dimethyl-[3-(3-methyl-1,5-diphenyl-pyrazol-4-yl)-prop-2-ynyl]-amine (322) 
 
A 25ml Schlenk flask was charged with 4-Iodo-3-methyl-1,5-diphenylpyrazole (320 mg, 1.0 
mmol), K2CO3 (332 mg, 2.4 mmol), CuI (20 mg, 0.1 mmol), 10 % Pd/C (44 mg, 0.04 mmol ), 
and PPh3 (42 mg, 0.16 mmol) in DME (10 ml) and water (10 ml). Argon was passed through 
the flask 3 times and the mixture was stirred at 25 °C for 0.5 h, then N,N-dimethylpropargyl 
amine 100 mg (1.2 mmol) was added. After refluxing under argon for 24 h the mixture was 
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cooled to 25 °C and filtered through a pad of Celite. After washing with EtOAc, the combined 
crude solution was washed with water (50 mL) twice. The organic layer was dried with 
anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography on silica gel, eluting with EtOAc:MeOH(1:0→6:1) and provided a light brown 
solid 306 mg, yield 97 %, mp 66-7 °C. 
N
N
Ph
Ph
NMe2
 
 
1H-NMR(CDCl3), δ(ppm) : 2.23 (s, 6 H, CH3), 2.36 (s, 3 H, CH3), 3.40 (s, 2 H; CH2), 7.14-
7.61 (m, 10 H, Ph-H). 
13C-NMR(CDCl3), δ (ppm): 12.65 CH3, 44.01 CH3, 48.73 CH2, 88.05 C, 104.10 C, 125.04 CH, 
127.32 CH, 128.26 CH, 128.50 CH, 128.89 CH, 129.39 CH,132.02 C, 133.24 C, 139.75 C, 
144.21 C, 151.95 C. 
 
Anal. Calcd. for C21H21N3 : C, 79.97; H, 6.71; N, 13.32. 
                                 Found: C, 80.12; H, 6.72; N, 13.15. 
 
 
7.11.3 Dimethyl-[3-(3-methyl-1,5-diphenyl-pyrazol-4-yl)-propyl]-amine (323) 
 
A solution dimethyl-[3-(3-methyl-1,5-diphenyl-pyrazol-4-yl)-prop-2-ynyl]-amine 322 (158 mg, 
0.5 mmol) in ethanol (15 ml) and 10 % palladium on charcoal (111 mg, 0.1 mmol on Pd, 0.2 
equiv) was stirred under hydrogen at room temperature and atmosphere 16 h. After complete 
conversion (TLC monitoring), the catalyst was filtered off through a pad of Celite, washed with 
ethyl acetate, the solvents were removed under reduced pressure, and the residue was purified 
by column chromatography on neutral Al2O3 gel, eluting with ethyl acetate:methanol (10:1) to 
give 122 mg of brown oil, yield, 76 %. 
N
N
Ph
Ph
NMe2
 
 
1H-NMR(CDCl3), δ(ppm): 1.48-1.58 (m, 2 H, CH2), 2.06 (s, 3 H, CH3), 2.12 (t, 2 H, J = 7.4 
Hz, CH2), 2.28 (s, 3 H, CH3), 2.37 (t, 2 H, J = 7.9 Hz, CH2), 7.07-7.62 (m,10 H, Ph-H). 
13C-NMR(CDCl3), δ(ppm): 12.19 CH3, 21.30 CH2, 28.91 CH2, 45.39 CH3, 59.44 CH2, 119.42 
C, 124.39 CH, 126.30 CH, 128.05 CH, 128.40 CH, 128.58, 129.80 CH, 131.12 C, 140.10 C, 
140.39 C, 148.31 C. 
 
HRMS (EI) calcd for C21H25N3 (M+) 319.2049, found 319.2046. 
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Anal. Calcd. for C21H25N3 (319.44): C, 78.96; H, 7.89; N, 13.15. 
                                               Found: C, 78.83; H, 8.02; N, 13.07. 
 
 
 
 
7.12 Synthesis imidazole derivatives 
 
7.12.1 Nucleophilic substitution of 4,5-diphenylimidazole 
 
Synthesis of 3-(4,5-diphenyl-imidazol-1-yl)-propylamine 335 
 
(1) 2-[3-(4,5-Diphenyl-imidazol-1-yl)-propyl]-isoindole-1,3-dione 334 
A mixture of 4,5-diphenylimidazole (440 mg, 2.0 mmol), N-3-bromopropylphthalimide (1.07 
g, 4.0 mmol), cesium carbonate (1.30 g, 4.0 mmol) and DMF 15 ml was heated at 60 °C for 4 
h, then the mixture was cooled and diluted with 30 ml water, the mixture was extracted with 
ethyl acetate (3 × 40 ml), the combined extract was washed with water (3 × 30 ml) and then 
brine 30 ml, the solution was dried with anhydrous sodium sulphate. Evaporated the solvent 
and the residue was purified by column chromatography on SiO2 gel, eluting with ethyl acetate 
and ethylacetate: methanol(10/1) and provided a white solid 767 mg, yield 94 %, mp 109-110 
°C. 
 
N
NPh
Ph N
O
O
334 
 
1H-NMR(CDCl3), δ(ppm): 1.79-1.89 (m, 2 H, CH2), 3.53 (t, 2 H, J = 6.6 Hz, CH2), 3.79 (t, 2 
H, J = 7.5 Hz, CH2), 7.01-7.37 (m, 10 H, Ph-H), 7.61 (s, 1 H, H-2), 7.64-7.76 (m, 4 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 30.07 CH2, 35.02 CH2, 42.80 CH2, 123.33 CH, 126.28 CH, 
126.47 CH, 128.08 CH, 128.63 CH, 129.00 CH, 130.61 C, 130.68 CH, 131.86 C, 134.09 CH, 
134.48 C, 136.72 CH(C-2), 138.38 C, 168.09 C(C=O). 
 
HRMS (EI) calcd for C26H21N3O2 (M+) 407.16338, found 407.16330. 
 
 
(2) 3-(4,5-Diphenyl-imidazol-1-yl)-propylamine (335) 
 
A soution of 2-[3-(4,5-diphenyl-imidazol-1-yl)-propyl]-isoindole-1,3-dione 334 (408 mg, 1.0 
mmol) 80 % hydrazine hydrate (75 mg, 1.2 mmol), and ethanol 15 ml was heated at reflux for 
8 h, then the solution was cooled, 4 N HCl solution 20 ml was added, and the solution was 
heated at reflux for 6 h, after cooled, the white precipitate was filtered away, the solution was 
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concentrated, the precipitate was removed again, then 30 ml water and excess Na2CO3 solid 
was added, the mixture was extracted with dichloromethane (4 × 30 ml), and dried the solution 
with anhydrous MgSO4, evaporated the solvent and 235 mg white solid was obtained, yield 85 
%, mp 42-4 °C. 
N
NPh
Ph NH2
335
 
 
 
1H-NMR(CDCl3), δ(ppm): 1.26 (m, 2 H, CH2), 1.66 (t, 2 H, J = 6.8 Hz, CH2), 2.58 (br, 2 H, 
NH2), 3.89 (t, 2 H, J = 7.2 Hz, CH2), 7.12-7.48 (m, 10 H, Ph-H), 7.63 (s, 1 H, H-2). 
13C-NMR(CDCl3), δ(ppm): 34.23 CH2, 38.72 CH2, 42.59 CH2, 126.22 CH, 126.50 CH, 128.09 
CH, 128.70 CH, 129.01 C, 129.10 CH, 130.80 CH, 130.84 C, 134.60 C, 136.78 CH(C-2), 
138.13 C. 
 
HRMS (EI) calcd for C18H19N3 (M+) 277.15790, found 277.15794. 
 
 
7.12.2 Sonogashira cross-coupling of 1-benzyl-2-bromo-4,5-diphenylimidazole 
 
1-Benzyl-4,5-diphenylimidazole (336) 
 
N
N
Ph
Ph
Ph
336
 
 
A mixture of 4,5-diphenylimidazole (6.61 g, 30 mmol), potassium carbonate (2.40 g, 17 mmol) 
and dry DMF 90 ml was passed with Argon, and heated to 80 °C, benzyl chloride (3.80 g, 30 
mmol) was added inside slowly, then stirred over night (16 h), the solid was filtered away, and 
the solvent was evaporated, the crude product was purified by column chromatography on 
silica gel, eluting with ethyl acetate: hexane (2/1), and a white solid 8.68 g was obtained, yield 
93 %, mp 112-4 °C. 
 
1H-NMR(CDCl3), δ(ppm): 4.96 (s, 2 H, CH2), 6.94-7.50 (m, 15 H, Ph-H), 7.61(s, 1 H, H-2) 
13C-NMR(CDCl3), δ(ppm): 48.79 CH2, 126.25 CH, 126.56 CH, 126.94 CH, 127.68 CH, 
127.99 CH, 128.15 CH, 128.79 CH, 128.93 CH, 130.94 CH, 133.23 C, 134.45 C, 134.90 C, 
136.50 C, 137.09 CH(C-2), 138.27 C. 
 
 
Anal. Calcd. for C22H18N2(310.39): C, 85.13; H, 5.85; N, 9.03 
                                              Found: C, 85.33; H, 5.99; N, 8.91 
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1-Benzyl-2-bromo-4,5-diphenylimidazole (338) 
 
A 50 ml flask was charged 1-benzyl-4,5-diphenylimidazole 336 (1244 mg, 4.0 mmol) NBS 
(890 mg, 5.0 mmol) and CH3CN 30 ml, the mixture was stirred at room temperature 2 h. The 
solvent was concentrated and the residue was purified by column chromatography on silica gel, 
eluting with ethyl acetate: hexane (1/6→1/2), and a yellow solid 929 mg was obtained, yield 60 
%, mp 106-8 °C. 
N
N
Ph
Ph
Ph
338
Br
 
 
 
1H-NMR(CDCl3), δ(ppm): 5.09 (s, 2 H, CH2), 6.98-7.55 (m, 15 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 48.99 CH2, 120.58 C(C-2), 126.34 CH, 126.51 CH, 126.76 CH, 
127.71 CH, 128.15 CH, 128.71 CH, 129.02 CH, 129.17 CH, 130.24 C, 130.92 CH, 131.39 C, 
133.52 C, 136.05 C, 139.17 C. 
 
Anal. Calcd. for C22H17BrN2(389.29): C, 67.88; H, 4.40; Br, 20.53; N, 7.20. 
                                                  Found: C, 67.65; H, 4.59; Br, 20.80; N, 7.02. 
 
 
[3-(1-Benzyl-4,5-diphenyl-imidazol-2-yl)-prop-2-ynyl]-dimethylamine (339) 
A 25 ml schlenk flask was charged 1-benzyl-2-bromo-4,5-diphenylimidazole 338 (195 mg, 0.5 
mmol), Pd(PPh3)2Cl2 (18 mg, 0.025 mmol), CuI (10 mg, 0.05 mmol), triethylamine 10 ml, and 
N, N-dimethylpropargylamine (83 mg, 1.0 mmol), Argon was passed three times and heated at 
80 °C for 24 h. The mixture was concentrated, the residue was purified by column 
chromatography on neutral Al2O3 gel, eluting with ethyl acetate: hexane (1/3→1/1), and 
provided a brown oil 85 mg, yield 43 %. When using DMF as solvent and reacted at 100 °C 24 
h, 339 was isolated in 27 % yield. 
N
N
Ph
Ph
Ph 339
CH2NMe2
 
 
1H-NMR(CDCl3), δ(ppm): 2.20 (s, 6 H, 2CH3), 3.49 (s, 2 H, CH2), 5.09 (s, 2 H, CH2), 6.88-
7.48 (m, 15 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 43.98 CH3, 48.34 CH2, 48.42 CH2, 75.58 C, 89.24 C, 126.57 CH, 
126.65 CH, 126.75 CH, 126.92 C, 127.57 CH, 128.07 CH, 128.58 C, 128.77 CH, 128.92 CH, 
130.28 C, 130.82 CH, 131.64 C, 133.86 C, 136.63 C, 138.49 C. 
 
HRMS (EI) calcd for C27H25N3 (M+) 391.20485, found 391.20462. 
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[3-(1-Benzyl-4,5-diphenyl-imidazol-2-yl)-propyl]-dimethylamine (340) 
 
A solution [3-(1-benzyl-4,5-diphenyl-imidazol-2-yl)-prop-2-ynyl]-dimethylamine 339 (70 mg, 
0.18 mmol), ethanol (15 ml) and 10 % palladium on charcoal (40 mg, 0.036 mmol on Pd, 0.2 
equiv) was stirred under hydrogen at room temperature and atmosphere 16 h. After complete 
conversion (TLC monitoring), the catalyst was filtered off through a pad of Celite, washed with 
ethyl acetate, the solvents were removed under reduced pressure, and the residue was purified 
by column chromatography on neutral Al2O3 gel, eluting with ethyl acetate to provide 45 mg of 
yellow oil, yield, 63 %. 
 
N
NPh
Ph
Ph
CH2NMe2
340  
 
1H-NMR(CDCl3), δ(ppm): 1.92-2.02 (m, 2 H, CH2), 2.19 (s, 6 H, 2CH3), 2,35 (t, 2 H, J = 7.8 
Hz, CH2), 2,70 (t, 2 H, J = 7.58 Hz, CH2), 5.01 (s, 2 H, CH2), 6.92-7.52 (m, 15 H, Ph-H). 
13C-NMR (CDCl3), δ(ppm): 25.14 CH2, 26.04 CH2, 45.34 CH3, 46.84 CH2, 59.05 CH2, 125.80 
CH, 126.07 CH, 126.69 CH, 127.45 CH, 128.07 C, 128.47 CH, 128.78 CH, 128.87 CH, 130.98 
CH, 132.43 C, 134.79 C, 136.70 C, 137.41 C, 148.28. 
 
HRMS (EI) calcd for C27H29N3 (M+) 395.2362, found 395.2359. 
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Zusammenfassung 
 
 
Unsere Forschungsziele sind die Entwicklung von neuen nichtpeptidischen Calcineurin-
Inhibitoren. Nach einem positiven Test von einigen Substanzen (Pyrazolopyrimidinen und 
Pyrazolotriazinen) wurde eine allgemeine Struktur 8 mit calcineurin-inhibierenden Potential 
formuliert. 
 
Heterocyclische 
Kern
Ar2Ar1
Y Aliphatische Kette Z 
Allgemeine Struktur 8 
 
 
Die Struktur besteht aus einem heterocyclischen Kern, zwei Aryl-Gruppen und einer 
Seitenkette.  
In dieser Dissertation versuchen wir, die zentralen N-heterocyclischen Kerne, die Seitenketten 
und deren Position zu variieren. In der allgemeinen Struktur 8, kann Y nicht nur NH, O und S 
sondern auch CH2 und CH2NH sein und die aliphatische Kette kann gesättigt und ungesättigt 
sein. Als synthetische Strategie wurden Palladium-katalysierte Kupplungsreaktionen 
verwendet, um Seitenketten und/oder Aryl-Substituenten einzuführen.  
 
Synthese von Halogensubstituierten Diarylheterocylen 
Halogensubstituierte Diarylheterocyclen sind wichtige Intermediate in der Synthese der 
allgemeine Strukture 8. Um Aryl-Gruppen einzuführen, ist die Suzuki-Reaktion der 
Schlüsselschritt. 
Andere Halo-Heterocyclen werden entweder durch Substitutionen von Hydroxylgruppen mit 
einem Halogen oder durch Halogenierung der unfunktionalisierten Position der Heterocyclen 
erreicht. Mehr als 30 Substanzen entsprechender Halo-Heterocyclen wurden synthetisiert. 
 
Einführung der Seitenketten durch Palladium-katalysierte Kupplungen 
Die Einführung der gewünschten Seitenketten durch C-C und C-N-Bindungsknüpfung wurde 
durch Sonogashira-Kupplung, Heck-Kupplung und Buchwald-Hartwig-Aminierung erzielt 
Mit der Sonogashira-Reaktion kann eine ω-funktionalisierte Alkynylgruppe in die 
heterocyclischen Kerne effektiv und bequem eingeführt werden. Eine anschliessende 
katalytische Hydrierung der Alkynylgruppe führt zu ω-funktionalisierten Alkyl substituierten 
Diarylheterocyclen. Fünf bicyclische und sechs monocyclische heterocyclischen Kerne 
können durch diese Reaktionsreinfolge erfolgreich dargestellt werden. 
Durch Heck-Reaktion von 3-Iodopyrazolo[1,5-a]pyrimidinen oder von 7-Bromopyrido[2,3-
b]pyrazinen mit Olefinen können ω-funktionalisierten Alkenylgruppen in diese 
heterocyclischen Kerne eingeführt werden. 
Durch Buchwald-Hartwig-Aminierung von 6-Bromoimidazo[1,2-a]pyridinen ,von 7-Bromo-
pyrido[2,3-b]pyrazinen oder von 4-Bromooxazolen mit den ω-funktionalisierten 
Alkylaminen, können die Aminoalkylketten in diese heterocyclischen Kerne eingeführt 
werden. 
Wir haben allgemeine Beiträge zu diesem Bereich und in Bezug auf die Beschränkung der 
Palladium-katalysierten Reaktionen in der Chemie der Heterocyclen geleistet. 
 
Calcineurin-inhibierende Aktivität 
Im Verlauf dieser Dissertation wurden Heterocyclen mit Grundkörpern von Purin, 
Pyridopyrazin, Imidazopyridin, Imidazopyridazin, Imidazol, Oxazol, Pyrazol, Pyridin und 
Pyrazin entwickelt und getestet. Die Ergebnisse zeigen, dass nur Pyrazolopyrimidine, 
Pyrazolotriazine und Pyrimidine wirkungsvoll sind. 
Das strukturelle Modell 8 der möglichen Calcineurin-Inhibitoren kann verfeinert werden. 
Wichtige Beiträge zu diesem Bereich und Beschränkungen wurden so mit zur Verfügung 
gestellt. Weitere Resultate zeigen die beträchtliche und vielseitige Verwendbarkeit der 
Palladium-katalysierten Kupplungsreaktionen in diesen neuen Bereichen der Chemie  der 
Heterocyclen. 
 
 
In der vorliegenden Arbeit wurden mehr als 180 Substanzen synthetisiert. Unter ihnen sind 
ungefähr 130 neue Substanzen. 86 von ihnen passen in die allgemeine Struktur 8. 
 
Fünf Publikationen entstanden aus diesen Resultaten. Zwei von ihnen sind schon erschienen. 
Eine ist im Druck, zwei weitere sind in Vorbereitung. 
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